<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">101673</article-id><article-id pub-id-type="doi">10.7554/eLife.101673</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.101673.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Secreted exosomes induce filopodia formation</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>McAtee</surname><given-names>Caitlin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Patel</surname><given-names>Mikin R</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hoshino</surname><given-names>Daisuke</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sung</surname><given-names>Bong Hwan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>von Lersner</surname><given-names>Ariana K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Mingjian</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Nan Hyung</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Krystofiak</surname><given-names>Evan</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zijlstra</surname><given-names>Andries</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="pa2">§</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Weaver</surname><given-names>Alissa M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4096-8636</contrib-id><email>alissa.weaver@vanderbilt.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vm5rt34</institution-id><institution>Department of Cell and Developmental Biology, Vanderbilt University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vm5rt34</institution-id><institution>Center for Extracellular Vesicle Research, Vanderbilt University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vm5rt34</institution-id><institution>Department of Biological Sciences, Vanderbilt University</institution></institution-wrap><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00aapa202</institution-id><institution>Kanagawa Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Yokohama</named-content></addr-line><country>Japan</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vm5rt34</institution-id><institution>Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dq2gs74</institution-id><institution>Department of Biomedical Informatics, Vanderbilt University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vm5rt34</institution-id><institution>Cell Imaging Shared Resource EM Facility, Vanderbilt University</institution></institution-wrap><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Applewhite</surname><given-names>Derek A</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00a6ram87</institution-id><institution>Reed College</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Araújo</surname><given-names>Sofia J</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/021018s57</institution-id><institution>Universitat de Barcelona</institution></institution-wrap><country>Spain</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work.</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>Baylor College of Medicine, Houston, United States</p></fn><fn fn-type="present-address" id="pa2"><label>§</label><p>StimulusBio, Houston, United States</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>14</day><month>01</month><year>2026</year></pub-date><volume>13</volume><elocation-id>RP101673</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-08-07"><day>07</day><month>08</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-07-22"><day>22</day><month>07</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.07.20.604139"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-10-18"><day>18</day><month>10</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101673.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-06-12"><day>12</day><month>06</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101673.2"/></event></pub-history><permissions><copyright-statement>© 2024, McAtee, Patel, Hoshino et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>McAtee, Patel, Hoshino et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-101673-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-101673-figures-v1.pdf"/><abstract><p>Filopodia are dynamic adhesive cytoskeletal structures that are critical for directional sensing, polarization, cell-cell adhesion, and migration of diverse cell types. Filopodia are also critical for neuronal synapse formation. While dynamic rearrangement of the actin cytoskeleton is known to be critical for filopodia biogenesis, little is known about the upstream extracellular signals. Here, we identify secreted exosomes as potent regulators of filopodia formation. Inhibition of exosome secretion inhibited the formation and stabilization of filopodia in both cancer cells and neurons and inhibited subsequent synapse formation by neurons. Rescue experiments with purified small and large extracellular vesicles (EVs) identified exosome-enriched small EVs (SEVs) as having potent filopodia-inducing activity. Proteomic analyses of cancer cell-derived SEVs identified the TGF-β family coreceptor endoglin as a key SEV-enriched cargo that regulates filopodia. Cancer cell endoglin levels also affected filopodia-dependent behaviors, including metastasis of cancer cells in chick embryos and 3D migration in collagen gels. As neurons do not express endoglin, we performed a second proteomics experiment to identify SEV cargoes regulated by endoglin that might promote filopodia in both cell types. We discovered a single SEV cargo that was altered in endoglin-KD cancer SEVs, the transmembrane protein Thrombospondin Type 1 Domain Containing 7A (THSD7A). We further found that both cancer cell and neuronal SEVs carry THSD7A and that add-back of purified THSD7A is sufficient to rescue filopodia defects of both endoglin-KD cancer cells and exosome-inhibited neurons. We also find that THSD7A induces filopodia formation through activation of the Rho GTPase, Cdc42. These findings suggest a new model for filopodia formation, triggered by exosomes carrying THSD7A.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Cell migration is a crucial process that underpins both healthy functions – such as organ and blood vessel development, and the formation of synaptic connections between neurons – and pathological events like cancer metastasis. For cells to migrate, they must reorganize their cytoskeleton to form specialized structures that support their movement.</p><p>This reorganization includes filopodia, which are slender protrusions that play key roles in sensing directional cues at the leading edge of migrating cells and initiating contact with other cells. The extracellular signals that trigger the formation of filopodia remain poorly understood, but recent research suggests that extracellular vesicles may be involved in this process.</p><p>Also known as exosomes, these vesicles are membrane-enclosed particles that carry proteins, lipids, and nucleic acids between cells, representing an alternative mode of cellular communication. McAtee et al. aimed to determine whether exosomes could also promote filopodia formation.</p><p>They studied two distinct systems: cancer cells, where filopodia facilitate metastasis, and rat neurons, where they promote synapse formation. In both contexts, exosomes emerged as potent, general regulators of filopodia formation, indicating a broad role in controlling this fundamental cellular behavior.</p><p>Using genetic inhibition of exosome secretion, combined with add-back of extracellular vesicles, McAtee et al. demonstrated a direct causal relationship between exosomes and filopodia formation. In neurons, filopodia matured into dendritic spines – critical structures for synaptic connectivity between neurons. A quantitative analysis of neurons confirmed that exosomes indeed promoted the formation of dendritic spines and synapses. They also identified the exosomal protein THSD7A as key in driving filopodia formation in both neurons and cancer cells. Moreover, in cancer cells, the secretion of THSD7A-containing exosomes, filopodia formation, cell migration, and metastatic colony formation were regulated by a growth factor receptor known as endoglin.</p><p>The study by McAtee et al. highlights a novel role for extracellular vesicles in filopodia formation, enhancing our understanding of how cells migrate in health and disease. Interestingly, both molecules identified as cargoes of filopodia-regulating exosomes are associated with disease: endoglin with hereditary hemorrhagic telangiectasia, and THSD7A with a kidney disease called secondary membranous nephropathy. This suggests that dysregulation of filopodia may occur in these conditions. Furthermore, endoglin and/or THSD7A could serve as potential targets for anti-cancer therapies. Indeed, some promising investigations have already employed anti-endoglin antibodies to inhibit metastasis.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>extracellular vesicles</kwd><kwd>filopodia</kwd><kwd>cell migration</kwd><kwd>Endoglin</kwd><kwd>THSD7A</kwd><kwd>synapse formation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Chicken</kwd><kwd>Human</kwd><kwd>Mouse</kwd><kwd>Rat</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01GM117916</award-id><principal-award-recipient><name><surname>Weaver</surname><given-names>Alissa M</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01CA206458</award-id><principal-award-recipient><name><surname>Weaver</surname><given-names>Alissa M</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01CA249684</award-id><principal-award-recipient><name><surname>Weaver</surname><given-names>Alissa M</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01CA249424</award-id><principal-award-recipient><name><surname>Weaver</surname><given-names>Alissa M</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013kjyp64</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>17POST33660473</award-id><principal-award-recipient><name><surname>McAtee</surname><given-names>Caitlin</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32CA009592</award-id><principal-award-recipient><name><surname>McAtee</surname><given-names>Caitlin</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hhkn466</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP 17K15005</award-id><principal-award-recipient><name><surname>Hoshino</surname><given-names>Daisuke</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R50CA283661</award-id><principal-award-recipient><name><surname>Sung</surname><given-names>Bong Hwan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Exosome-associated THSD7A is identified as a key trigger of filopodia formation in cancer cells and neurons, revealing a novel pathway with implications for metastasis, neuronal connectivity, and other filopodia-dependent processes.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Dynamic rearrangement of the actin cytoskeleton is critical for cell shape changes, elaboration of specialized cell structures, and cell movement. Thin actin-rich structures called filopodia are used for directional sensing and making initial contacts between neighboring cells (<xref ref-type="bibr" rid="bib9">Blake and Gallop, 2023</xref>; <xref ref-type="bibr" rid="bib28">Heckman and Plummer, 2013</xref>; <xref ref-type="bibr" rid="bib52">Mattila and Lappalainen, 2008</xref>). In migrating cells, filopodia protrude from the cell’s leading edge to promote cell polarization and facilitate adhesion (<xref ref-type="bibr" rid="bib2">Arjonen et al., 2011</xref>; <xref ref-type="bibr" rid="bib34">Jacquemet et al., 2015</xref>). Filopodia are also important for establishing cell contacts (<xref ref-type="bibr" rid="bib1">Almagro et al., 2010</xref>; <xref ref-type="bibr" rid="bib26">Hammers et al., 2021</xref>; <xref ref-type="bibr" rid="bib29">Heimsath et al., 2017</xref>; <xref ref-type="bibr" rid="bib100">Vasioukhin et al., 2000</xref>). In neurons, filopodia initiate synapse formation by contacting the axon of neighboring neurons and then develop into specialized postsynaptic structures called dendritic spines that are important for learning and memory (<xref ref-type="bibr" rid="bib19">Fiala et al., 1998</xref>; <xref ref-type="bibr" rid="bib38">Kanjhan et al., 2016</xref>; <xref ref-type="bibr" rid="bib107">Wit and Hiesinger, 2023</xref>; <xref ref-type="bibr" rid="bib114">Ziv and Smith, 1996</xref>). Filopodia have also been shown to contribute to invasive cancer cell behaviors, including metastasis (<xref ref-type="bibr" rid="bib2">Arjonen et al., 2011</xref>; <xref ref-type="bibr" rid="bib34">Jacquemet et al., 2015</xref>; <xref ref-type="bibr" rid="bib3">Arjonen et al., 2014</xref>; <xref ref-type="bibr" rid="bib27">Hashimoto et al., 2011</xref>; <xref ref-type="bibr" rid="bib35">Jacquemet et al., 2017</xref>; <xref ref-type="bibr" rid="bib48">Machesky, 2008</xref>; <xref ref-type="bibr" rid="bib49">Machesky and Li, 2010</xref>; <xref ref-type="bibr" rid="bib68">Pan et al., 2023</xref>; <xref ref-type="bibr" rid="bib84">Sun et al., 2011</xref>; <xref ref-type="bibr" rid="bib110">Zhang et al., 2021</xref>).</p><p>Several different mechanisms have been described to promote filopodia formation, including direct nucleation of unbranched actin filaments by formins and other nucleators and reorganization of branched cortical actin filaments followed by actin polymerization (<xref ref-type="bibr" rid="bib9">Blake and Gallop, 2023</xref>; <xref ref-type="bibr" rid="bib52">Mattila and Lappalainen, 2008</xref>; <xref ref-type="bibr" rid="bib21">Gallop, 2020</xref>). Additional actin regulatory proteins promote uncapping of the barbed ends, elongation, and bundling of actin filaments. These actin regulatory proteins are controlled upstream by phosphatidylinositols, especially PI(4,5)P2, PI(3,4,5)P3, and PI(3,4)P2, and Rho GTPases, particularly Cdc42 (<xref ref-type="bibr" rid="bib9">Blake and Gallop, 2023</xref>; <xref ref-type="bibr" rid="bib62">Nobes and Hall, 1995</xref>). Myosin-X may further promote filopodia maintenance by transporting and/or organizing cytoskeletal and adhesion molecules at filopodia tips (<xref ref-type="bibr" rid="bib1">Almagro et al., 2010</xref>; <xref ref-type="bibr" rid="bib10">Bohil et al., 2006</xref>; <xref ref-type="bibr" rid="bib59">Miihkinen et al., 2021</xref>; <xref ref-type="bibr" rid="bib72">Popović et al., 2023</xref>; <xref ref-type="bibr" rid="bib109">Zhang et al., 2004</xref>).</p><p>While the intracellular cytoskeletal machinery that drives filopodia formation has been heavily studied, there is little known about the extracellular cues that activate that machinery. Bone morphogenic proteins (BMPs) have been shown to regulate filopodia in endothelial cells, myoblasts, and neurons, often through activation of the Rho GTPase Cdc42 (<xref ref-type="bibr" rid="bib22">Gamell et al., 2008</xref>; <xref ref-type="bibr" rid="bib42">Lee-Hoeflich et al., 2004</xref>; <xref ref-type="bibr" rid="bib101">Wakayama et al., 2015</xref>). VEGFA has also been shown to promote endothelial sprouting and filopodia formation (<xref ref-type="bibr" rid="bib23">Gerhardt et al., 2003</xref>). In neurons, a variety of extracellular molecules have been shown to regulate filopodia formation and dynamics, including brain-derived neurotrophic factor (<xref ref-type="bibr" rid="bib55">Menna et al., 2009</xref>), Slit (<xref ref-type="bibr" rid="bib54">McConnell et al., 2016</xref>), Netrin-1 (<xref ref-type="bibr" rid="bib79">Shekarabi and Kennedy, 2002</xref>), and nerve growth factor (<xref ref-type="bibr" rid="bib39">Ketschek and Gallo, 2010</xref>). Filopodia formation has also been shown to be influenced in tumor cells by TGF-β signaling-induced alterations in gene expression, specifically upregulation of fascin protein (<xref ref-type="bibr" rid="bib84">Sun et al., 2011</xref>). While these studies have identified some extracellular regulators of filopodia formation, the molecular mechanisms are poorly understood, and some are indirect, via inducing gene expression changes in cytoskeletal components.</p><p>Exosomes are small extracellular vesicles (EVs) that are formed within multivesicular late endosomes (MVEs) and released into the extracellular space by fusion of MVEs with the plasma membrane. Exosomes carry bioactive cargoes, including proteins, lipids, and nucleic acids and promote autocrine and paracrine cell communication across a variety of systems (<xref ref-type="bibr" rid="bib17">Dixson et al., 2023</xref>; <xref ref-type="bibr" rid="bib47">Maas et al., 2017</xref>; <xref ref-type="bibr" rid="bib99">van Niel et al., 2018</xref>). Notably, exosomes have been shown to promote polarization and motility of multiple cell types, including cancer cells, immune cells, and single-celled amoebae (<xref ref-type="bibr" rid="bib11">Brown et al., 2018</xref>; <xref ref-type="bibr" rid="bib40">Kriebel et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Majumdar et al., 2021</xref>; <xref ref-type="bibr" rid="bib86">Sung et al., 2015</xref>; <xref ref-type="bibr" rid="bib89">Sung et al., 2021</xref>; <xref ref-type="bibr" rid="bib87">Sung and Weaver, 2017</xref>). Exosomes also play a key role in metastasis by seeding metastatic niches (<xref ref-type="bibr" rid="bib4">Asao et al., 2023</xref>; <xref ref-type="bibr" rid="bib70">Peinado et al., 2012</xref>; <xref ref-type="bibr" rid="bib108">Wortzel et al., 2019</xref>).</p><p>In previous studies, we found that exosome secretion is critical for the formation of two motility-related actin cytoskeletal structures: invadopodia and nascent cell-matrix adhesions (<xref ref-type="bibr" rid="bib86">Sung et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Hoshino et al., 2013</xref>). In our live imaging studies, we also frequently observed filopodia formation in close proximity to sites of exosome secretion and adhesion formation (<xref ref-type="bibr" rid="bib86">Sung et al., 2015</xref>). Here, we directly investigate the role of exosomes in filopodia formation and stability. In both cancer cells and primary rat neurons, we find that genetic inhibition of exosome biogenesis or secretion inhibits filopodia formation and stability. In neurons, the reduction of filopodia was accompanied by a decrease in dendritic spines and synapses, which are structures that develop from filopodia. Filopodial defects of exosome-inhibited cells were fully rescued by the add-back of purified small EVs (SEVs, containing exosomes) but not larger ectosome-type EVs (LEVs). Proteomic comparison of SEVs and LEVs purified from melanoma cells identified the TGF-β co-receptor endoglin as a cargo that is unique to the SEV fraction. Endoglin was found to promote filopodia formation by cancer cells, as well as the filopodia-dependent behaviors of cancer cell metastasis and 3D motility. A quantitative proteomic comparison of exosomes purified from control and endoglin-KD melanoma cells revealed that the filopodia regulatory transmembrane molecule thrombospondin type 1 domain containing 7A (THSD7A) is reduced in endoglin-KD exosomes. Further investigation revealed that THSD7A is present on both cancer cell and neuronal exosomes and that recombinant purified THSD7A is sufficient to rescue filopodia defects resulting from exosome inhibition in both cell types. THSD7A-induced filopodia formation was diminished in the presence of a chemical inhibitor of the small GTPase Cdc42. Altogether, we find that exosomes drive filopodia formation in multiple cell types by carrying the filopodia regulator THSD7A.</p><p>Authors’ Note: Throughout this paper, we use both the term ‘exosomes’ and ‘small extracellular vesicles (SEVs)’. ‘Exosomes’ is used when we have perturbed the endocytic pathway to specifically inhibit exosome biogenesis within MVE or secretion (via affecting docking of MVE with the plasma membrane) and can, therefore, attribute the biogenesis of those EVs to the endocytic pathway. ‘SEVs’ is used for purified EV preparations where we have isolated a heterogeneous population of EVs and cannot define their origin.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Exosome markers localize to filopodia</title><p>To visualize exosome association with cytoskeletal structures, we stained for CD63 in HT1080 fibrosarcoma cells, which form numerous filopodia. The cells were fixed and co-stained with phalloidin-Alexa Fluor 488 to visualize filamentous actin (F-actin) in filopodia. Confocal images of the cells show localization of CD63 puncta at the tips of filopodia (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, arrowheads). To observe the dynamic relationship between exosome secretion and filopodia formation, we utilized a live cell reporter that allows us to dynamically visualize the fusion of MVE with the plasma membrane, pHluorin-M153R-CD63-mScarlet (<xref ref-type="bibr" rid="bib88">Sung et al., 2020</xref>). pHluorin is a pH-sensitive form of GFP that is non-fluorescent at acidic pH inside late endosomes and fluoresces at neutral pH (<xref ref-type="bibr" rid="bib58">Miesenböck et al., 1998</xref>), such as occurs upon endosome-plasma membrane fusion, whereas mScarlet is a pH-insensitive red fluorescent protein (<xref ref-type="bibr" rid="bib8">Bindels et al., 2017</xref>) and can report on MVE movements within the cell. Using this probe stably expressed in HT1080 fibrosarcoma cells, we observed localization of MVEs at (red signal) and fusion with (yellow puncta) the plasma membrane immediately before or coincident with filopodia initiation (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="video" rid="fig1video1">Figure 1—video 1</xref>). Quantitative analysis of the timing of yellow fluorescence appearance at the plasma membrane revealed that exosome secretion occurred with a median time of 20 s before filopodia formation (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>). We also examined the localization of MVE markers to filopodia in primary cortical neurons by transiently transfecting neurons with the MVE docking factor GFP-Rab27b (<xref ref-type="bibr" rid="bib63">Ostrowski et al., 2010</xref>) along with mCherry as a cytoplasmic ‘filler’ to visualize cellular neuronal structures. Notably, GFP-Rab27b localized to both the base and tips of neuronal filopodia (<xref ref-type="fig" rid="fig1">Figure 1E and F</xref>), with more localized to the base than to the tips (63% vs 37%, <xref ref-type="fig" rid="fig1">Figure 1F</xref>). Together, both the cancer cell and neuron data suggest an association of MVEs and exosomes with filopodia.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Exosome markers localize to the base and tips of filopodia in cancer cells and cortical neurons.</title><p>(<bold>A</bold>) Representative confocal image of HT1080 cells stained with phalloidin-Alexa fluor 488 and CD63 shown in red. The red channel has been edited using brightness and contrast tools for ease of visibility. Note the localization of the exosome marker CD63 in extracellular deposits and at or near the tips of filopodia (arrowheads). Representative of 20 images. Scale bar is 10 mm in each panel. (<bold>B</bold>) Time series of pHluorin-M153R-CD63-mScarlet movie in HT1080 cells. Yellow arrowheads indicate fusion sites and yellow arrows indicate filopodia. Note a filopodium forming shortly after MVE fusion. (<bold>C</bold>) Representative kymographs showing MVE docking (red), fusion (yellow), and filopodia formation in HT1080 cells. Yellow arrowheads denote MVE fusion events, and black arrowheads denote the formation of a filopodium. Each pixel is 10 s x 0.2857 mm. (<bold>D</bold>) Quantification of the time elapsed between MVE fusion and filopodia formation. n=420 kymographs from 46 cells from three independent experiments (biological replicates). (<bold>E</bold>) Primary cortical neurons were co-transfected with GFP-Rab27b (green) and mCherry as a filler to visualize filopodia (red) on <italic>DIV</italic>5 and fixed for imaging on <italic>DIV</italic>6. SV2 negative staining (no signal) identifies these structures as filopodia instead of dendritic spines. Arrows in merged images indicate localization of GFP-Rab27b to tips and bases of filopodia. Scale bars = 5 µm. (<bold>F</bold>) Percent GFP-Rab27b localization to tips and bases of filopodia in 70 individual cortical neurons from three independent experiments (biological replicates). Red line indicates the median. Error bars, SEM. ns, not significant; * p&lt;0.05; ** p&lt;0.01; *** p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig1-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-101673-fig1-video1.mp4" id="fig1video1"><label>Figure 1—video 1.</label><caption><title>Visualization of exosome secretion and filopodia formation dynamics.</title><p>HT1080 cells stably expressing pHLuorin_M153R-CD63-mScarlet were seeded onto glass bottom MatTek plates and imaged live. Images were taken every 10 s.</p></caption></media></fig-group></sec><sec id="s2-2"><title>Exosomes promote filopodia formation and stability in cancer cells</title><p>To directly test whether exosomes affect filopodia formation and/or stability, shRNA targeting Rab27a or Hrs was expressed in B16F1 melanoma cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and B</xref>), a frequently used cell line for studying filopodia, and shRNA targeting Rab27a was expressed in HT1080 cells (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). Rab27a is a key factor controlling MVE docking at the plasma membrane, which allows intraluminal vesicles to be secreted as exosomes (<xref ref-type="bibr" rid="bib63">Ostrowski et al., 2010</xref>). The ESCRT-0 protein Hrs plays an important role in the biogenesis of intraluminal vesicles within MVEs (<xref ref-type="bibr" rid="bib17">Dixson et al., 2023</xref>; <xref ref-type="bibr" rid="bib93">Tamai et al., 2010</xref>). The exosome-enriched small EV (SEV) population was isolated by cushion density gradient ultracentrifugation (<xref ref-type="bibr" rid="bib43">Li et al., 2018</xref>), after isolation of large EVs by differential centrifugation from conditioned media (see Materials and methods). Consistent with current standards in the field (<xref ref-type="bibr" rid="bib46">Lötvall et al., 2014</xref>; <xref ref-type="bibr" rid="bib94">Théry et al., 2018</xref>; <xref ref-type="bibr" rid="bib106">Welsh et al., 2024</xref>), the EVs carried typical EV markers and were of the expected size and morphology by nanoparticle tracking analysis (NTA) and negative stain transmission electron microscopy (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C and E</xref>; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B and C</xref>). Quantitation by NTA of EVs isolated from conditioned media confirmed that B16F1 Rab27a- and Hrs-knockdown (KD) cells secrete fewer SEVs compared to control cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Consistent with a selective effect on MVE docking and biogenesis, these constructs had no effect on secretion of LEVs, which should contain primarily shed ectosomes (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Phalloidin staining of actin filaments in Rab27a- and Hrs-KD B16F1 cells revealed reduced numbers of filopodia compared with control B16F1 cells (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>). Similarly, inhibition of exosome secretion by Rab27a KD in HT1080 fibrosarcoma cells also led to a decrease in filopodia numbers (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D–F</xref>). Consistent with a specific role for exosomes in controlling filopodia dynamics, the addition of SEVs purified from control B16F1 cells to Hrs-KD B16F1 cells rescued the defect in filopodia numbers (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>). By contrast, there was no effect of LEVs on filopodia numbers. The addition of SEVs to B16F1 shScr control cells also increased filopodia number in a dose-dependent manner, while LEVs had no effect (<xref ref-type="fig" rid="fig2">Figure 2F</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Exosomes promote filopodia formation and stability in cancer cells.</title><p>(<bold>A</bold>) EVs secreted from equal numbers of control (shLacZ), Rab27a-KD, and Hrs-KD B16F1 cells over 48 hr were quantified using NanoSight particle tracking analysis (N=3 biological replicates). (<bold>B</bold>) Representative images of control (shLacZ), Hrs-KD, and Rab27a-KD B16F1 cells stained with rhodamine-phalloidin. Arrowheads show examples of filopodia. Images have been edited with brightness and contrast for ease of visibility. (<bold>C</bold>) Quantification of filopodia from images as in B (≥27 total cells per condition from three biological replicates). Filopodia number per 500 mm<sup>2</sup> cell area. (<bold>D</bold>) Representative images of filopodia in B16F1 control (shLacZ) and exosome-depleted (shHrs) cells treated for 18 hr with LEVs or SEVs isolated from control cells. Arrowheads show examples of filopodia. Images have been edited with brightness and contrast for ease of visibility. (<bold>E</bold>) Quantification of filopodia from images as in D (≥20 total cells per condition from three biological replicates). (<bold>F</bold>) Filopodia number in B16F1 shScr cells treated with indicated numbers of purified LEVs or SEVs, for 18 hr (≥25 total cells per condition from three biological replicates). (<bold>G</bold>) Control (shLacZ) and exosome-depleted (shHrs) B16F1 cells were transiently transfected with tdTomato-F-tractin to visualize filopodia formation. Live images were taken every 30 s for 15 min and newly formed filopodia were counted at each time point. Only filopodia that form and fully retract during the duration of the video were quantified. (≥20 total cells per type per biological replicate, from three biological replicates). (<bold>H</bold>) Lifetime of newly formed filopodia from G. Lifetime is defined as the time from first formation of the filopodia to full retraction. Bars represent mean and error bars are SEM. Scale bars in wide field and zoom insets = 10 mm. Error bars, SEM. ns, not significant; * p&lt;0.05; ** p&lt;0.01; *** p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Characterization of B16F1 cells and EV preparations.</title><p>(<bold>A</bold>) Western blot of Hrs-KD in B16F1 cells. (<bold>B</bold>) Western blot of Rab27a-KD in B16F1 cells. (<bold>C</bold>) Nanoparticle tracking analysis representative traces showing particle size distributions that correspond to the data for control SEVs and LEVs in <xref ref-type="fig" rid="fig2">Figure 2A</xref>. (<bold>D</bold>) Western blot of gradient fractions for SEVs prepared by the cushion density gradient (DG) method. TCL, total cell lysate. LEVs also run on gel. (<bold>E</bold>) TEM of negatively stained LEVs and SEVs prepared by the cushion-DG method. Scale bar = 200 nm in each image.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>PDF file containing the original western blots from <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig2-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata3"><label>Figure 2—figure supplement 1—source data 3.</label><caption><title>PDF file containing the original western blots from <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig2-figsupp1-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata4"><label>Figure 2—figure supplement 1—source data 4.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig2-figsupp1-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata5"><label>Figure 2—figure supplement 1—source data 5.</label><caption><title>PDF file containing the original western blots from <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig2-figsupp1-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata6"><label>Figure 2—figure supplement 1—source data 6.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig2-figsupp1-data6-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Characterization of HT1080 cells and EV preparations and comparison of graphing methods.</title><p>(<bold>A</bold>) WB of Rab27a KD in HT1080 cell lysates. (<bold>B</bold>) TEM of SEVs (purified by cushion DG) and LEVs from HT1080 cells. Scale bar = 200 nm in each image. (<bold>C</bold>) Secretion rates of SEVs from HT1080 cell lines (N=3). Nanoparticle tracking analysis traces of SEVs from shScr and shRab27a HT1080 cells showing size (diameter) distribution of SEVs and particles/mL/cell. (<bold>D</bold>) Representative images showing filopodia in control and Rab27a-KD H1080 cells. Images have been edited with brightness and contrast tools for ease of visibility. Scale bars in wide field and zoom insets = 10 mm. (<bold>E</bold>) Quantification of filopodia in control and Rab27a-KD HT1080 cell lines. ≥20 cells per condition per biological replicate, from three biological replicates. (<bold>F</bold>) Data from graph in E displayed as filopodia per cell. (<bold>G</bold>) Data in <xref ref-type="fig" rid="fig2">Figure 2C</xref> displayed as filopodia per cell. (<bold>H</bold>). Data from <xref ref-type="fig" rid="fig2">Figure 2E</xref> displayed as filopodia per cell. (<bold>I</bold>) Data from <xref ref-type="fig" rid="fig2">Figure 2F</xref> displayed as filopodia per cell. (<bold>J</bold>) Data from <xref ref-type="fig" rid="fig2">Figure 2G</xref> displayed as filopodia per cell. (<bold>K</bold>) Cell areas of cells used for quantification in <xref ref-type="fig" rid="fig2">Figure 2G</xref>. Error bars, SEM. ns, not significant; * p&lt;0.05; ** p&lt;0.01; *** p&lt;0.001.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>PDF file containing the original western blots from <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig2-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata2"><label>Figure 2—figure supplement 2—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig2-figsupp2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig2-figsupp2-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-101673-fig2-video1.mp4" id="fig2video1"><label>Figure 2—video 1.</label><caption><title>Live imaging of filopodia in B16F1 control and shHrs cells.</title><p>B16F1 cells stably expressing shHrs or control plasmid (shLacZ) were transiently transfected with tdTomato-fTractin and seeded onto PDL-coated glass bottom MatTek Plates 24 hr post-transfection. Live cells were imaged every 30 s for 15 min. Movies were inverted, de-noised, and brightness/contrast was adjusted to facilitate visualization of filopodia.</p></caption></media></fig-group><p>To determine whether exosome secretion affects filopodia formation and/or stability, live imaging of B16F1 cells expressing the actin marker tdTomato-F-tractin <xref ref-type="bibr" rid="bib77">Schell et al., 2001</xref> was performed. Analysis of the number of new filopodia formed over time, as well as the lifetime of those filopodia, revealed that Hrs-KD reduces both the formation (<xref ref-type="fig" rid="fig2">Figure 2G</xref>) and stability (<xref ref-type="fig" rid="fig2">Figure 2H</xref>) of filopodia (see also <xref ref-type="video" rid="fig2video1">Figure 2—video 1</xref>).</p><p>We quantified filopodia in tumor cells as ‘filopodia per cell area’ to match with corresponding primary neuron data (<xref ref-type="fig" rid="fig3">Figure 3</xref>), in which we had to plot filopodia per 100 μm length to account for the fact that the entire neuron body was too large to fit in a field of view. To address concerns about this graphing choice, we have included the data presented in <xref ref-type="fig" rid="fig2">Figure 2</xref> plotted as filopodia per cell (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2G–J</xref>). The data are highly similar, with the one exception being the de novo filopodia in shHrs-2 cells trending the same but not being statistically significant (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2J</xref>). It is possible that this data set is no longer significantly different than the control cells because the cell area of the shHrs-2 cells is slightly higher than that of control cells, although not significantly different.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Exosomes promote filopodia, spine, and synapse formation in cortical neurons.</title><p>Primary cortical neurons were co-transfected with plasmids for expression or inhibition of exosome regulatory molecules and mCherry (red) as a cytoplasmic filler to image neuronal protrusions, then fixed and immunostained with SV2 (pseudo-colored in cyan) to visualize synapses. Filopodia were identified as thin SV2-negative, mCherry-positive protrusions. Spines were identified as dendritic protrusions that co-localize with SV2. Synapses were identified as SV2-positive puncta present on both dendritic protrusions and dendritic shafts. (<bold>A, C</bold>) Representative images of primary rat cortical neurons co-transfected at DIV6 when filopodia typically form (<bold>A</bold>) or DIV12 when synapses typically form (<bold>C</bold>) with GFP or GFP-Rab27b (green, left images) and mCherry (red) and co-stained with SV2 (blue, right images). (<bold>B, D</bold>) Quantification of filopodia (DIV6), spine and synapse density (DIV12) from images as in A and C. (<bold>E–G</bold>) Images and analysis from neurons transfected with control shRNA (NTshRNA) or shRNAs against Rab27b (<bold>E</bold>) or Hrs (<bold>G</bold>) and immunostained for SV2. Quantification of filopodia (DIV6), spine and synapse density (DIV12) for Rab27b-KD (<bold>F</bold>) or Hrs-KD (<bold>H</bold>) neurons. (<bold>I, J</bold>) Rescue experiments. Control and KD neurons (as indicated) expressing shRNAs and mCherry were treated with purified SEVs on <italic>DIV</italic>5 for 24 hr at a dose of 200 EVs per neuron, then fixed and stained for SV2 at <italic>DIV</italic>6. Filopodia, spine, and synapse density were quantified from more than 30 primary or secondary dendritic shafts from three independent experiments (biological replicates) for each condition. Scale bars = 5 mm. Error bars, SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Exosome secretion enhances filopodia, spine, and synapse numbers in primary hippocampal neurons.</title><p>(<bold>A, B</bold>) Primary rat hippocampal neurons were co-transfected with GFP-Rab27b or GFP, and mCherry filler (red) on <italic>DIV</italic>5 and immunostained for SV2 (cyan) on <italic>DIV</italic>6. Overlay images showing localization of GFP-Rab27b at the base and tips of filopodia and quantification of percent GFP-Rab27b localization at tips and bases of filopodia in hippocampal neurons are shown in <xref ref-type="fig" rid="fig1">Figure 1E and F</xref>. (<bold>A</bold>) Representative mCherry and SV2 overlay images. (<bold>B</bold>) Quantification of filopodia, spine, and synapse density from images as in A. (<bold>C–F</bold>) Hippocampal neurons were transfected with NTshRNA or shRNAs against Rab27b (<bold>C, D</bold>) or Hrs (<bold>E, F</bold>) and immunostained for SV2 at <italic>DIV</italic>6 for filopodia analysis or <italic>DIV</italic>12 for spine and synapse analysis. Quantification of the number of filopodia, spines, and synapses for Rab27b-KD (<bold>D</bold>) or Hrs-KD (<bold>F</bold>) neurons. Filopodia, spine, and synapse density quantified from ≥30 primary or secondary dendritic shafts from three independent experiments (biological replicates) for each condition. Scale bar = 5 µm. Error bars, SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Analysis of exosome gene knockdown and SEV rescue in cortical neurons.</title><p>(<bold>A, B</bold>) Representative images of neurons co-transfected with NTshRNA, Hrs shRNA, or Rab27b shRNA, and mCerulean, as indicated, and immunostained for Hrs or Rab27b. Blue arrows indicate mCerulean-expressing neurons, which are the ones assumed to be cotransfected with shRNA and are quantitated for filopodia, spine, and synapse density. White arrows indicate non-mCerulean-expressing neurons. (<bold>C, D</bold>) Quantitation of Hrs (<bold>C</bold>) or Rab27b (<bold>D</bold>) immunofluorescence levels in mCerulean-expressing neurons for the indicated transfection conditions. (<bold>E–G</bold>) Analysis of SEVs purified from cortical neurons (CN). (<bold>E</bold>) Nanoparticle tracking analysis trace showing size distribution. (<bold>F</bold>) Western blot analysis of positive (TSG101, Flotillin-1, Alix) and negative (GM130) markers. (<bold>G</bold>) Negative stain TEM image. (<bold>H, I</bold>) Representative images of control and exosome-KD cortical neurons +/-addback of purified SEVs (+SEV). Arrows indicate filopodia. Scale bar = 5 mm. Quantitation is in <xref ref-type="fig" rid="fig3">Figure 3I and J</xref>. Error bars, SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>PDF file containing the original western blots from <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2F</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig3-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s2sdata2"><label>Figure 3—figure supplement 2—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig3-figsupp2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig3-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Exosomes promote filopodia and synapse formation in neurons</title><p>In neurons, filopodia formation is critical for the subsequent development of synapses as filopodia mature into postsynaptic specializations called dendritic spines. In primary rat neuron cultures, numerous filopodia are present on dendritic shafts at day in vitro (<italic>DIV</italic>)6, while dendritic spines are predominant around <italic>DIV</italic>12. To test whether exosomes control filopodia in neurons, we altered the expression of exosome regulators in primary rat hippocampal and cortical neurons. Both Rab27a and Rab27b regulate exosome secretion by respectively promoting MVE docking with the PM and regulating the anterograde movement of MVEs to the PM (<xref ref-type="bibr" rid="bib63">Ostrowski et al., 2010</xref>). However, in some cell types, one form of Rab27 is expressed more highly than the other, suggesting some possible redundant functions (<xref ref-type="bibr" rid="bib6">Barral et al., 2002</xref>). Since Rab27b is the predominant form of Rab27 protein present in the brain (<xref ref-type="bibr" rid="bib111">Zhao et al., 2002</xref>; <xref ref-type="bibr" rid="bib73">Ramalho et al., 2001</xref>), we overexpressed Rab27b in primary neurons. Cortical neurons overexpressing GFP-Rab27b exhibited a significant increase in the number of filopodia examined at <italic>DIV</italic>6, quantitated as thin protrusions that were negative for the synapse marker SV2 (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). This increase in filopodia density translated into an increased number of SV2-positive dendritic spines and synapses at DIV12 (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref>). A similar increase in filopodia, spine, and synapse density occurred in primary hippocampal neurons upon GFP-Rab27b expression (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref>).</p><p>To inhibit exosome secretion in primary cortical and hippocampal neurons, we knocked down Hrs or Rab27b by transient transfection of two different shRNAs along with mCerulean at least 48 hr prior to immunostaining. For both genes, shRNA-transfected neurons (recognized by mCerulean co-transfection) exhibited 40–60% reduction in protein expression analyzed by fluorescence intensity, compared to cells transfected with nontargeting shRNA (NTshRNA, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A–D</xref>). Analysis of immunostained cells revealed that loss of either Rab27b or Hrs in KD neurons led to a significant reduction in filopodia, spines, and synapse density compared to NTshRNA controls (<xref ref-type="fig" rid="fig3">Figure 3E-H</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C-F</xref>). To further confirm that the effect of gene KD on filopodia density was due to loss of exosome release, we performed rescue experiments by treating Rab27b- or Hrs-KD primary cortical neurons for 24 hr with SEVs isolated by differential centrifugation from <italic>DIV</italic>9 primary cortical neurons (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2E–G</xref>). LEVs were not tested due to the low recovery of LEVs from neuronal conditioned media. The dose of 200 SEVs per neuron was chosen based on the estimated SEV secretion rate from primary cortical neurons over the 24 hr time period of the assay. In the Rab27b-KD condition, SEV treatment fully rescued the filopodia number defects of untreated KD controls (<xref ref-type="fig" rid="fig3">Figure 3I</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2H</xref>). For the Hrs-KD condition, there was partial rescue in filopodia density upon SEV treatment (<xref ref-type="fig" rid="fig3">Figure 3J</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2H</xref>). These data indicate that - similar to cancer cells - endogenous exosomes secreted by neurons promote filopodia formation.</p></sec><sec id="s2-4"><title>Endoglin is an SEV cargo that promotes filopodia formation in cancer cells</title><p>EVs carry multiple bioactive protein cargoes. Because only SEVs but not LEVs were able to rescue or induce filopodia numbers in B16F1 melanoma cells (<xref ref-type="fig" rid="fig2">Figure 2</xref>), we identified unique SEV cargoes by running SEV and LEV lysates on an SDS-PAGE gel, staining it with colloidal Coomassie, extracting four bands that were enriched in the SEV lysates (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, arrowheads), and performing proteomic analysis of trypsin digests of the extracted protein bands. Our approach was validated by the presence of typical exosomal/SEV proteins CD63, LAMP1, and the ESCRT-1 protein Multivesicular Body Subunit 12B (MVB12B) in one of the unique bands analyzed from the SEV lane (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). In SEV lane bands 1 and 2, we identified the TGF-β co-receptor endoglin (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). A full list of proteins identified in the SEV-enriched bands is shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Western blot analysis confirmed that endoglin is enriched in SEVs compared to LEVs (<xref ref-type="fig" rid="fig4">Figure 4B</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Endoglin is an SEV-enriched cargo that promotes filopodia formation.</title><p>(<bold>A</bold>) Purified LEVs and SEVs were run on a colloidal blue-stained gel. Four arrows denote SEV bands that were cut and submitted for proteomics, along with notable proteins identified (see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> for the full proteomics results). (<bold>B</bold>) B16F1 total cell lysate (TCL), LEVs, and density gradient purified SEVs were run on an SDS-PAGE gel and probed by western blot for endoglin, and EV positive (HSP70, TSG101, flotillin-1, and CD63) and negative (GM130) markers. (<bold>C</bold>) Total cell lysate (TCL) and small EVs (SEVs) from endoglin-KD (shEng) and control (shScr) B16F1 cells were run on an SDS-PAGE gel and probed by western blot for endoglin, EV marker TSG101, and EV-negative marker GM130. (<bold>D</bold>) Representative images from control (shScr) or endoglin-KD (shEng) B16F1 cell lines incubated for 18 hr with no EVs (left panels), or with SEVs purified from control (+shScr SEVs) or shEng cell lines (+shEng SEVs) (right panels). Arrowheads indicate example filopodia. Scale bar = 10 mm. (<bold>E</bold>) Quantification of filopodia in control (shScr) and endoglin knockdown (shEng) cells treated with the indicated number of LEVs or SEVs for 18 hr (≥20 cells per condition per biological replicate, from three biological replicates). (<bold>F</bold>) Filopodia number in B16F1 control (shLacZ) or exosome-depleted (shHrs) cells treated with indicated numbers of LEVs, control (shScr) SEVs, or endoglin-KD (shEng1) SEVs for 18 hr. ≥20 cells per condition per biological replicate, from three biological replicates. Representative images for this experiment are shown in <xref ref-type="fig" rid="fig5">Figure 5E</xref>. (<bold>G, H</bold>) B16F1 cells were transfected with tdTomato-F-Tractin and imaged live every 30 s for 15 min. Only filopodia that form and fully retract during the duration of each video were quantified. (<bold>G</bold>) De novo filopodia formation. (<bold>H</bold>) Filopodia lifetime, defined as the time from initial filopodia formation to full retraction. Bars represent mean and error bars are SEM. (³25 total cells per type per biological replicate, from three biological replicates) ns, not significant; * p&lt;0.05; ** p&lt;0.01; *** p&lt;0.001.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>PDF file containing original blot for <xref ref-type="fig" rid="fig4">Figure 4A</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Original file for Coomassie blue gel displayed in <xref ref-type="fig" rid="fig4">Figure 4A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>PDF file containing the original western blots from <xref ref-type="fig" rid="fig4">Figure 4B</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig4-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4—source data 4.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4">Figure 4B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig4-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata5"><label>Figure 4—source data 5.</label><caption><title>PDF file containing the original western blots from <xref ref-type="fig" rid="fig4">Figure 4C</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig4-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata6"><label>Figure 4—source data 6.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig4-data6-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>KD of endoglin affects filopodia numbers but not EV numbers in B16F1 melanoma cells.</title><p>(<bold>A</bold>) Nanoparticle tracking analysis traces for B16F1 control (shScr) and endoglin-KD (shEng) SEVs. (<bold>B</bold>) SEV secretion rates from B16F1 shEng stable lines. N=5 biological replicates. (<bold>C</bold>) Representative western blot of Endoglin-KD in transient siRNA-transfected B16F1 cells. (<bold>D</bold>) Filopodia numbers in siRNA-transfected B16F1 cells (≥23 cells per condition per biological replicate, from three biological replicates). (<bold>E</bold>) Images from control and shHrs cells incubated with purified EV, corresponding to graph in <xref ref-type="fig" rid="fig4">Figure 4F</xref>. Scale bar in wide field and zoom insets = 10 mm. Error bars, SEM. ns, not significant; * p&lt;0.05; ** p&lt;0.01; *** p&lt;0.001.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>PDF file containing the original western blots from <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>HT1080 Endoglin-KD cells have reduced filopodia.</title><p>(<bold>A</bold>) Western blot of Endoglin KD in HT1080 cells. (<bold>B</bold>) Nanoparticle tracking analysis traces of SEVs purified from shScr and shEng HT1080 cells showing size distribution (diameter) of SEVs and particles/mL/cell (N=3 biological replicates). (<bold>C</bold>) SEV secretion rates of HT1080 shScr and shEng HT1080 cells. (<bold>D</bold>) Representative images of HT1080 shScr and shEng cells. Images have been edited with brightness and contrast for ease of visibility. Scale bar in wide field and zoom insets = 10 mm. (<bold>E</bold>) Quantitation of filopodia density for control and shEng HT1080 cells.≥20 cells per condition per biological replicate, from four biological replicates. Error bars, SEM. ns, not significant; * p&lt;0.05; ** p&lt;0.01; *** p&lt;0.001.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>PDF file containing the original western blots from <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig4-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s2sdata2"><label>Figure 4—figure supplement 2—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig4-figsupp2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig4-figsupp2-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-101673-fig4-video1.mp4" id="fig4video1"><label>Figure 4—video 1.</label><caption><title>Live imaging of filopodia in B16F1 control and shEng cells.</title><p>B16F1 cells stably expressing shEng or control plasmid (shScr) were transiently transfected with tdTomato-fTractin and seeded onto PDL-coated glass bottom MatTek plates 24 hr post-transfection. Live cells were imaged every 30 s for 15 min. Movies were inverted and brightness/contrast was adjusted to facilitate visualization of filopodia.</p></caption></media></fig-group><p>Endoglin is a TGF-β co-receptor that regulates multiple processes relevant to motility and filopodia, including cellular signaling, adhesion, and cytoskeletal regulation (<xref ref-type="bibr" rid="bib14">Cheifetz et al., 1992</xref>; <xref ref-type="bibr" rid="bib60">Nassiri et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">Rossi et al., 2019</xref>; <xref ref-type="bibr" rid="bib78">Schoonderwoerd et al., 2020</xref>). To test whether endoglin regulates filopodia formation, we stably expressed endoglin-targeting shRNAs in B16F1 melanoma cells and confirmed that endoglin levels are reduced in both SEVs and cells (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Compared with control cells, stable endoglin-KD cells exhibit a reduction in filopodia number (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>) but no significant effect on SEV release from cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A and B</xref>). Likewise, transient KD of endoglin in B16F1 cells also leads to a significant reduction in filopodia numbers (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C and D</xref>). Whereas the addition of LEVs to stable endoglin-KD cells has little effect on filopodia numbers, treatment with control SEVs fully rescues the filopodia number defects of endoglin-KD cells (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>). Consistent with endoglin being a key SEV cargo that controls filopodia, add-back of endoglin-KD SEVs does not rescue the filopodia defects of endoglin-KD cells (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>). Furthermore, control - but not endoglin-KD - SEVs also rescue filopodia defects of exosome-inhibited B16F1 Hrs-KD cells (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>). To determine whether endoglin selectively controls filopodia formation or stability, we performed live imaging of endoglin-KD B16F1 cells. We found a specific defect of endoglin-KD cells in de novo filopodia formation (<xref ref-type="fig" rid="fig4">Figure 4G</xref>) with no change in filopodia lifetime (<xref ref-type="fig" rid="fig4">Figure 4H</xref>, see also <xref ref-type="video" rid="fig4video1">Figure 4—video 1</xref>). These data suggest that endoglin specifically affects filopodia formation, whereas additional exosome cargoes may affect filopodia lifetime, since Hrs-KD cells had a defect in both filopodia formation and lifetime (<xref ref-type="fig" rid="fig2">Figure 2G and H</xref>). Finally, we assessed the role of endoglin in filopodia formation in HT1080 fibrosarcoma cells. Similar to B16F1 cells, KD of endoglin in HT1080 cells reduced filopodia numbers (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A–E</xref>). These data suggest that endoglin and/or endoglin-regulated cargoes carried by exosomes have important functions in controlling filopodia dynamics.</p></sec><sec id="s2-5"><title>Endoglin promotes cancer cell metastasis and cell motility</title><p>We previously observed that exosome secretion is critical for metastasis and directional migration of cancer cells in chick embryos (<xref ref-type="bibr" rid="bib86">Sung et al., 2015</xref>; <xref ref-type="bibr" rid="bib87">Sung and Weaver, 2017</xref>). Since filopodia have been implicated in both of these behaviors (<xref ref-type="bibr" rid="bib52">Mattila and Lappalainen, 2008</xref>; <xref ref-type="bibr" rid="bib2">Arjonen et al., 2011</xref>), we tested the role of endoglin in promoting cancer metastasis in this model. The chick embryo chorioallantoic membrane (CAM) model has been established as an effective way to study experimental metastasis by intravenous injection of tumor cells (<xref ref-type="bibr" rid="bib66">Palmer et al., 2011</xref>). To seed tumor cells at metastatic sites, we injected fluorescently labeled control and endoglin KD HT1080 cells intravascularly. After 4 days, we harvested and imaged the chick CAM to visualize metastatic cells and colonies (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Many cancer cells and colonies were present in the CAM from shScr control cells. By contrast, CAMs from chick embryos injected with endoglin-KD HT1080 cells had reduced numbers of individual metastatic cancer cells and colonies (<xref ref-type="fig" rid="fig5">Figure 5B–D</xref>). Furthermore, there was an increased number of large colonies, which is a phenotype typically observed in cells with defects in migration away from growing colonies (<xref ref-type="fig" rid="fig5">Figure 5E</xref>; <xref ref-type="bibr" rid="bib86">Sung et al., 2015</xref>; <xref ref-type="bibr" rid="bib112">Zijlstra et al., 2008</xref>; <xref ref-type="bibr" rid="bib67">Palmer et al., 2014</xref>). This phenotype is similar to that which we previously observed with Rab27a-KD HT1080 cells (<xref ref-type="bibr" rid="bib86">Sung et al., 2015</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Exosomal endoglin controls motility and metastatic colony formation.</title><p>(<bold>A</bold>) Cartoon diagram of metastatic colony assay in avian embryos. On day 0, fluorescent HT1080 cells were injected (100,000 cells per egg) into the vein of the chicken embryo. On day 4, the egg was opened, the embryo was sacrificed, and a circular tool was used to punch holes through the shell. The chorioallantoic membrane (CAM) was peeled away from the shell, placed on a glass slide with a coverslip, and immediately imaged. The cartoon was created using <ext-link ext-link-type="uri" xlink:href="https://biorender.com/o3qeu33">BioRender.com</ext-link>. (<bold>B</bold>) Representative low power wide field images of colony formation in the CAM. Scale bar = 200 mm. (<bold>C</bold>) Representative high-power wide field images of colony formation in the CAM. Scale bar = 100 mm. (<bold>D, E</bold>) Quantification of CAM colony number (<bold>D</bold>) and size (<bold>E</bold>) from high-power images as in C. 4–7 eggs were harvested per replicate for each condition for three biological replicates. (<bold>D</bold>) Colony number is graphed per field of view using 25–30 fields of view per egg. (<bold>E</bold>) Quantification of the percent of large (≥5000 mm<sup>2</sup>) colonies formed by control and shEng HT1080 cells. (<bold>F</bold>) 3D invasion in collagen. HT1080 cell spheroids were seeded in collagen gels and imaged for 8 hr. Invasion is quantified as fold area increase in the size of each spheroid over 8 hr. Scale bar = 100 mm. Error bars, SEM. ns, not significant; *p&lt;0.05; ** p&lt;0.01; *** p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig5-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-101673-fig5-video1.mp4" id="fig5video1"><label>Figure 5—video 1.</label><caption><title>Endoglin controls 3D migration in type I collagen.</title><p>The indicated HT1080 cell types were induced to form spheroids and then mixed into 3D type I collagen. Spheroids were imaged every 30 min for 8 hr. Scale bar = 100 mm.</p></caption></media></fig-group><p>To determine whether alterations in exosomes were responsible for the effect of endoglin in vivo, we tested whether coinjection of SEVs with the cells could rescue the metastatic defects of endoglin-KD cells. The number of SEVs that were injected with cells was determined using the estimated SEV secretion rate calculated from nanoparticle tracking analysis (NTA) data of 9.28 SEVs per cell per hour for HT1080 control cells. Since the chick CAM experiment was conducted over a period of 96 hr, and each injection contained 100,000 cells, we used 89 million SEVs per injection. Indeed, coinjection of SEVs led to a full rescue of the endoglin-KD phenotype, both increasing the number of metastatic colonies and decreasing the number of large colonies (<xref ref-type="fig" rid="fig5">Figure 5B–E</xref>).</p><p>Given the known role of filopodia in directed cell migration (<xref ref-type="bibr" rid="bib34">Jacquemet et al., 2015</xref>) and the presence of large, potentially nonmotile, colonies formed by endoglin-KD cells in the chick CAM, we hypothesized that endoglin-KD cells would have a defect in cellular migration. To test this possibility, control and endoglin-KD HT1080 cells were allowed to form spheroids and then embedded in 3D type I collagen. Movies were taken to observe and quantitate cell migration away from the spheroids (<xref ref-type="video" rid="fig5video1">Figure 5—video 1</xref>). Comparison of the spheroid area increase after 8 hr, including migration of individual cells away from the spheroids, revealed that endoglin-KD cells indeed have a defect in 3D cell migration compared to controls. This migratory defect was rescued by re-expression of WT endoglin in the KD cells, confirming that it was not due to an off-target effect of the shRNA (<xref ref-type="fig" rid="fig5">Figure 5F</xref>, <xref ref-type="video" rid="fig5video1">Figure 5—video 1</xref>).</p></sec><sec id="s2-6"><title>Endoglin controls levels of the filopodia regulator THSD7A in cancer cell SEVs</title><p>Endoglin is not expressed in neurons (<xref ref-type="bibr" rid="bib51">Matsubara et al., 2000</xref>); therefore, it could not be a universal filopodia regulator. In addition, as a TGFβ coreceptor, it is difficult to imagine how endoglin as an EV cargo could directly induce filopodia formation by recipient cells. However, endoglin interacts with numerous proteins, including TGFβ receptors Alk1 and Alk5, TGFβ family ligand BMP9, and α5β1 integrin, and could potentially alter their sorting into exosomes (<xref ref-type="bibr" rid="bib14">Cheifetz et al., 1992</xref>; <xref ref-type="bibr" rid="bib78">Schoonderwoerd et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">Barbara et al., 1999</xref>; <xref ref-type="bibr" rid="bib36">Jonker, 2014</xref>; <xref ref-type="bibr" rid="bib95">Tian et al., 2012</xref>). Thus, we hypothesized that endoglin could promote filopodia formation by carrying a key filopodia-inducing cargo into exosomes. Surprisingly, Western blot analysis of control and endoglin-KD SEVs did not reveal reductions in several candidate endoglin binding partners in KD SEVs, including TGF-β1, Alk1, or β1 integrin (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). As BMP9 is the only TGFβ family member reported to directly bind to endoglin (<xref ref-type="bibr" rid="bib13">Castonguay et al., 2011</xref>), we also tested whether BMP9 could affect filopodia formation. Contrary to expectation, purified BMP9 did not rescue the defect in filopodia formation by endoglin-KD cells and instead decreased filopodia numbers in control shScr cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). We also tested whether the addition of TGF-β1 or coating the culture surfaces with fibronectin might rescue the filopodial defect of endoglin-KD cells. While both of those ligands slightly enhanced the number of filopodia in control cells, there was no effect on endoglin-KD cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C and D</xref>).</p><p>To determine whether endoglin may regulate the transport of any novel proteins into exosomes, we performed a quantitative proteomic comparison between SEVs purified from control and endoglin-KD B16F1 cells. Equal amounts of protein extracted from the SEVs were subjected to isobaric tagging for relative and absolute quantitation (iTRAQ) and mass spectrometry analysis (<xref ref-type="bibr" rid="bib56">Mertins et al., 2012</xref>; <xref ref-type="bibr" rid="bib75">Ross et al., 2004</xref>). Consistent with our western blot results (Fig. S7A), the proteomics data showed no significant differences in the expression of any integrins or TGFβ family ligands or receptors (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Analysis of the data further revealed only two proteins that were significantly lower in both endoglin KD1 and KD2 samples compared to control samples (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>), endoglin and the extracellular matrix (ECM) protein thrombospondin type 1 domain containing 7 a protein (THSD7A).</p><p>THSD7A is a transmembrane protein that is known to be expressed in endothelial cells, neurons, and kidney podocytes (<xref ref-type="bibr" rid="bib30">Herwig et al., 2019</xref>; <xref ref-type="bibr" rid="bib41">Kuo et al., 2011</xref>; <xref ref-type="bibr" rid="bib45">Liu et al., 2016</xref>; <xref ref-type="bibr" rid="bib102">Wang et al., 2010</xref>). Interestingly, although little is known about this protein, a soluble form of THSD7A was reported to promote filopodia formation in endothelial cells (<xref ref-type="bibr" rid="bib41">Kuo et al., 2011</xref>). Additionally, THSD7A has been shown to be aberrantly expressed in a variety of cancers and autoantibodies against THSD7A are a frequent cause of a paraneoplastic autoimmune kidney disease, secondary membranous nephropathy (<xref ref-type="bibr" rid="bib33">Hou et al., 2017</xref>; <xref ref-type="bibr" rid="bib82">Stahl et al., 2017</xref>; <xref ref-type="bibr" rid="bib104">Wang et al., 2019</xref>). Autoantibodies against THSD7A are also a cause of idiopathic (primary) membranous nephropathy (<xref ref-type="bibr" rid="bib96">Tomas et al., 2014</xref>).</p><p>To validate our finding that THSD7A levels are downregulated in SEVs from endoglin-KD cancer cells, we performed Western blot analysis of control and endoglin-KD SEVs from B16F1 and HT1080 cells (<xref ref-type="fig" rid="fig6">Figure 6A, B</xref>). Detection of THSD7A in B16F1 SEVs necessitated using native gels and thus endoglin and SEV marker CD63 ran at a significantly higher molecular weight (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Indeed, THSD7A was present on control SEVs and was reduced on endoglin-KD SEVs purified from either cell line. THSD7A was also present on SEVs isolated from primary cortical neurons (<xref ref-type="fig" rid="fig6">Figure 6C</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Exosomal endoglin promotes filopodia formation through THSD7A.</title><p>(<bold>A</bold>) Native gel Western blot of B16F1 SEVs. (<bold>B</bold>) Standard western blot of HT1080 SEVs. (<bold>C</bold>) Western blot of cortical neuron total cell lysate (TCL) and SEVs. (<bold>D</bold>) Representative images and quantitation of filopodia number in control (lipofectamine) and THSD7A-mScarlet-transfected HT1080 cells. Arrowheads indicate THSD7A at the ends of filopodia (white arrowheads) or in extracellular deposits (red arrowheads). Scale bars in wide field and zoom insets = 10 mm. (<bold>E</bold>) (Left) Western blot of control shRNA (NTC) and shTHSD7A (C-04, C05, C-06) - expressing HT1080 cell lines. Vinculin is used as a loading control and numbers below the blot indicate normalized THSD7A levels. (Right) Filopodia counts in control and shTHSD7A HT1080 cells. ≥20 cells per condition per biological replicate, from three biological replicates. (<bold>F</bold>) THSD7A coated coverslips rescue filopodia defect in shEng B16F1 and HT1080 cells.≥20 cells per condition per biological replicate, from three biological replicates. (<bold>G, H</bold>) Cortical neurons were transfected with a FLAG-THSD7A expression vector (<xref ref-type="bibr" rid="bib41">Kuo et al., 2011</xref>) or vector control, fixed, and stained with an antibody against THSD7A, and imaged by confocal microscopy. (<bold>G</bold>) Representative images. Arrows indicate THSD7A localization to the tips of filopodia. Scale bar = 5 mm. (<bold>H</bold>) Quantification of filopodia in neurons expressing FLAG-THSD7A or control vector. n=42 neurons from three separate experiments (biological replicates). (<bold>I</bold>) Rescue of filopodia numbers in shHrs neurons plated on dishes coated with various concentrations of recombinant human THSD7A, as indicated. Error bars, SEM. ns, not significant; * p&lt;0.05; ** p&lt;0.01; *** p&lt;0.001.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>PDF file containing the original western blots and Ponceau stain from <xref ref-type="fig" rid="fig6">Figure 6A</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig6-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Original files for western blot and Ponceau analysis displayed in <xref ref-type="fig" rid="fig6">Figure 6A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig6-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>PDF file containing the original western blots from <xref ref-type="fig" rid="fig6">Figure 6B</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig6-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata4"><label>Figure 6—source data 4.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig6">Figure 6B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig6-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata5"><label>Figure 6—source data 5.</label><caption><title>PDF file containing the original western blots from <xref ref-type="fig" rid="fig6">Figure 6C</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig6-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata6"><label>Figure 6—source data 6.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig6">Figure 6C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig6-data6-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata7"><label>Figure 6—source data 7.</label><caption><title>PDF file containing the original western blots from <xref ref-type="fig" rid="fig6">Figure 6E</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig6-data7-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata8"><label>Figure 6—source data 8.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig6">Figure 6E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig6-data8-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Analysis of candidate EV cargoes for rescue of filopodia defects in shEng cells.</title><p>(<bold>A</bold>) Western blot showing b1-integrin, TGFb1, ALK1 levels in control (shScr) and endoglin-KD (shEng) B16F1 SEVs. (<bold>B</bold>) Filopodia density analysis of B16F1 shScr and shEng cells treated with BMP-9.≥20 cells per condition per biological replicate, from three biological replicates. (<bold>C</bold>) Filopodia density analysis of B16F1 shScr and shEng cells treated with TGFb1.≥20 cells per condition per biological replicate, from three biological replicates. (<bold>D</bold>) Filopodia density analysis of B16F1 shScr and shEng cells plated on 20 µg/ml fibronectin (FN) or 100 µg/mL poly-D-lysine (PDL). ≥20 cells per condition per biological replicate, from three biological replicates. (<bold>E</bold>) Filopodia density analysis of B16F1 shScr and shEng cells plated on PDL or 2 µg/mL rhTHSD7A for the indicated time points, then fixed and stained for filopodia. ≥20 cells per condition per biological replicate, from biological replicates.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>PDF file containing the original western blots from <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig6-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata2"><label>Figure 6—figure supplement 1—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig6-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig6-figsupp1-v1.tif"/></fig></fig-group><p>To test whether THSD7A regulates filopodia formation in our system, we overexpressed THSD7A tagged with mScarlet fluorescent protein in HT1080 cells. THSD7A-mScarlet localized to the tips of filopodia as well as in extracellular deposits similar to those we have previously observed with exosomes (<xref ref-type="fig" rid="fig6">Figure 6</xref>, <xref ref-type="bibr" rid="bib86">Sung et al., 2015</xref>; <xref ref-type="bibr" rid="bib88">Sung et al., 2020</xref>). Notably, expression of THSD7A-mScarlet increased filopodia numbers in HT1080 cells (<xref ref-type="fig" rid="fig6">Figure 6D</xref>, graph). To further test the role of THSD7A in filopodia formation, we knocked down THSD7A in HT1080 cells using 3 different targeting shRNAs (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Analysis of filopodia numbers revealed a significant reduction in THSD7A-KD cells (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). To determine the role of THSD7A in filopodia regulation by endoglin, we plated control and endoglin-KD cells on coverslips coated with various concentrations of recombinant THSD7A protein. Indeed, recombinant human THSD7A fully rescued the filopodia defects of endoglin-KD for both HT1080 and B16F1 melanoma cells (<xref ref-type="fig" rid="fig6">Figure 6F</xref>).</p><p>Our typical filopodia analysis is performed after culturing cells for 48 hr on coverslips. To determine whether THSD7A can boost filopodia formation in a short time period as would be expected for a direct regulator, we plated cells on coverslips coated with poly-D-Lysine or recombinant THSD7A for 15 min-2 hr and found that recombinant THSD7A fully rescued the filopodia defect of endoglin-KD cells at the shortest timepoint of 15 min (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref>).</p><p>Although neurons do not express endoglin (<xref ref-type="bibr" rid="bib51">Matsubara et al., 2000</xref>), they do rely on exosomes for filopodia induction (<xref ref-type="fig" rid="fig3">Figure 3</xref>) and they express THSD7A (<xref ref-type="fig" rid="fig6">Figure 6C</xref>, <xref ref-type="bibr" rid="bib45">Liu et al., 2016</xref>; <xref ref-type="bibr" rid="bib103">Wang et al., 2011</xref>). To test the role of THSD7A in neuronal filopodia formation, we transiently expressed FLAG-tagged THSD7A in cortical neurons. Immunostaining analysis revealed that neurons expressing FLAG-THSD7A had localization of the THSD7A to filopodia tips and increased numbers of filopodia compared to vector control transfected neurons (<xref ref-type="fig" rid="fig6">Figure 6G and H</xref>). In addition, plating exosome-inhibited Hrs-KD neurons on recombinant THSD7A-coated coverslips fully rescued filopodia formation in a dose-dependent manner (<xref ref-type="fig" rid="fig6">Figure 6I</xref>). These data indicate that THSD7A is an important filopodia-inducing SEV cargo in diverse cell types.</p></sec><sec id="s2-7"><title>Endoglin regulates THSD7A trafficking into cancer cell exosomes</title><p>Based on the observed decreases in THSD7A expression in SEVs from endoglin-KD cancer cells (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>) and the role of endoglin as a co-receptor that traffics through endosomes, we hypothesized that endoglin may alter the trafficking of THSD7A to SEVs/exosomes. To test this hypothesis, we first investigated the relative abundance of THSD7A in control and endoglin-KD HT1080 cells and SEVs by Western blot analysis. Indeed, lysates of endoglin-KD cells had increased levels of THSD7A compared to control cells, while endoglin KD SEVs had decreased levels of THSD7A (<xref ref-type="fig" rid="fig7">Figure 7A–C</xref>). These data are consistent with an alteration in THSD7A trafficking in endoglin-KD cells rather than a decrease in the overall protein expression of THSD7A. We performed a rescue experiment, in which endoglin-KD cells were stably transfected with either wild-type endoglin (+WT) or an empty vector control (+vector). Interestingly, we found that the high cellular levels of THSD7A in endoglin-KD cells were decreased with re-expression of WT endoglin (<xref ref-type="fig" rid="fig7">Figure 7A–C</xref>). These changes were paralleled by increased THSD7A in +WT endoglin rescue SEVs. In parallel, expression of WT endoglin in HT1080 endoglin KD cells also rescues filopodia defects (<xref ref-type="fig" rid="fig7">Figure 7D</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Endoglin controls THSD7A trafficking to exosomes.</title><p>(<bold>A</bold>) Western blot analysis of total cell lysates (TCL) and SEVs from HT1080 control and shEng cells +/-rescue with WT endoglin or control expression vectors. The figure was made from cropped images of membranes to remove irrelevant lanes. (<bold>B</bold>) Quantification of endoglin expression (normalized to flotillin-1 as a loading control, and relative to shScr control) from triplicate Western blots as in A. (<bold>C</bold>) Quantification of THSD7A expression (relative to flotillin-1 as a loading control, and relative to shScr control) from triplicate Western blots as in A. (<bold>D</bold>) Quantification of filopodia in HT1080 control cells and shEng cells rescued with WT endoglin expression. N=3, at least 30 total cells per condition. (<bold>E</bold>) Representative confocal images of THSD7A-mScarlet-expressing control and shEng HT1080 cells immunostained for CD63. Box 1 shows extracellular THSD7A and CD63 deposits. Box 2 shows intracellular CD63-positive MVEs. For both boxes, the zoomed images have been adjusted for brightness and contrast (to equivalent levels for control and shEng cells) for easy visualization. Note that the overlap of THSD7A (magenta) and CD63 (green) gives a white signal, pointed out with white arrowheads in the shEng merged image in Zoom 2. Scale bar is 10 mm in wider field view and 5 mm in zoom insets. (<bold>F</bold>) Quantification of colocalization of internal CD63 and mScarlet signals in HT1080 cells from nonadjusted images.≥20 cells per condition per biological replicate, from three biological replicates. Error bars, SEM. ns, not significant; * p&lt;0.05; ** p&lt;0.01; *** p&lt;0.001.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>PDF file containing the original western blots from <xref ref-type="fig" rid="fig7">Figure 7A</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig7-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig7">Figure 7A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig7-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig7-v1.tif"/></fig><p>To determine whether endoglin might affect the trafficking of THSD7A to MVE, we expressed THSD7A-mScarlet in control and endoglin-KD HT1080 cells and co-stained with an anti-CD63 antibody to label MVEs as well as with phalloidin to visualize the cell boundary (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). Consistent with less THSD7A being secreted in EVs, there was much less extracellular THSD7A surrounding endoglin-KD cells compared to control cells (<xref ref-type="fig" rid="fig7">Figure 7E</xref>, Zoom 1). In addition, we observed increased accumulation of THSD7A in CD63-positive MVE in endoglin-KD cells compared to control cells (<xref ref-type="fig" rid="fig7">Figure 7E</xref>, Zoom 2). Thus, the percentage of intracellular THSD7A colocalized with CD63-positive compartments was increased in KD cells compared with control cells (<xref ref-type="fig" rid="fig7">Figure 7F</xref>), suggesting increased accumulation in endolysosomal compartments. These data suggest that endoglin alters the endolysosomal trafficking of THSD7A, leading to decreased THSD7A release in exosomes.</p></sec><sec id="s2-8"><title>Cdc42 activity is required for filopodia induction by THSD7A and endoglin</title><p>Finally, we sought to identify downstream signaling pathways responsible for modulating filopodia dynamics via exosomal endoglin and THSD7A. To assess any changes in TGFβ signaling, we assayed for downstream Smad phosphorylation and did not detect any increases from treatment with rhTHSD7A coating (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). Because the small GTPase Cdc42 has been shown to regulate filopodia across diverse cell types (<xref ref-type="bibr" rid="bib9">Blake and Gallop, 2023</xref>; <xref ref-type="bibr" rid="bib62">Nobes and Hall, 1995</xref>), we hypothesized that THSD7A and endoglin might induce filopodia formation via Cdc42 activation. To test this hypothesis, we determined whether filopodia induced by THSD7A could be inhibited with a specific Cdc42 inhibitor or, conversely, whether expressing a constitutively active form of Cdc42 could rescue the filopodia defects of endoglin-KD cells (<xref ref-type="fig" rid="fig8">Figure 8</xref>). The Q61L mutant of Cdc42 (Cdc42-Q61L) is a dominant active, GTPase-defective, GTP-bound form of Cdc42 (<xref ref-type="bibr" rid="bib113">Ziman et al., 1991</xref>). ML141 has been identified as a non-competitive inhibitor of Cdc42 and effectively inhibits Cdc42-Q61L (<xref ref-type="bibr" rid="bib91">Surviladze et al., 2010</xref>). Consistent with a role for Cdc42 activation in basal filopodia formation by our cells, we found that treatment of control HT1080 cells with the ML141 inhibitor significantly reduces filopodia numbers (<xref ref-type="fig" rid="fig8">Figure 8</xref>). Likewise, the rescue of filopodia numbers that occurs when endoglin-KD cells are seeded on THSD7A-coated coverslips is ablated when combined with ML141 treatment (<xref ref-type="fig" rid="fig8">Figure 8</xref>). In addition, the filopodia defect of endoglin-KD cells is rescued by expression of Cdc42-Q61L. The filopodia induction by Cdc42-Q61L in HT1080 endoglin-KD cells was inhibited by ML141, confirming that ML141 acts to inhibit Cdc42 at the doses and times used (<xref ref-type="fig" rid="fig8">Figure 8</xref>).</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Filopodia formation induced by THSD7A depends on Cdc42 activity.</title><p>Control and endoglin-KD HT1080 cells were plated on coverslips coated with poly-D-lysine (PDL) or THSD7A. In some cases, cells were treated with the Cdc42 inhibitor ML141 (10 µM) or transfected with the dominant active Cdc42 mutant Q61L, as indicated.≥20 cells per condition per biological replicate, from three biological replicates. Error bars, SEM. ns, not significant; * p&lt;0.05; ** p&lt;0.01; *** p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Total cell lysates of B16F1 cells were seeded on PDL +/-THSD7 A and treated with or without TGF-b1 and inhibitor.</title><p>Cell lysates were probed for phospho-Smad and total Smad levels. Representative of three blots. Error bars, SEM. ns, not significant; * p&lt;0.05; ** p&lt;0.01; *** p&lt;0.001.</p><p><supplementary-material id="fig8s1sdata1"><label>Figure 8—figure supplement 1—source data 1.</label><caption><title>PDF file containing the original western blots from <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig8-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig8s1sdata2"><label>Figure 8—figure supplement 1—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101673-fig8-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig8-figsupp1-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Filopodia are adhesive cellular structures that control cell polarization, chemical and physical sensing, and motility. Using a genetic inhibition and rescue approach, we found that autocrine secretion of exosomes controls the number and stability of filopodia in both cancer cells and neurons. The decrease in filopodia in neurons was paralleled by a similar decrease in synapse formation. In cancer cells, we identified endoglin as a key SEV cargo and molecular regulator of this process, controlling filopodia formation, cell migration, and metastasis of cancer cells via SEVs. As endoglin seemed unlikely to directly induce filopodia formation and is not present in neurons, we performed quantitative proteomics of control and endoglin-KD SEVs and identified the transmembrane ECM protein THSD7A as regulated in cancer cell SEVs by endoglin. In neurons, THSD7A was also present on SEVs and regulated filopodia formation. Indeed, purified THSD7A was able to rescue filopodia defects in both endoglin-KD cancer cells and exosome-inhibited neurons. Finally, we found that Cdc42 activity is important for filopodia formation controlled by endoglin and THSD7A. Altogether, we identify THSD7A carried by exosomes as a key controller of filopodia formation in diverse cell types and further identify endoglin as a key regulator of THSD7A secretion in exosomes in cancer cells. These data suggest a new model for filopodia induction via secreted exosomes (<xref ref-type="fig" rid="fig9">Figure 9</xref>).</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Model of exosome-induced filopodia formation.</title><p>(<bold>A</bold>) In tumor cells, endoglin and THSD7A are trafficked into intralumenal vesicles (ILV) in multivesicular endosomes (MVEs) for secretion. Inhibiting the exosome biogenesis pathway by blocking Hrs or inhibiting MVE docking by blocking Rab27a subsequently reduces exosome secretion and filopodia formation. SEVs carrying THSD7A can induce filopodia on target cells via Cdc42, leading to increased cell motility and metastasis. When endoglin levels are lowered (such as by KD), THSD7A is retained inside cells in CD63-positive endosomes, and its levels in SEVs are greatly decreased. The drop in THSD7A levels in endoglin-KD EVs could be due either to a lack of trafficking into ILVs or, alternatively, enhanced lysosomal degradation of THSD7A-containing MVEs. Given that THSD7A accumulates in CD63-positive endolysosomal compartments in endoglin-KD cells (<xref ref-type="fig" rid="fig7">Figure 7E and F</xref>), the latter possibility seems more likely. The cartoon was created using <ext-link ext-link-type="uri" xlink:href="https://biorender.com/r10h575">BioRender.com</ext-link>. (<bold>B</bold>) In primary neurons, exosome biogenesis is controlled by the formation of ILVs by Hrs and MVE docking is controlled by Rab27b. Knockdown of either of these proteins results in reduced formation of filopodia, dendritic spines, and synapses in both cortical and hippocampal neurons. Similar to cancer cells, THSD7A is carried in neuronal SEVs and induces filopodia. The cartoon was created using <ext-link ext-link-type="uri" xlink:href="https://biorender.com/7ljyfta">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101673-fig9-v1.tif"/></fig><p>Exosomes have been shown to regulate cell migration and invasion in a variety of contexts (<xref ref-type="bibr" rid="bib40">Kriebel et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Majumdar et al., 2021</xref>; <xref ref-type="bibr" rid="bib86">Sung et al., 2015</xref>; <xref ref-type="bibr" rid="bib89">Sung et al., 2021</xref>; <xref ref-type="bibr" rid="bib87">Sung and Weaver, 2017</xref>; <xref ref-type="bibr" rid="bib88">Sung et al., 2020</xref>). In order for cells to migrate, they must form adhesive and sensing cytoskeletal structures, including lamellipodia, focal complexes, invadopodia, and filopodia. Our finding that exosomes promote filopodia formation adds to our previous findings that exosome secretion promotes the formation of nascent adhesions and invadopodia (<xref ref-type="bibr" rid="bib86">Sung et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Hoshino et al., 2013</xref>) and likely stabilizes lamellipodia (<xref ref-type="bibr" rid="bib12">Bryce et al., 2005</xref>; <xref ref-type="bibr" rid="bib85">Sung et al., 2011</xref>; <xref ref-type="bibr" rid="bib81">Sinha et al., 2016</xref>). While some of these activities are likely related, the filopodia activity appears to be distinct. Indeed, while we previously found that fibronectin was a critical exosome cargo driving nascent adhesion formation, lamellipodia stabilization, and cell speed in HT1080 fibrosarcoma cells (<xref ref-type="bibr" rid="bib86">Sung et al., 2015</xref>; <xref ref-type="bibr" rid="bib85">Sung et al., 2011</xref>; <xref ref-type="bibr" rid="bib81">Sinha et al., 2016</xref>), fibronectin was unable to rescue the filopodia defect of endoglin-KD HT1080 cells in this study (Fig. S7D). Instead, THSD7A was identified as a distinct exosome cargo that specifically promotes de novo filopodia formation in HT1080 and other cell types and rescued defects of exosome-inhibited cells in filopodia formation. Thus, multiple exosome cargoes contribute to diverse aspects of cytoskeletal reorganization and cell migration.</p><p>While no study has previously shown that EVs can induce filopodia formation, filopodia have previously been shown to interact with EVs in diverse ways. EVs were shown to bind and ‘surf’ on filopodia before entering cells (<xref ref-type="bibr" rid="bib31">Heusermann et al., 2016</xref>). EVs have also been shown to bud from the surface of filopodia and other similar protrusions (<xref ref-type="bibr" rid="bib17">Dixson et al., 2023</xref>; <xref ref-type="bibr" rid="bib53">McConnell et al., 2009</xref>; <xref ref-type="bibr" rid="bib61">Nishimura et al., 2021</xref>; <xref ref-type="bibr" rid="bib74">Rilla et al., 2013</xref>; <xref ref-type="bibr" rid="bib105">Wang et al., 2021</xref>). These various interactions influence cells in a variety of ways, including the delivery and release of EV cargoes and the promotion of cellular migration and invasion.</p><p>Filopodia are important for directional sensing, directional migration, and cell-cell contact formation in a variety of cell types (<xref ref-type="bibr" rid="bib9">Blake and Gallop, 2023</xref>; <xref ref-type="bibr" rid="bib2">Arjonen et al., 2011</xref>; <xref ref-type="bibr" rid="bib34">Jacquemet et al., 2015</xref>). In cancer, filopodia formation is associated with aggressive behavior and cancer metastasis. Indeed, we found that endoglin-KD cancer cells had defects in not only filopodia formation but also in 3D migration and metastasis to chick embryo chorioallantoic membranes. In neurons, inhibition of exosome secretion reduced both filopodia and synapse formation. Thus, in two very different cell types, exosomes regulate these fundamental, filopodia-dependent behaviors. Future studies could further test the importance of exosomes and exosome-associated THSD7A in controlling filopodia in additional cell types, including endothelial cells that use filopodia during cell-cell contact formation and angiogenesis (<xref ref-type="bibr" rid="bib20">Fischer et al., 2019</xref>). It would also be interesting to see whether THSD7A carried by EVs regulates kidney podocyte foot process formation downstream of filopodia and whether it is soluble proteolyzed THSD7A or THSD7A-carrying EVs released into the circulation by cancer cells that leads to autoimmune secondary membranous nephropathy (<xref ref-type="bibr" rid="bib30">Herwig et al., 2019</xref>; <xref ref-type="bibr" rid="bib104">Wang et al., 2019</xref>).</p><p>In our first proteomics dataset identifying SEV-enriched cargoes, we identified endoglin as a candidate molecule to regulate filopodia formation. While we originally hypothesized that endoglin was regulating filopodia formation through one of its known binding partners, our tests of candidates did not yield any positive results. Instead, through our proteomic comparison of control and endoglin-KD SEVs, we identified THSD7A as a possible filopodia-inducing EV cargo regulated by endoglin. Indeed, recombinant purified THSD7A rapidly induced filopodia formation, rescuing filopodia defects of endoglin-KD cells within 15 min (Fig. S7E). As neurons do not express endoglin (<xref ref-type="bibr" rid="bib51">Matsubara et al., 2000</xref>) but do express THSD7A, we expect that sorting of THSD7A to exosomes is controlled by additional molecules. In addition, we found for the first time that Cdc42 activity was required for THSD7A to promote filopodia formation. However, the intermediary proteins that link THSD7A to Cdc42 remain unknown. Future studies to identify THSD7A-binding partners will be important to understand both the mechanism by which THSD7A selectively induces filopodia formation via Cdc42 and how its trafficking is regulated in neurons and other cell types.</p><p>Endoglin is highly expressed in endothelial cells and regulates angiogenesis (<xref ref-type="bibr" rid="bib60">Nassiri et al., 2011</xref>). Indeed, mutations in endoglin are a frequent cause of hereditary hemorrhagic telangiectasia – a disease in which abnormal vascular structures are formed in the skin, mucous membranes, and some organs (<xref ref-type="bibr" rid="bib25">Govani and Shovlin, 2009</xref>). Endoglin expression is also upregulated in several cancers (<xref ref-type="bibr" rid="bib71">Pérez-Gómez et al., 2010</xref>), including melanoma (<xref ref-type="bibr" rid="bib69">Pardali et al., 2011</xref>), ovarian cancer (<xref ref-type="bibr" rid="bib83">Steg et al., 2012</xref>), breast cancer (<xref ref-type="bibr" rid="bib15">Davidson et al., 2010</xref>), and gastric cancer (<xref ref-type="bibr" rid="bib57">Miao et al., 2016</xref>). In breast cancer, these elevated endoglin levels are correlated with reduced survival and invasive phenotype (<xref ref-type="bibr" rid="bib15">Davidson et al., 2010</xref>; <xref ref-type="bibr" rid="bib64">Oxmann et al., 2008</xref>). There is also blood vessel enrichment of endoglin in ovarian tumors (<xref ref-type="bibr" rid="bib92">Szubert et al., 2016</xref>) and head and neck squamous cell carcinoma (<xref ref-type="bibr" rid="bib16">de Oliveira et al., 2014</xref>). In fact, anti-endoglin antibodies are being evaluated as potential anti-cancer therapy and inhibit angiogenesis and metastasis in pre-clinical models (<xref ref-type="bibr" rid="bib7">Bernabeu et al., 2023</xref>; <xref ref-type="bibr" rid="bib24">González Muñoz et al., 2021</xref>; <xref ref-type="bibr" rid="bib65">Paauwe et al., 2016</xref>; <xref ref-type="bibr" rid="bib98">Uneda et al., 2009</xref>). Given our new findings that endoglin is a key regulator of filopodia via regulating THSD7A trafficking to SEVs, an important future direction could be to test the contribution of THSD7A to endoglin-dependent phenotypes, including angiogenesis and cancer metastasis.</p><p>In summary, we found that exosomes promote filopodia formation in diverse cell types by carrying the transmembrane ECM molecule THSD7A. This appears to be a major mechanism for filopodia formation with broad importance for a variety of cellular processes, including cancer cell migration and neuronal synapse formation.</p><sec id="s3-1"><title>Limitations of the study</title><p>The main findings of this study are (1) exosomes induce filopodia formation in both cancer cells and neurons and synapse formation in primary neurons; (2) endoglin and THSD7A are exosomal cargoes that promote filopodia formation; (3) endoglin regulates the levels of THSD7A in cancer cell SEVs and promotes cancer metastasis; (4) THSD7A is expressed by both cancer cells and neurons and directly induces filopodia formation, including in cells that cannot secrete exosomes due to genetic engineering. As a first step to identify the mechanism by which THSD7A induces filopodia formation, we tested whether the candidate molecule Cdc42 is required downstream of THSD7A. We used the inhibitor ML141 and a dominant active Cdc42 molecule to show respectively that induction of filopodia by THSD7A is inhibited with ML141 and that activation of Cdc42 can overcome the filopodia defects of endoglin-KD. One limitation of the study is that we did not use a biochemical method to show that exosomes can activate Cdc42 in cells. Activation of Cdc42 is typically quantified by assessing the ratio of the GDP-bound inactive form to the GTP-bound active form via methods such as bead pulldown assays and Western blots. We were unable to detect active Cdc42 in our cancer cell lysates, suggesting the need to greatly scale up and further optimize in order to achieve the required signal for this assay. Thus, while our data show promising results to support the role of Cdc42 in this process, further experimentation using orthogonal methods such as Cdc42 activity assays and testing Cdc42 knockdown would strengthen this finding and be an important future direction. Another future direction could be to test the role of additional proteins known to be involved in filopodia formation, such as actin-binding proteins like mDia or ENA/VASP proteins, or BAR domain proteins. A second limitation is that we have not worked out the full mechanism by which endoglin regulates THSD7A secretion in exosomes. In order to do so, we would need to determine definitively how THSD7A trafficking is altered by endoglin, i.e. alterations in secretion vs. formation of THSD7A-containing EVs (<xref ref-type="fig" rid="fig9">Figure 9A</xref>). More in-depth assessments of the cellular distribution of THSD7A and endoglin, along with trafficking assays, would aid this endeavor.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Reagent type (species) or resource</th><th align="left" valign="top">Designation</th><th align="left" valign="top">Source or reference</th><th align="left" valign="top">Identifiers</th><th align="left" valign="top">Additional information</th></tr></thead><tbody><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-CD63 (Mouse monoclonal)</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">ab8219</td><td align="left" valign="top">IF 1:500</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-mouse Endoglin (Rabbit polyclonal)</td><td align="left" valign="top">Cell Signaling</td><td align="left" valign="top">3290</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-human Endoglin (Rabbit monoclonal)</td><td align="left" valign="top">Cell Signaling</td><td align="left" valign="top">4335</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-CD63 (Rabbit polyclonal)</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">ab68418</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-Beta actin (Rabbit monoclonal)</td><td align="left" valign="top">Cell Signaling</td><td align="left" valign="top">4970</td><td align="left" valign="top">WB 1:5000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-TSG101 (Rabbit polyclonal)</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">ab30871</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-Flotillin-1 (Rabbit polyclonal)</td><td align="left" valign="top">Cell Signaling</td><td align="left" valign="top">3253</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-TGFbeta1 (Rabbit polyclonal)</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">ab92486</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-HSP70 (Mouse monoclonal)</td><td align="left" valign="top">Santa Cruz</td><td align="left" valign="top">sc-24</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-CD29 (beta1-integrin; Mouse monoclonal)</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">610467</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-ALK1/ACVRL1 (Rabbit polyclonal)</td><td align="left" valign="top">Abcepta</td><td align="left" valign="top">AP7807a</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-Rab27a (Rabbit monoclonal)</td><td align="left" valign="top">Cell Signaling</td><td align="left" valign="top">69295</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-Hrs (M-79) (Rabbit polyclonal)</td><td align="left" valign="top">Santa Cruz</td><td align="left" valign="top">sc-30221</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">rabbit anti-GM130 (Rabbit monoclonal)</td><td align="left" valign="top">ThermoFisher</td><td align="left" valign="top">MA5-35107</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-THSD7A (Rabbit polyclonal)</td><td align="left" valign="top">Sigma</td><td align="left" valign="top">HPA000923</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-Vinculin (Mouse monoclonal)</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">V9131</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-THSD7A (Rabbit polyclonal)</td><td align="left" valign="top">Nicola Tomas, University Medical Center Hamburg-Eppendorf</td><td align="left" valign="top"/><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-pSmad1/5/9 (Rabbit monoclonal)</td><td align="left" valign="top">Cell Signaling</td><td align="left" valign="top">13820</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-Smad1 (Rabbit monoclonal)</td><td align="left" valign="top">Cell Signaling</td><td align="left" valign="top">6944</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-pSmad2 (Rabbit monoclonal)</td><td align="left" valign="top">Cell Signaling</td><td align="left" valign="top">3108</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-Smad2 (Rabbit monoclonal)</td><td align="left" valign="top">Cell Signaling</td><td align="left" valign="top">5339</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti- SV2 (Mouse monoclonal)</td><td align="left" valign="top">Developmental Studies Hybridoma Bank</td><td align="left" valign="top"/><td align="left" valign="top">IF 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-Flotillin-1 (Mouse monoclonal)</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">610820</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-Alix (Mouse monoclonal)</td><td align="left" valign="top">Cell Signaling</td><td align="left" valign="top">2171</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">anti-GM130 (Mouse monoclonal)</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">610822</td><td align="left" valign="top">WB 1:1000</td></tr><tr><td align="left" valign="top">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="top">B16F1</td><td align="left" valign="top">ATCC</td><td align="left" valign="top"/><td align="left" valign="top">mouse melanoma</td></tr><tr><td align="left" valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="top">HT1080</td><td align="left" valign="top">ATCC</td><td align="left" valign="top"/><td align="left" valign="top">human fibrosarcoma</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">mCherry-pTαS2<break/>(plasmid)</td><td align="left" valign="top">Donna J. Webb, Vanderbilt University</td><td align="left" valign="top"/><td align="left" valign="top">Expression of mCherry in neurons</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">GFP-pTαS2<break/>(plasmid)</td><td align="left" valign="top">Donna J. Webb, Vanderbilt University</td><td align="left" valign="top"/><td align="left" valign="top">Expression of GFP in neurons</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">mScarlet-pTαS2<break/>(plasmid)</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">Expression of mScarlet in neurons, described in Neuron methods: Reagents and constructs</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">GFP-Rab27b<break/>(plasmid)</td><td align="left" valign="top">Addgene</td><td align="left" valign="top">89447</td><td align="left" valign="top">Expression of GFP-tagged human Rab27B; a gift from Wendy Westbroek to Addgene</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pCMV-Tag4-THSD7A-FLAG<break/>(plasmid)</td><td align="left" valign="top">Yung-Jen Chuang, National Tsing Hua University, Taiwan</td><td align="left" valign="top"/><td align="left" valign="top">Expression of THSD7A-FLAG</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pCMV-Tag4<break/>(plasmid)</td><td align="left" valign="top">Yung-Jen Chuang, National Tsing Hua University, Taiwan</td><td align="left" valign="top"/><td align="left" valign="top">Empty vector for C-terminal FLAG-tagged expression</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pCytERM_mScarlet_N1<break/>(plasmid)</td><td align="left" valign="top">Addgene</td><td align="left" valign="top">85066</td><td align="left" valign="top">Expression of mScarlet-tagged cytochrome p450 aa 1–29; A gift from Dorus Gadella to Addgene</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pCMV-Tag4-THSD7A-mScarlet<break/>(plasmid)</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">Expression of mScarlet-tagged THSD7A, described in Cancer cell methods: Plasmids and reagents</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pLenti6/V5-DEST<break/>(plasmid)</td><td align="left" valign="top">Thermo Fisher</td><td align="left" valign="top">V49610</td><td align="left" valign="top">Empty vector for V5-tagged expression</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pLenti6-WT-Eng-V5<break/>(plasmid)</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">Expression of shRNA-resistant WT endoglin-V5, described in Cancer cell methods: Plasmids and reagents</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pRK5-myc-Cdc42-Q61L<break/>(plasmid)</td><td align="left" valign="top">Addgene</td><td align="left" valign="top">12974</td><td align="left" valign="top">Expression of myc-tagged Cdc42 constitutively active; a gift from Gary Bokoch to Addgene</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pHluorin_M153R-CD63-mScarlet (plasmid)</td><td align="left" valign="top">BH Sung et al., Nat Commun., 2020</td><td align="left" valign="top"/><td align="left" valign="top">Expression of dual color CD63 reporter of exosome secretion and uptake</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">tdTomato-fTractin (plasmid)</td><td align="left" valign="top">Robert S. Fischer,<break/>NIH</td><td align="left" valign="top"/><td align="left" valign="top">Expression of tdTomato-tagged F-actin. Provided by Robert Fischer</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="top">shHrs-1</td><td align="left" valign="top">Dharmacon p-Blockit</td><td align="left" valign="top"/><td align="left" valign="top">5’-<named-content content-type="sequence">GGAACGAACCCAAGTACAAGG</named-content>-3’</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="top">shHrs-2</td><td align="left" valign="top">Dharmacon p-Blockit</td><td align="left" valign="top"/><td align="left" valign="top">5’-<named-content content-type="sequence">GCATGAAGACGAACCACATGC</named-content>-3’</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="top">shRab27a-1</td><td align="left" valign="top">Dharmacon p-Blockit</td><td align="left" valign="top"/><td align="left" valign="top">5’-<named-content content-type="sequence">GTGCGATCAAATGGTCATGCC</named-content>-3’</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="top">shRab27a-2</td><td align="left" valign="top">Dharmacon p-Blockit</td><td align="left" valign="top"/><td align="left" valign="top">5’-<named-content content-type="sequence">CGTTCTTCAGAGATGCTATGC</named-content>-3’</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="top">pBlockit-shLacZ</td><td align="left" valign="top">Dharmacon p-Blockit</td><td align="left" valign="top"/><td align="left" valign="top">control shRNA</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="top">shEng-1</td><td align="left" valign="top">Dharmacon TRC lentiviral shRNA (pLKO.1)</td><td align="left" valign="top">TRCN0000094354</td><td align="left" valign="top">5’-<named-content content-type="sequence">TTAGGCTTCTAAGCAGCATGG</named-content>-3’</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="top">shEng-2</td><td align="left" valign="top">Dharmacon TRC lentiviral shRNA (pLKO.1)</td><td align="left" valign="top">TRCN0000094355</td><td align="left" valign="top">5’-<named-content content-type="sequence">TATAGATGACAAACAGCAGGG</named-content>-3’</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="top">shScr</td><td align="left" valign="top">Dharmacon TRC lentiviral shRNA (pLKO.1)</td><td align="left" valign="top"/><td align="left" valign="top">control shRNA</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>H. sapiens</italic>)</td><td align="left" valign="top">shEng-1</td><td align="left" valign="top">Dharmacon TRC lentiviral shRNA (pLKO.1)</td><td align="left" valign="top">TRCN0000083138</td><td align="left" valign="top">5’-<named-content content-type="sequence">ATCCAGGTTCAAATGACAGGG</named-content>-3’</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>H. sapiens</italic>)</td><td align="left" valign="top">shEng-2</td><td align="left" valign="top">Dharmacon TRC lentiviral shRNA (pLKO.1)</td><td align="left" valign="top">TRCN0000083141</td><td align="left" valign="top">5’-<named-content content-type="sequence">ATCATACTTGCTGACACCTGC</named-content>-3’</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>H. sapiens</italic>)</td><td align="left" valign="top">shEng</td><td align="left" valign="top">Dharmacon TRC lentiviral shRNA (pLKO.1)</td><td align="left" valign="top">TRCN0000083139</td><td align="left" valign="top">5’-<named-content content-type="sequence">TAGTGGTATATGTCACCTCGC</named-content>-3’</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>H. sapiens</italic>)</td><td align="left" valign="top">shTHSD7A</td><td align="left" valign="top">Dharmacon SMARTvector Lentiviral shRNAs</td><td align="left" valign="top">V3SH11240-226004853</td><td align="left" valign="top">N/A, proprietary to Dharmacon</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>H. sapiens</italic>)</td><td align="left" valign="top">shTHSD7A</td><td align="left" valign="top">Dharmacon SMARTvector Lentiviral shRNAs</td><td align="left" valign="top">V3SH11240-226644723</td><td align="left" valign="top">N/A, proprietary to Dharmacon</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>H. sapiens</italic>)</td><td align="left" valign="top">shTHSD7A</td><td align="left" valign="top">Dharmacon SMARTvector Lentiviral shRNAs</td><td align="left" valign="top">V3SH11240-227287134</td><td align="left" valign="top">N/A, proprietary to Dharmacon</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>H. sapiens</italic>)</td><td align="left" valign="top">NTC (non-targeting control)</td><td align="left" valign="top">Dharmacon SMARTvector Lentiviral shRNAs</td><td align="left" valign="top"/><td align="left" valign="top">N/A, proprietary to Dharmacon</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>Rattus norvegicus</italic>)</td><td align="left" valign="top">Hrs shRNA</td><td align="left" valign="top">pSUPER, doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1068999">10.1126/science.1068999</ext-link></td><td align="left" valign="top"/><td align="left" valign="top">5’-<named-content content-type="sequence">AATGAACCCAAGTACAAGG</named-content>-3’<break/>For transfection of neurons</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>R. norvegicus</italic>)</td><td align="left" valign="top">Hrs shRNA</td><td align="left" valign="top">pSUPER Vector, doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1068999">10.1126/science.1068999</ext-link></td><td align="left" valign="top"/><td align="left" valign="top">5’-<named-content content-type="sequence">ATGAAGAGCAACCACATGA</named-content>-3’<break/>For transfection of neurons</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>R. norvegicus</italic>)</td><td align="left" valign="top">Rab27b shRNA</td><td align="left" valign="top">pSUPER Vector, doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1068999">10.1126/science.1068999</ext-link></td><td align="left" valign="top"/><td align="left" valign="top">5’-<named-content content-type="sequence">CCGATACACAGACAATAAA</named-content>-3’<break/>For transfection of neurons</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>R. norvegicus</italic>)</td><td align="left" valign="top">Rab27b shRNA</td><td align="left" valign="top">pSUPER Vector, doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1068999">10.1126/science.1068999</ext-link></td><td align="left" valign="top"/><td align="left" valign="top">5’-<named-content content-type="sequence">TGAGTCAACTGCAGGCAAA</named-content>-3’<break/>For transfection of neurons</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="top">Endoglin siRNA</td><td align="left" valign="top">Dharmacon ON-TARGETplus siRNA SMARTpool</td><td align="left" valign="top">L-045109-00-0005</td><td align="left" valign="top">N/A, proprietary to Dharmacon</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="top">NTC (non-targeting control)</td><td align="left" valign="top">Dharmacon</td><td align="left" valign="top">D-001810-01-05</td><td align="left" valign="top">N/A, proprietary to Dharmacon</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">human BMP-9</td><td align="left" valign="top">R&amp;D Systems</td><td align="left" valign="top">3209 BP</td><td align="left" valign="top">recombinant protein</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">human TGF-beta1</td><td align="left" valign="top">R&amp;D Systems</td><td align="left" valign="top">240-B-002</td><td align="left" valign="top">recombinant protein</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">human Fibronectin</td><td align="left" valign="top">Cultrex</td><td align="left" valign="top">3420-001-01</td><td align="left" valign="top">recombinant protein</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">human THSD7A</td><td align="left" valign="top">R&amp;D Systems</td><td align="left" valign="top">9524-TH</td><td align="left" valign="top">recombinant protein</td></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">EZSHPERE 96-well plate</td><td align="left" valign="top">SGC Techno Glass</td><td align="left" valign="top">AG4860900SP</td><td align="left" valign="top">spheroid collagen invasion assay plate</td></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">type 1 A collagen solution</td><td align="left" valign="top">Nitta gelatin</td><td align="left" valign="top">Type-1-A</td><td align="left" valign="top">spheroid collagen invasion culture medium</td></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">ML141</td><td align="left" valign="top">Millipore</td><td align="left" valign="top">217708</td><td align="left" valign="top">Cdc42 inhibitor</td></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">OptiPrep Density Gradient Medium</td><td align="left" valign="top">Sigma</td><td align="left" valign="top">D1556</td><td align="left" valign="top">iodixanol-based solution for density gradient</td></tr><tr><td align="left" valign="top">Commercial assay, kit</td><td align="left" valign="top">Coomassie Brilliant Blue R-250 Staining Solutions Kit</td><td align="left" valign="top">BioRad</td><td align="left" valign="top">1610435</td><td align="left" valign="top">protein stain</td></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Phenylmethylsulfonyl fluoride (PMSF)</td><td align="left" valign="top">Research Products International</td><td align="left" valign="top">P20270</td><td align="left" valign="top">Serine protease inhibitor</td></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">cOmplete Protease Inhibitor Cocktail</td><td align="left" valign="top">Roche</td><td align="left" valign="top">4693116001</td><td align="left" valign="top">protease inhibitor cocktail</td></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">TGF-beta1 inhibitor SB 431542</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">S4317</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">PhosSTOP</td><td align="left" valign="top">Roche</td><td align="left" valign="top">4906845001</td><td align="left" valign="top">Phosphatase inhibitor cocktail</td></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">BCA Protein Assay Kit</td><td align="left" valign="top">Pierce</td><td align="left" valign="top">23225</td><td align="left" valign="top">Protein quantification assay</td></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">Micro BCA Protein Assay Kit</td><td align="left" valign="top">Pierce</td><td align="left" valign="top">23235</td><td align="left" valign="top">Protein quantification assay</td></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Lipofectamine RNAiMAX</td><td align="left" valign="top">Life Technologies</td><td align="left" valign="top">13778150</td><td align="left" valign="top">transfection reagent</td></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Lipofectamine 2000</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">11668–027</td><td align="left" valign="top">transfection reagent</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Materials availability statement</title><p>The pLenti6-WT-Eng-V5 and pCMV-Tag4-THSD7A-mScarlet plasmids were newly created for these experiments and can be requested by contacting Alissa Weaver.</p></sec><sec id="s4-2"><title>Cancer cell methods</title><sec id="s4-2-1"><title>Cell culture</title><p>Cell lines were obtained from ATCC and checked regularly for mycoplasma contamination. Cells used for experiments were mycoplasma-negative. B16F1 mouse melanoma cells (ATCC CRL-6323) were maintained in DMEM supplemented with 10% FBS. HT1080 human fibrosarcoma cells (ATCC CCL-121) were maintained in DMEM supplemented with 10% bovine growth serum (BGS). Cells were maintained at 37°C in 5% CO2. Transient transfections were done using Lipofectamine 2000 (Invitrogen #11668–027).</p></sec><sec id="s4-2-2"><title>Plasmids and reagents</title><p>Stable knockdown of Hrs in B16F1 cells was achieved by using the Dharmacon p-Blockit system with target sequences: 5’-<named-content content-type="sequence">GGAACGAACCCAAGTACAAGG</named-content>-3’ (shHrs-1) and 5’-<named-content content-type="sequence">GCATGAAGACGAACCACATGC</named-content>-3’ (shHrs-2), stably selected with blasticidin. Stable knockdown of Rab27a in B16F1 cells was achieved by using the p-Blockit system with target sequences: 5’-<named-content content-type="sequence">GTGCGATCAAATGGTCATGCC</named-content>-3’ (shRab27a-1) and 5’-<named-content content-type="sequence">CGTTCTTCAGAGATGCTATGC</named-content>-3’ (shRab27a-2), stably selected with blasticidin. Control lines were simultaneously selected using the pBlockit-shLacZ plasmid. Stable knockdown of endoglin in B16F1 cells was achieved using the Dharmacon TRC lentiviral shRNA (pLKO.1): 3’UTR target shEng-1 (TRCN0000094354): 5’-<named-content content-type="sequence">TTAGGCTTCTAAGCAGCATGG</named-content>-3’, ORF target shEng-2 (TRCN0000094355): 5’-<named-content content-type="sequence">TATAGATGACAAACAGCAGGG</named-content>-3’. B16F1 shEng cells were stably selected using puromycin. The control line was simultaneously selected using the shScr control plasmid. Transient endoglin knockdown in B16F1 cells was obtained with ON-TARGETplus siRNA SMARTpool (L-045109-00-0005; GE Dharmacon) using Lipofectamine RNAiMAX (Life Technologies). As a control for the knockdown, a nontargeting control pool was used (D-001810-01-05; GE Dharmacon). Stable knockdown of endoglin in HT1080 (mCitrine expressing) cells was achieved using Dharmacon TRC lentiviral shRNA (pLKO.1): 3’UTR shEng-1 (TRCN0000083138): 5’-<named-content content-type="sequence">ATCCAGGTTCAAATGACAGGG</named-content>-3’, ORF shEng-2 (TRCN0000083141): 5’-<named-content content-type="sequence">ATCATACTTGCTGACACCTGC</named-content>-3’, CDS shEng (TRCN0000083139): 5’-<named-content content-type="sequence">TAGTGGTATATGTCACCTCGC</named-content>-3’. Cells were selected with puromycin and maintained in blasticidin and puromycin to retain mCitrine expression and endoglin knockdown. The control line was simultaneously selected using the shScr control plasmid. Knockdown of THSD7A in HT1080 cells was achieved using Dharmacon SMARTvector Lentiviral shRNAs Cat# V3SH11240-226004853, V3SH11240-226644723, and V3SH11240-227287134. A non-targeting control (NTC) shRNA was used as a control.</p><p>The pCMV-Tag4-THSD7A-FLAG plasmid and vector control pCMV-Tag4 were generously provided by the Chuang laboratory (<xref ref-type="bibr" rid="bib41">Kuo et al., 2011</xref>). The pCMV-Tag4-THSD7A-mScarlet plasmid was created by subcloning the mScarlet region from pCytERM_mScarlet_N1 (Addgene #85066) into the C-terminal end of THSD7A in the pCMV-Tag4-THSD7A plasmid. For mechanistic studies, the END gene was amplified from HT1080-derived cDNA and subcloned into the pENTR vector. Silent mutations were inserted to confer shEng resistance, and the coding sequence was confirmed by Sanger sequencing. The resulting pENTR-Eng plasmid was Gateway recombined with pLenti6/V5-DEST, in which the <italic>BSD</italic> (blasticidin resistance) gene in pLenti6/V5-DEST was replaced with <italic>neo</italic> to confer neomycin resistance. HT1080 shEng cells were transfected with pLenti6/V5-DEST or pLenti6-WT-Eng-V5 and stable lines were isolated by selection with G418 sulfate. pRK5-myc-Cdc42-Q61L was purchased from Addgene (Plasmid #12974). HT1080 cells stably expressing mCitrine fluorescent protein were obtained from Andries Zijlstra’s laboratory. HT1080 cells stably expressing the dual tagged CD63 live imaging reporter pHluorin_M153R-CD63-mScarlet were previously described (<xref ref-type="bibr" rid="bib90">Sung and Weaver, 2023</xref>).</p></sec><sec id="s4-2-3"><title>EV isolation and characterization</title><p>48 hr conditioned Opti-MEM (a serum-free but growth factor-containing medium) was collected for isolation of EVs from cancer cells. A 5-min 300 x <italic>g</italic> spin and 25-min 2000 x <italic>g</italic> spin were performed to remove dead cells and large particulate matter. The supernatant was then spun at 10,000 x <italic>g</italic> for 30 minutes to pellet the LEVs (Ti45 rotor, Beckman Coulter). This LEV fraction was later washed with PBS spins and used for western blotting and rescue experiments. To isolate SEVs from cancer cells, we used a cushion density gradient ultracentrifugation method, which reduces vesicle and protein aggregation and leads to a highly purified preparation (<xref ref-type="bibr" rid="bib43">Li et al., 2018</xref>). For iodixanol cushion and gradient, OptiPrep Density Gradient Medium was purchased from Sigma (D1556). The supernatant from the 10,000 x <italic>g</italic> spin was layered on top of a 2 ml 60% iodixanol cushion and spun for 4 hr at 100,000 x <italic>g</italic> (SW32 Ti rotor, Beckman Coulter). The bottom 3 ml of the cushion was obtained and layered at the bottom of a discontinuous gradient, followed by three 3 ml layers of 20%, 10%, and 5% iodixanol diluted with 0.25 M sucrose/10 mM Tris, pH 7.5. The discontinuous gradient was spun for 18 hours at 100,000 x <italic>g</italic> and collected into 12 1-ml fractions (SW40 Ti rotor, Beckman Coulter). SEVs are typically located in fractions 6 and 7, and these fractions are then washed by resuspending with PBS and repelleting. After final resuspension with PBS, SEV purification is checked using nanoparticle tracking for particle number and size, western blot validation of EV proteins, and electron microscopy for morphology (<xref ref-type="bibr" rid="bib46">Lötvall et al., 2014</xref>; <xref ref-type="bibr" rid="bib94">Théry et al., 2018</xref>; <xref ref-type="bibr" rid="bib106">Welsh et al., 2024</xref>). Large volumes of conditioned media were concentrated prior to the cushion centrifugation step using Vivacell 70 ultrafiltration units with 100,000 MWCO. The number of vesicles added back in rescue experiments was determined by calculating the physiological SEV secretion rate for each cell line. The total vesicle number was counted using nanoparticle tracking analysis (Particle Metrix ZetaView or NanoSight), and the vesicle per cell per hour secretion rate was calculated. This rate was used to determine a range of physiologically relevant vesicle numbers to treat cells.</p></sec><sec id="s4-2-4"><title>Electron microscopy</title><p>Freshly isolated SEVs or LEVs suspended in PBS were used for TEM imaging. Samples were incubated on glow-discharged 300 mesh carbon-coated grids for 30 s followed by fixation in 1% glutaraldehyde for 1 min. Samples were washed twice and negative stained in 2% uranyl acetate. TEM was performed on a Tecnai T12 operating at 100 keV using an AMT nanosprint5 CMOS camera.</p></sec><sec id="s4-2-5"><title>Immunofluorescence and analysis</title><p>Cells were seeded onto 100 µg/ml PDL-coated glass coverslips. For all experiments, fields of view containing stained cells were randomly selected for imaging and filopodia quantification. For steady-state filopodia quantification, cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 or 0.1% saponin, and stained with Alexa Fluor conjugated phalloidin (rhodamine-phalloidin or phalloidin-Alexa Fluor 488) 24 hr after seeding. Co-staining was done using mouse anti-CD63 (Abcam ab8219) and goat anti-mouse Alexa Fluor 546. For EV rescue experiments, SEVs or LEVs are added to live cells 24 hr post-seeding, and cells are fixed and stained with conjugated phalloidin 18 hr post-EV treatment. For BMP-9 treatment, human recombinant BMP-9 (R&amp;D Systems Cat# 3209 BP) was reconstituted in sterile 4 mM HCl +0.1% BSA, diluted in OptiMEM, and added to cells for 1 hr at 37°C, then cells are fixed and stained with conjugated phalloidin. For TGF-β1 treatment, desired concentration of recombinant human TGF-β1 (R&amp;D Systems Cat #240-B-002; reconstituted in sterile 4 mM HCl +0.1% BSA) was diluted in OptiMEM, added to cells at time of seeding, and cells were fixed and stained 48 hr post-seeding. For FN coating experiments, glass coverslips were coated with indicated concentrations of FN (Cultrex Human Fibronectin Cat# 3420-001-01, diluted in sterile PBS) overnight and cells were seeded onto coverslips. Cells were fixed and stained 24 hr post-seeding. For THSD7A rescue experiments, coverslips were first coated with 100 µg/ml PDL overnight, then washed, then coated with indicated concentrations of recombinant human THSD7A overnight (diluted in sterile PBS; R&amp;D Systems Cat# 9524-TH). Cells were seeded onto THSD7A-coated coverslips and fixed and stained 24 hr post-seeding. For THSD7A-mScarlet expression experiments, THSD7A-mScarlet was transiently transfected into HT1080 cells and cells that were visibly expressing the fusion protein were imaged using a Nikon A1R HD25 confocal microscope with a Plan Apo λ 60 x/1.4 oil objective. Cells were seeded onto PDL-coated glass coverslips overnight, then fixed and stained for phalloidin and CD63. Cell edges were manually drawn and only the internal THSD7A-mScarlet and CD63 signals were quantified. JACoP Fiji plugin was used to calculate M1 value from manually thresholded channels. All fixed cells were imaged using either a Nikon Eclipse TE2000-E epifluorescence microscope and Metamorph software (Molecular Devices) or Nikon A1R confocal microscope and NIS-Elements Software. Cell area was calculated by tracing cell outlines using ImageJ software. Filopodia were counted using the Filoquant ImageJ plugin <xref ref-type="bibr" rid="bib35">Jacquemet et al., 2017</xref> with manual adjustment for any plugin errors.</p></sec></sec><sec id="s4-3"><title>Live cell imaging</title><sec id="s4-3-1"><title>MVE fusion movies</title><p>HT1080 cells stably expressing pHluorin_M153R-CD63-mScarlet were cultured on PDL-coated glass-bottomed MatTek dishes. Cells were imaged every 10 s for 20 min on a Nikon A1R confocal microscope using a Plan Apo λ 60x/1.4 oil objective and a humidified 37°C chamber with 5% CO<sub>2</sub>. MVE fusion events are identified as MVEs expressing mScarlet-CD63 approaching the cell edge followed by a burst of green fluorescence, suggesting exposure to extracellular neutral pH and MVE fusion. Filopodia that arose at the region of MVE fusion soon after were counted in the quantification. CD63 green burst and filopodia formation were noted based on the time frame, and the timing between these events was quantified and graphed.</p></sec><sec id="s4-3-2"><title>Filopodia dynamics</title><p>B16F1 control (shLacZ) and Hrs-KD cell lines were transiently transfected with tdTomato-fTractin 2 days prior to seeding onto PDL-coated glass-bottomed MatTek dishes. Prior to imaging, cell media was switched to Leibovitz’s L-15 (Gibco)+10% FBS. Cells were imaged on Nikon Eclipse TE2000-E epifluorescence microscope using Apo 60x oil objective and warmed 37°C chamber and an image was captured every 30 s for 15 min with MetaMorph software (Molecular Devices). B16F1 control (shScr) and Eng-KD cell lines were transiently transfected with tdTomato-fTractin 2 days prior to seeding onto PDL-coated glass-bottom MatTek plates. Cells were imaged on Nikon A1R confocal microscope using Plan Apo λ 60 x/1.4 oil objective and a humidified 37°C chamber with 5% CO<sub>2</sub>. An image was captured every 30 s for 15 min with NIS-Elements software. Only filopodia that were formed and completely retracted during the 15-min time period were quantified as de novo, and lifetime was defined as the total amount of time the filopodia persisted from formation to complete retraction.</p></sec></sec><sec id="s4-4"><title>Proteomics analyses</title><sec id="s4-4-1"><title>Identification of individual bands isolated from colloidal Coomassie blue-stained gel</title><p>Purified LEVs and SEVs isolated from B16F1 cells were run on a standard SDS-PAGE gel using fresh buffers and after washing the gel apparatus and cleaning it with 70% ethanol. After staining and destaining with the BioRad Coomassie Brilliant Blue R-250 Staining Solutions Kit (#1610435), four bands that were apparent in the SEV sample but missing in the LEV sample were identified, cut from the gel, and submitted for proteomics analysis using trypsin as a digestion enzyme. MS/MS samples were analyzed using Sequest (Thermo Fisher Scientific, San Jose, CA, USA; version 27, rev. 12) and X! Tandem (The GPM, <ext-link ext-link-type="uri" xlink:href="http://thegpm.org/">thegpm.org</ext-link>; version CYCLONE (2010.12.01.1)). Sequest was set up to search the uniprot-mouse-reference-canonical_20121112_rev database (unknown version, 86222 entries), assuming the digestion enzyme trypsin. X! Tandem was set up to search the uniprot-mouse-reference-canonical_20121112_rev database (unknown version, 86222 entries), also assuming trypsin. Sequest was searched with a fragment ion mass tolerance of 0.00 Da and a parent ion tolerance of 2.5 Da. X! Tandem was searched with a fragment ion mass tolerance of 0.50 Da and a parent ion tolerance of 2.5 Da. Glu-&gt;pyro-&gt;Glu of the n-terminus, ammonia-loss of the n-terminus, gln-&gt;pyro-&gt;Glu of the N-terminus, oxidation of methionine and carbamidomethyl of cysteine were specified in X! Tandem as variable modifications. Oxidation of methionine and carbamidomethyl of cysteine was specified in Sequest as variable modifications. Criteria for protein identification: Scaffold (version Scaffold_4.8.8, Proteome Software Inc, Portland, OR) was used to validate MS/MS based peptide and protein identifications. Peptide identifications were accepted if they could be established at greater than 50.0% probability to achieve an FDR less than 5.0% by the Peptide Prophet algorithm (Keller, A. et al. Anal. Chem. 2002;74(20):5483–92). Protein identifications were accepted if they could be established at greater than 81.0% probability to achieve an FDR less than 5.0% and contained at least two identified peptides. Protein probabilities were assigned by the Protein Prophet algorithm (Nesvizhskii, Al et al. Anal. Chem. 2003;75(17):4646–58). Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. The full proteomics results are shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-4-2"><title>iTRAQ analysis of SEVs</title><p>For iTRAQ proteomics analysis, isolated exosomes from multiple cushion-density gradient preparations were pooled together for each cell type. Each individual preparation was tested for purity using Zetaview nanoparticle tracking and Western blot for typical exosomal markers. Pooled SEVs were resuspended in PBS and mixed 1:1 with 2x ‘exosome lysis buffer’ (200 mM TEAB, 600 mM NaCl, 2% NP-40, and 1% sodium deoxycholate). After mixing, samples were then sonicated using a Bioruptor in cold ice water (30 s on/30 s off for 15 min). After sonication, samples were spun down to pellet insoluble proteins, and the supernatant was submitted and run by the Vanderbilt University MSRC Proteomics Core Laboratory. MS/MS spectra were searched against a mouse subset of the UniProt KB protein database, and autovalidation procedures in Spectrum Mill were used to filter the data to &lt;1% false discovery rates at the protein and peptide level. The median log2 iTRAQ protein ratios were calculated over all peptides identified for each protein, and frequency distributions were generated in GraphPad Prism. Log2 ratios typically follow a normal distribution and were fit using least squares regression. The mean and standard deviation values derived from the Gaussian fit were used to calculate p-values using Z-score statistics. A given iTRAQ protein ratio, with the calculated mean and standard deviation of the fitted dataset, is transformed to a standard normal variable (z = (x-μ)/σ). Since the properties of the standard normal curve are known, area under the curve for a particular value can be calculated, providing a p-value for each measured protein ratio. Calculated p-values were subsequently corrected for multiple comparisons using the Benjamini-Hochberg method. The full proteomics results are shown in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p></sec><sec id="s4-4-3"><title>Western blot analysis</title><p>Samples for Western blotting were run on a reducing SDS-PAGE gel and transferred to a nitrocellulose membrane (unless otherwise noted). Cell lysate samples were collected by scraping cells directly from a tissue culture dish using RIPA cell lysis buffer (50 mM Tris pH 7.6, 150 mM NaCl, 1% NP-40, 1% SDS, 0.5% sodium deoxycholate) with 1 mM Phenylmethylsulfonyl fluoride (PMSF) (Research Products International Cat# P20270) and cOmplete Protease Inhibitor Cocktail (Roche Cat# 04693116001, used as directed by manufacturer). EV samples were lysed by mixing directly with Laemmli sample buffer containing SDS, DTT, and BME. Samples were loaded at equal protein amounts; protein amount was quantified from samples by using a BCA assay or micro BCA assay (Pierce BCA Protein Assay Kit, Thermo Fisher Scientific Cat# 23225; Micro BCA Protein Assay Kit, Thermo Fisher Scientific Cat# 23235). Antibodies (for cancer cells): rabbit anti-Endoglin (mouse specific) (Cell Signaling Cat# 3290), rabbit anti-Endoglin (human specific) (Cell Signaling Cat# 4335), rabbit anti-CD63 (Abcam Cat# ab68418), rabbit anti-beta actin (Cell Signaling Cat# 4970), rabbit anti-TSG101 (Abcam Cat# ab30871), rabbit anti-flotillin-1 (Cell Signaling Cat# 3253), rabbit anti-TGFbeta1 (Abcam Cat# ab92486), mouse anti-HSP70 (Santa Cruz Cat# sc-24), mouse anti-CD29 (beta1-integrin; BD Biosciences Cat# 610467), rabbit anti-ALK1/ACVRL1 (Abcepta Cat# AP7807a), rabbit anti-Rab27a (Cell Signaling Cat# 69295), rabbit anti-Hrs (M-79) (Santa Cruz Cat# sc-30221), rabbit anti-GM130 (Thermo Fisher Cat# MA5-35107), rabbit anti-THSD7A (Sigma Cat# HPA000923), mouse anti-vinculin (Sigma-Aldrich Cat# V9131).</p><p>To detect THSD7A in HT1080 TCLs and SEVs, reducing western blot conditions and rabbit anti-THSD7A (Sigma HPA000923) were used. To detect THSD7A in B16F1 SEV samples, SEVs were solubilized in NP-40 lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1.0% NP-40, 1 mM PMSF mixed 1:1 with SEVs resuspended in PBS) in non-reducing conditions and ran on native gels using non-SDS running buffer. After transfer, the membrane was probed with rabbit anti-THSD7A IgG, generously provided by Nicola M. Tomas, Rolf A.K. Stahl, and Friedrich Koch-Nolte at University Medical Center Hamburg-Eppendorf in Hamburg, Germany (<xref ref-type="bibr" rid="bib97">Tomas et al., 2017</xref>).</p><p>For detecting Smad phosphorylation, TGF-β1 was used as a positive control and added to indicated conditions for 1 hr at 10 ng/ml. TGF-β1 was reconstituted in sterile 4 mM HCl +0.1% BSA according to manufacturer’s instructions (R&amp;D Systems Cat# 240-B-002). Indicated conditions were treated with the TGF-β1 inhibitor SB 431542 (Sigma-Aldrich Cat# S4317; solubilized in DMSO) for 5 min at 10 μM prior to TGF-β1 treatment. Cells were seeded on 100 µg/ml PDL +/-2 µg/ml rhTHSD7A. At experiment endpoint, media was aspirated and adherent cells were lysed with RIPA lysis buffer (50 mM Tris pH 7.6, 150 mM NaCl, 1% NP-40, 1% SDS, 0.5% sodium deoxycholate) containing 1 mM phenylmethylsulfonyl fluoride (PMSF) (Research Products International (RPI) Cat# P202705) and PhosSTOP (Roche Cat# 4906845001). Lysates were passed through a 27-gauge needle three times prior to boiling and preparing for Western blot. pSmad1/5/9 (Cell Signaling #13820) and Smad1 (Cell Signaling #6944) were probed on one membrane and pSmad2 (Cell Signaling #3108) and Smad2 (Cell Signaling #5339) were probed on a separate membrane. Membranes were blocked with 5% BSA in TBS/0.1% Tween-20 overnight, probed with indicated phospho-antibody and then stripped and reprobed with indicated total Smad antibody.</p></sec><sec id="s4-4-4"><title>Avian embryo model of metastasis</title><p>Avian embryo experimental metastasis model protocol was based on previously published methods (<xref ref-type="bibr" rid="bib66">Palmer et al., 2011</xref>). At the time points of the experiments, the chicken embryos are not considered vertebrate animals and therefore are not subject to IACUC regulation. Live fertilized chicken eggs were incubated for 11 days prior to injections. Eggs were chosen for injection based on the ease of visualizing the allantoic vein. Eggs with clear vein visibility were chosen at random for cell and SEV injection conditions. HT1080 control and KD cells expressing mCitrine were suspended in PBS at a concentration of 1 x 10<sup>6</sup> cells/mL and 100,000 cells (100 μl) were injected into the allantoic vein in the direction of blood flow. Eggs were returned to the incubator for 4 days. After 4 days post-injection, chicks were sacrificed, and three circular areas of CAM were harvested from inside the shell 4 days post-injection. The membrane was then peeled away from the eggshell and placed between a glass slide and coverslip for imaging. 25–30 fields of view were captured for each egg harvested and 4–7 eggs were sacrificed for each condition. Sample size was determined by time constraints of number of embryos that could be sacrificed and immediately imaged within a 12-hr time period. Embryos that died during the prior 4-day incubation period were excluded from analysis. Preliminary low-power wide-field images were obtained using a Zeiss Lumar V12 fluorescence stereomicroscope with ×10 magnification. For higher power wide-field images, fluorescent cell extravasation and metastasis were observed using X10/0.40 UPlanSApo objective lens with a 10X ocular (100X total) on an Olympus BX-61 microscope equipped with a digital camera controlled with Volocity image acquisition software. For SEV rescue experiments, control SEVs were isolated using the cushion-density gradient method and were premixed with cells immediately prior to injection into chick embryo intravascularly. The number of SEVs per injection was calculated using the SEV secretion rate for the HT1080 shScr cell line according to data collected with the Zetaview nanoparticle tracking instrument (89 x 10<sup>6</sup> SEVs per 100,000 cells). Images were analyzed in ImageJ by manually thresholding each image to include visible cells and avoid capturing background signals. The colony number and colony area of each thresholded image were quantified.</p></sec><sec id="s4-4-5"><title>Spheroid collagen invasion model</title><p>1.5 × 10<sup>4</sup> HT1080 cells were cultured in an EZSPHERE micro-fabricated 96-well plate (AGC Techno Glass, Shizuoka, Japan). After 20 hr, the spheroids from each well were collected into a 15 ml tube by adding 5 ml of DMEM medium and centrifuging at 300 × <italic>g</italic> for 1 min. For collagen gel culture, a cold 3 mg/ml type 1A collagen solution (Nitta gelatin, Osaka, Japan Cat# Type-1-A) was neutralized by adding an 8:1:1 ratio of collagen: 10 x DMEM/F12: reconstitution buffer 200 mM HEPES, 50 mM NaOH, and 260 mM NaHCO3, then diluted in cold PBS to achieve a final concentration of 1.2 mg/ml. 10 μl of the neutralized collagen/medium solution was coated onto a 35 mm glass bottomed culture dish and solidified at 37°C for 30 min. The collected spheroids were suspended in 100 μl of the ice-cold collagen/medium solution, domed onto the lower collagen gel, and solidified at 37°C for 30 min. 2 ml of the complete medium was gently added to the dish, and Time-Lapse images were captured using a Keyence digital fluorescence microscope BZ-9000 using the 10X phase contrast objective lens.</p></sec><sec id="s4-4-6"><title>Cdc42 inhibition assay</title><p>Cells were transiently transfected with constitutively active Cdc42-Q61L 24 hr prior to seeding on 100 µg/ml PDL coated coverslips with or without 2 µg/ml rhTHSD7A. 24 hr after seeding, cells were treated with either vehicle (DMSO) or 10 µM ML141 (Millipore Cat# 217708) diluted in OptiMEM media for 60 min. After treatment, cells were fixed with 4% paraformaldehyde and stained with phalloidin to visualize filopodia and Hoechst to visualize nuclei.</p></sec></sec><sec id="s4-5"><title>Neuron methods</title><sec id="s4-5-1"><title>Reagents and constructs</title><p>mCherry-pTαS2 and GFP-pTαS2 vectors were a kind gift from the laboratory of Donna Webb at Vanderbilt University (<xref ref-type="bibr" rid="bib80">Shi et al., 2013</xref>). Stable knockdown in neurons was achieved by using the pSuper system with target sequences against Hrs: 5’-<named-content content-type="sequence">AATGAACCCAAGTACAAGG</named-content>-3’ and 5’- <named-content content-type="sequence">ATGAAGAGCAACCACATGA</named-content>-3’, and against Rab27b: 5’- <named-content content-type="sequence">CCGATACACAGACAATAAA</named-content>-3’ (shRab27b-1) and 5’-<named-content content-type="sequence">TGAGTCAACTGCAGGCAAA</named-content>-3’. SV2 monoclonal antibodies were obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA). Alexa Fluor 488 Anti-Rabbit and Alexa Fluor 647 Anti-Mouse were from Molecular Probes. For neuronal cultures, B27 media was prepared by adding 2% B27 supplement and L-glutamine to neurobasal media.</p></sec><sec id="s4-5-2"><title>Primary cultures of neurons</title><p>Rat hippocampal and cortical neurons were isolated from day 19 embryos and plated on 1 mg/ml Poly-L-Lysine (PLL) or 50 µg/ml Poly-D-Lysine coated glass coverslips. Low-density cultures were prepared as described previously. In brief, the hippocampus and cortex were removed from dissected brains of day 19 rat embryos and incubated in 0.05% trypsin in HBSS for 10 min at 37°C. Neurons were washed with HBSS, homogenized by gentle mixing, and plated on PLL or PDL-coated coverslips. After 3–4 hr, neuron coverslips were transferred to 60 mm dishes containing primary astroglia for co-culture to promote neuronal health (<xref ref-type="bibr" rid="bib37">Kaech and Banker, 2006</xref>).</p></sec><sec id="s4-5-3"><title>SEV isolation and characterization</title><p>For neuronal SEVs, day in vitro (<italic>DIV</italic>) 9 cortical neurons cultured at high density (2.6 million in 100 mm culture dishes) were washed three times with HBSS. After the final wash, HBSS was replaced with 4 ml Neurobasal media per 100 mm dish. Neurobasal media does not contain serum but contains growth factors. Neurobasal conditioned media was collected after 4 hr incubation and processed for differential ultracentrifugation. Briefly, conditioned media was centrifuged sequentially at 300 x <italic>g</italic> for 10 min, 2000 x <italic>g</italic> for 25 min in a tabletop centrifuge, and 10,000 x <italic>g</italic> for 30 min in a Type 45 Ti ultracentrifuge rotor (Beckman) to remove live cells, cell debris, and LEVs, respectively. The supernatant from the 10,000 x <italic>g</italic> spin was centrifuged at 100,000 x <italic>g</italic> for 18 hr in a Type 45 Ti rotor to obtain SEVs. The 100,000 x <italic>g</italic> SEV-containing pellets were resuspended in 3 ml sterile cold PBS and repelleted at 100,000 x <italic>g</italic> for 4 hrs in a TLA110 rotor (Beckman). SEVs were analyzed for size and number by nanoparticle tracking (ZetaView, ParticleMetrix), for morphology by TEM, and for common SEV markers by western blotting.</p></sec><sec id="s4-5-4"><title>Western blot analysis</title><p>Neuron TCL and EV samples for western blot were prepared as described above in the cancer cell Western blot methods section. Antibodies (for neurons): rabbit anti-TSG101 (Abcam Cat# ab30871), mouse anti-Flotillin-1 (BD Biosciences Cat# 610820), Mouse anti-Alix (Cell Signaling Cat# 2171), mouse anti-GM130 (BD Biosciences Cat# 610822), rabbit anti-THSD7A (Sigma Cat# HPA000923).</p></sec><sec id="s4-5-5"><title>Calcium phosphate transfection</title><p>Neurons plated at low density on coated glass coverslips were transfected with a modified calcium phosphate transfection method at day 3 or 5 as previously described (<xref ref-type="bibr" rid="bib44">Lin et al., 2013</xref>). 1 µg of mCherry-pTαS2 and either 1 µg of GFP-pTαS2 or 3 µgs of GFP-Rab27b/ shRNAs or 2 µgs of pCMV-FLAG/pCMV-FLAG-THSD7A were mixed with 120 µl of 250 mM CaCl<sub>2</sub> in an Eppendorf tube. 120 µl of 2X HEPES Buffered Saline (HBS; 274 mM NaCl, 9.5 mM KCl, 15 mM glucose, 42 mM HEPES, 1.4 mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.15) was added drop by drop to the DNA-CaCl<sub>2</sub> mixture with continuous aeration and incubated at room temperature for 15 min. The neuron coverslips were removed from co-cultures and transferred to sterile petri dishes, containing glial conditioned media, for dropwise addition of the transfection mixtures. Neurons were kept in the incubator at 37<sup>o</sup>C for 30–40 min and then washed three times with HBSS (135 mM NaCl, 4 mM KCl, 2 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 10 mM glucose, 20 mM HEPES, pH 7.35). The neuron coverslips were then transferred back to the home dishes containing astrocytes. The transfection efficiency was in the range of 5–10% using this method. Knockdown or expression of target genes was analyzed by immunofluorescence together with expression of co-transfected mCherry filler (shRNAs, see <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>) or fluorescence (GFP or GFP-Rab27b). Analysis of KD phenotypes was performed in transfected neurons, as assessed by fluorescence of the mCherry filler, as in previous publications (<xref ref-type="bibr" rid="bib18">Evans et al., 2015</xref>).</p></sec><sec id="s4-5-6"><title>Immunocytochemistry</title><p>For most antibodies, neurons were fixed in 4% paraformaldehyde in PBS for 15 min at RT and then permeabilized with 0.2% triton-X in PBS for 5 min at RT. For PSD95 staining, neurons were fixed in 4% paraformaldehyde in PBS for 3 min at RT and then incubated in cold methanol for 10 min at –20°C. Next, neurons were incubated for 1 hr with 20% goat serum to block non-specific antibody binding. Primary antibody was diluted in 5% goat serum in PBS with 1:1000 dilutions of antibody. Neurons were incubated with the primary antibody mixture overnight at 4°C. The secondary antibody mixture was prepared similarly to the primary antibody mixture. Neurons were incubated for 1 hr at room temperature with the secondary antibody mixture. Cells were washed three times with 1x PBS between each step. After the final wash with PBS, neuron coverslips were mounted on glass slides using AquaPoly Mount and allowed to dry overnight.</p></sec><sec id="s4-5-7"><title>Microscopy and image analysis</title><p>Neuronal imaging was performed on a Quorum Wave-FX Yokogawa CSU-X1 spinning disk confocal system with a Nikon Eclipse Ti microscope. Images were acquired using MetaMorph software (Molecular Devices, Sunnyvale, CA) and a Plan Apo TIRF 60x (NA 1.49) objective. Images for GFP, mCherry, and SV2 647/PSD95 647 were acquired by laser excitation at 491 nm, 561 nm, and 642 nm, respectively. Emission filters for these fluorophores were 525/50, 593/40, or 620/60 and 700/75, respectively (Semrock, Rochester, NY). Primary or secondary dendrites from confocal images were randomly selected for quantification of filopodia and spine density. Dendritic filopodia were defined as thin headless protrusions. Dendritic spines were identified as dendritic protrusions that co-localize with synaptic markers SV2. Synapses were defined as SV2-positive puncta present on both dendritic protrusions and dendritic shafts.</p></sec><sec id="s4-5-8"><title>Statistical analysis</title><p>The figure legends list the n values and independent experiment numbers for both quantitated data and representative images from experiments. All datasets were tested for normality using GraphPad Prism’s Kolmogorov-Smirnov or Shapiro-Wilk normality test. No sample or data points were omitted from analysis. The two-sided unpaired Mann-Whitney or two-sided paired Wilcoxon test compared nonparametric data groups. Parametric data were compared using a two-sided unpaired or paired Student’s t-test. Scatter plots were plotted with median and interquartile range or mean ± standard error of the mean. Bar graphs were plotted as mean ± standard error of the mean. All graphs were created using GraphPad Prism.</p></sec><sec id="s4-5-9"><title>Adherence to community standards</title><p>Characterization of extracellular vesicle populations was done in accordance with the ‘Minimal information for studies of extracellular vesicles’ (MISEV) published guidelines (<xref ref-type="bibr" rid="bib94">Théry et al., 2018</xref>; <xref ref-type="bibr" rid="bib106">Welsh et al., 2024</xref>).</p></sec></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Validation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Formal analysis</p></fn><fn fn-type="con" id="con9"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Resources, Supervision, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The use of rats for the isolation of embryonic neurons was conducted under the Vanderbilt Institutional Animal Care and Use Committee (IACUC)-approved Protocol #M1800027-00 to ensure humane care and treatment, and all experiments adhered to all relevant federal, state, and local laws and regulations. Experiments were designed to follow the 3Rs principle by minimizing animal use, employing alternative methods where possible, and refining procedures to reduce discomfort. Animals were housed and received appropriate care from the Vanderbilt Division of Animal Care.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Proteomics results from bands cut from colloidal blue gel in <xref ref-type="fig" rid="fig4">Figure 4A</xref>.</title></caption><media xlink:href="elife-101673-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>iTRAQ proteomics results from control and endoglin-KD B16F1 SEVs.</title></caption><media xlink:href="elife-101673-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-101673-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Two proteomics datasets were generated, and both the raw and analyzed data are provided in <xref ref-type="supplementary-material" rid="supp1 supp2">Supplementary files 1 and 2</xref>. All data generated or analyzed are included in the figures; source data files have been provided for all gels and blots in the manuscript, including <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>, <xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>, <xref ref-type="fig" rid="fig6">Figure 6</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>, <xref ref-type="fig" rid="fig7">Figure 7</xref> and <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>.</p></sec><ack id="ack"><title>Acknowledgements</title><p>Funding was provided by NIH R01GM117916, R01CA206458, R01CA249684, and R01CA249424 grants to AMW, by AHA fellowship 17POST33660473 and NIH training grant T32CA009592 support of COM, by Grant-in-Aid for JSPS KAKENHI (JP 17K15005) to DH, by NIH R50CA283661 to BHS. This project was begun as a collaborative project with Dr. Donna Webb, who passed away before her time. We acknowledge her important scientific contributions to this work, including her mentorship of Dr. Mikin Patel, her conceptual contributions to the project, expertise in neuroscience and cell adhesion mechanisms, and her insightful suggestions.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almagro</surname><given-names>S</given-names></name><name><surname>Durmort</surname><given-names>C</given-names></name><name><surname>Chervin-Pétinot</surname><given-names>A</given-names></name><name><surname>Heyraud</surname><given-names>S</given-names></name><name><surname>Dubois</surname><given-names>M</given-names></name><name><surname>Lambert</surname><given-names>O</given-names></name><name><surname>Maillefaud</surname><given-names>C</given-names></name><name><surname>Hewat</surname><given-names>E</given-names></name><name><surname>Schaal</surname><given-names>JP</given-names></name><name><surname>Huber</surname><given-names>P</given-names></name><name><surname>Gulino-Debrac</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The motor protein myosin-X transports VE-cadherin along filopodia to allow the formation of early endothelial cell-cell contacts</article-title><source>Molecular and Cellular Biology</source><volume>30</volume><fpage>1703</fpage><lpage>1717</lpage><pub-id pub-id-type="doi">10.1128/MCB.01226-09</pub-id><pub-id pub-id-type="pmid">20123970</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arjonen</surname><given-names>A</given-names></name><name><surname>Kaukonen</surname><given-names>R</given-names></name><name><surname>Ivaska</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Filopodia and adhesion in cancer cell motility</article-title><source>Cell Adhesion &amp; Migration</source><volume>5</volume><fpage>421</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.4161/cam.5.5.17723</pub-id><pub-id pub-id-type="pmid">21975551</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arjonen</surname><given-names>A</given-names></name><name><surname>Kaukonen</surname><given-names>R</given-names></name><name><surname>Mattila</surname><given-names>E</given-names></name><name><surname>Rouhi</surname><given-names>P</given-names></name><name><surname>Högnäs</surname><given-names>G</given-names></name><name><surname>Sihto</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>BW</given-names></name><name><surname>Morton</surname><given-names>JP</given-names></name><name><surname>Bucher</surname><given-names>E</given-names></name><name><surname>Taimen</surname><given-names>P</given-names></name><name><surname>Virtakoivu</surname><given-names>R</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Sansom</surname><given-names>OJ</given-names></name><name><surname>Joensuu</surname><given-names>H</given-names></name><name><surname>Ivaska</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis</article-title><source>The Journal of Clinical Investigation</source><volume>124</volume><fpage>1069</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1172/JCI67280</pub-id><pub-id pub-id-type="pmid">24487586</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asao</surname><given-names>T</given-names></name><name><surname>Tobias</surname><given-names>GC</given-names></name><name><surname>Lucotti</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>DR</given-names></name><name><surname>Matei</surname><given-names>I</given-names></name><name><surname>Lyden</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Extracellular vesicles and particles as mediators of long-range communication in cancer: connecting biological function to clinical applications</article-title><source>Extracellular Vesicles and Circulating Nucleic Acids</source><volume>4</volume><fpage>461</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.20517/evcna.2023.37</pub-id><pub-id pub-id-type="pmid">38707985</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbara</surname><given-names>NP</given-names></name><name><surname>Wrana</surname><given-names>JL</given-names></name><name><surname>Letarte</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily</article-title><source>The Journal of Biological Chemistry</source><volume>274</volume><fpage>584</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.2.584</pub-id><pub-id pub-id-type="pmid">9872992</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barral</surname><given-names>DC</given-names></name><name><surname>Ramalho</surname><given-names>JS</given-names></name><name><surname>Anders</surname><given-names>R</given-names></name><name><surname>Hume</surname><given-names>AN</given-names></name><name><surname>Knapton</surname><given-names>HJ</given-names></name><name><surname>Tolmachova</surname><given-names>T</given-names></name><name><surname>Collinson</surname><given-names>LM</given-names></name><name><surname>Goulding</surname><given-names>D</given-names></name><name><surname>Authi</surname><given-names>KS</given-names></name><name><surname>Seabra</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Functional redundancy of Rab27 proteins and the pathogenesis of Griscelli syndrome</article-title><source>The Journal of Clinical Investigation</source><volume>110</volume><fpage>247</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1172/JCI15058</pub-id><pub-id pub-id-type="pmid">12122117</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernabeu</surname><given-names>C</given-names></name><name><surname>Olivieri</surname><given-names>C</given-names></name><name><surname>Rossi</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Editorial: Role of membrane-bound and circulating endoglin in disease</article-title><source>Frontiers in Medicine</source><volume>10</volume><elocation-id>1271756</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2023.1271756</pub-id><pub-id pub-id-type="pmid">37731711</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bindels</surname><given-names>DS</given-names></name><name><surname>Haarbosch</surname><given-names>L</given-names></name><name><surname>van Weeren</surname><given-names>L</given-names></name><name><surname>Postma</surname><given-names>M</given-names></name><name><surname>Wiese</surname><given-names>KE</given-names></name><name><surname>Mastop</surname><given-names>M</given-names></name><name><surname>Aumonier</surname><given-names>S</given-names></name><name><surname>Gotthard</surname><given-names>G</given-names></name><name><surname>Royant</surname><given-names>A</given-names></name><name><surname>Hink</surname><given-names>MA</given-names></name><name><surname>Gadella</surname><given-names>TWJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>mScarlet: a bright monomeric red fluorescent protein for cellular imaging</article-title><source>Nature Methods</source><volume>14</volume><fpage>53</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4074</pub-id><pub-id pub-id-type="pmid">27869816</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blake</surname><given-names>TCA</given-names></name><name><surname>Gallop</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Filopodia in vitro and in vivo</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>39</volume><fpage>307</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1146/annurev-cellbio-020223-025210</pub-id><pub-id pub-id-type="pmid">37406300</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohil</surname><given-names>AB</given-names></name><name><surname>Robertson</surname><given-names>BW</given-names></name><name><surname>Cheney</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Myosin-X is a molecular motor that functions in filopodia formation</article-title><source>PNAS</source><volume>103</volume><fpage>12411</fpage><lpage>12416</lpage><pub-id pub-id-type="doi">10.1073/pnas.0602443103</pub-id><pub-id pub-id-type="pmid">16894163</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Leone</surname><given-names>DA</given-names></name><name><surname>Majek</surname><given-names>P</given-names></name><name><surname>Vaahtomeri</surname><given-names>K</given-names></name><name><surname>Senfter</surname><given-names>D</given-names></name><name><surname>Bukosza</surname><given-names>N</given-names></name><name><surname>Schachner</surname><given-names>H</given-names></name><name><surname>Asfour</surname><given-names>G</given-names></name><name><surname>Langer</surname><given-names>B</given-names></name><name><surname>Hauschild</surname><given-names>R</given-names></name><name><surname>Parapatics</surname><given-names>K</given-names></name><name><surname>Hong</surname><given-names>YK</given-names></name><name><surname>Bennett</surname><given-names>KL</given-names></name><name><surname>Kain</surname><given-names>R</given-names></name><name><surname>Detmar</surname><given-names>M</given-names></name><name><surname>Sixt</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>DG</given-names></name><name><surname>Kerjaschki</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Lymphatic exosomes promote dendritic cell migration along guidance cues</article-title><source>The Journal of Cell Biology</source><volume>217</volume><fpage>2205</fpage><lpage>2221</lpage><pub-id pub-id-type="doi">10.1083/jcb.201612051</pub-id><pub-id pub-id-type="pmid">29650776</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryce</surname><given-names>NS</given-names></name><name><surname>Clark</surname><given-names>ES</given-names></name><name><surname>Leysath</surname><given-names>JL</given-names></name><name><surname>Currie</surname><given-names>JD</given-names></name><name><surname>Webb</surname><given-names>DJ</given-names></name><name><surname>Weaver</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Cortactin promotes cell motility by enhancing lamellipodial persistence</article-title><source>Current Biology</source><volume>15</volume><fpage>1276</fpage><lpage>1285</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2005.06.043</pub-id><pub-id pub-id-type="pmid">16051170</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castonguay</surname><given-names>R</given-names></name><name><surname>Werner</surname><given-names>ED</given-names></name><name><surname>Matthews</surname><given-names>RG</given-names></name><name><surname>Presman</surname><given-names>E</given-names></name><name><surname>Mulivor</surname><given-names>AW</given-names></name><name><surname>Solban</surname><given-names>N</given-names></name><name><surname>Sako</surname><given-names>D</given-names></name><name><surname>Pearsall</surname><given-names>RS</given-names></name><name><surname>Underwood</surname><given-names>KW</given-names></name><name><surname>Seehra</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Grinberg</surname><given-names>AV</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>30034</fpage><lpage>30046</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.260133</pub-id><pub-id pub-id-type="pmid">21737454</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheifetz</surname><given-names>S</given-names></name><name><surname>Bellón</surname><given-names>T</given-names></name><name><surname>Calés</surname><given-names>C</given-names></name><name><surname>Vera</surname><given-names>S</given-names></name><name><surname>Bernabeu</surname><given-names>C</given-names></name><name><surname>Massagué</surname><given-names>J</given-names></name><name><surname>Letarte</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells</article-title><source>The Journal of Biological Chemistry</source><volume>267</volume><fpage>19027</fpage><lpage>19030</lpage><pub-id pub-id-type="pmid">1326540</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>B</given-names></name><name><surname>Stavnes</surname><given-names>HT</given-names></name><name><surname>Førsund</surname><given-names>M</given-names></name><name><surname>Berner</surname><given-names>A</given-names></name><name><surname>Staff</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival</article-title><source>Breast</source><volume>19</volume><fpage>493</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/j.breast.2010.05.013</pub-id><pub-id pub-id-type="pmid">21078485</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Oliveira</surname><given-names>MVM</given-names></name><name><surname>de Carvalho Fraga</surname><given-names>CA</given-names></name><name><surname>Barros</surname><given-names>LO</given-names></name><name><surname>Pereira</surname><given-names>CS</given-names></name><name><surname>Santos</surname><given-names>SHS</given-names></name><name><surname>Basile</surname><given-names>JR</given-names></name><name><surname>Gomez</surname><given-names>RS</given-names></name><name><surname>Guimarães</surname><given-names>ALS</given-names></name><name><surname>De-Paula</surname><given-names>AMB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>High expression of S100A4 and endoglin is associated with metastatic disease in head and neck squamous cell carcinoma</article-title><source>Clinical &amp; Experimental Metastasis</source><volume>31</volume><fpage>639</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1007/s10585-014-9655-4</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixson</surname><given-names>AC</given-names></name><name><surname>Dawson</surname><given-names>TR</given-names></name><name><surname>Di Vizio</surname><given-names>D</given-names></name><name><surname>Weaver</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Context-specific regulation of extracellular vesicle biogenesis and cargo selection</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>24</volume><fpage>454</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1038/s41580-023-00576-0</pub-id><pub-id pub-id-type="pmid">36765164</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>JC</given-names></name><name><surname>Robinson</surname><given-names>CM</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Webb</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The guanine nucleotide exchange factor (GEF) Asef2 promotes dendritic spine formation via Rac activation and spinophilin-dependent targeting</article-title><source>The Journal of Biological Chemistry</source><volume>290</volume><fpage>10295</fpage><lpage>10308</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.605543</pub-id><pub-id pub-id-type="pmid">25750125</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiala</surname><given-names>JC</given-names></name><name><surname>Feinberg</surname><given-names>M</given-names></name><name><surname>Popov</surname><given-names>V</given-names></name><name><surname>Harris</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Synaptogenesis via dendritic filopodia in developing hippocampal area CA1</article-title><source>The Journal of Neuroscience</source><volume>18</volume><fpage>8900</fpage><lpage>8911</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.18-21-08900.1998</pub-id><pub-id pub-id-type="pmid">9786995</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>RS</given-names></name><name><surname>Lam</surname><given-names>PY</given-names></name><name><surname>Huttenlocher</surname><given-names>A</given-names></name><name><surname>Waterman</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Filopodia and focal adhesions: An integrated system driving branching morphogenesis in neuronal pathfinding and angiogenesis</article-title><source>Developmental Biology</source><volume>451</volume><fpage>86</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2018.08.015</pub-id><pub-id pub-id-type="pmid">30193787</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallop</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Filopodia and their links with membrane traffic and cell adhesion</article-title><source>Seminars in Cell &amp; Developmental Biology</source><volume>102</volume><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2019.11.017</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamell</surname><given-names>C</given-names></name><name><surname>Osses</surname><given-names>N</given-names></name><name><surname>Bartrons</surname><given-names>R</given-names></name><name><surname>Rückle</surname><given-names>T</given-names></name><name><surname>Camps</surname><given-names>M</given-names></name><name><surname>Rosa</surname><given-names>JL</given-names></name><name><surname>Ventura</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>BMP2 induction of actin cytoskeleton reorganization and cell migration requires PI3-kinase and Cdc42 activity</article-title><source>Journal of Cell Science</source><volume>121</volume><fpage>3960</fpage><lpage>3970</lpage><pub-id pub-id-type="doi">10.1242/jcs.031286</pub-id><pub-id pub-id-type="pmid">19001503</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerhardt</surname><given-names>H</given-names></name><name><surname>Golding</surname><given-names>M</given-names></name><name><surname>Fruttiger</surname><given-names>M</given-names></name><name><surname>Ruhrberg</surname><given-names>C</given-names></name><name><surname>Lundkvist</surname><given-names>A</given-names></name><name><surname>Abramsson</surname><given-names>A</given-names></name><name><surname>Jeltsch</surname><given-names>M</given-names></name><name><surname>Mitchell</surname><given-names>C</given-names></name><name><surname>Alitalo</surname><given-names>K</given-names></name><name><surname>Shima</surname><given-names>D</given-names></name><name><surname>Betsholtz</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia</article-title><source>The Journal of Cell Biology</source><volume>161</volume><fpage>1163</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1083/jcb.200302047</pub-id><pub-id pub-id-type="pmid">12810700</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González Muñoz</surname><given-names>T</given-names></name><name><surname>Amaral</surname><given-names>AT</given-names></name><name><surname>Puerto-Camacho</surname><given-names>P</given-names></name><name><surname>Peinado</surname><given-names>H</given-names></name><name><surname>de Álava</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Endoglin in the spotlight to treat cancer</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>3186</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22063186</pub-id><pub-id pub-id-type="pmid">33804796</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govani</surname><given-names>FS</given-names></name><name><surname>Shovlin</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Hereditary haemorrhagic telangiectasia: a clinical and scientific review</article-title><source>European Journal of Human Genetics</source><volume>17</volume><fpage>860</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2009.35</pub-id><pub-id pub-id-type="pmid">19337313</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammers</surname><given-names>DW</given-names></name><name><surname>Hart</surname><given-names>CC</given-names></name><name><surname>Matheny</surname><given-names>MK</given-names></name><name><surname>Heimsath</surname><given-names>EG</given-names></name><name><surname>Lee</surname><given-names>YI</given-names></name><name><surname>Hammer</surname><given-names>JA</given-names></name><name><surname>Cheney</surname><given-names>RE</given-names></name><name><surname>Sweeney</surname><given-names>HL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Filopodia powered by class x myosin promote fusion of mammalian myoblasts</article-title><source>eLife</source><volume>10</volume><elocation-id>e72419</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.72419</pub-id><pub-id pub-id-type="pmid">34519272</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>DJ</given-names></name><name><surname>Adams</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The roles of fascins in health and disease</article-title><source>The Journal of Pathology</source><volume>224</volume><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1002/path.2894</pub-id><pub-id pub-id-type="pmid">21618240</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heckman</surname><given-names>CA</given-names></name><name><surname>Plummer</surname><given-names>HK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Filopodia as sensors</article-title><source>Cellular Signalling</source><volume>25</volume><fpage>2298</fpage><lpage>2311</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2013.07.006</pub-id><pub-id pub-id-type="pmid">23876793</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heimsath</surname><given-names>EG</given-names></name><name><surname>Yim</surname><given-names>YI</given-names></name><name><surname>Mustapha</surname><given-names>M</given-names></name><name><surname>Hammer</surname><given-names>JA</given-names></name><name><surname>Cheney</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Myosin-X knockout is semi-lethal and demonstrates that myosin-X functions in neural tube closure, pigmentation, hyaloid vasculature regression, and filopodia formation</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>17354</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-17638-x</pub-id><pub-id pub-id-type="pmid">29229982</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herwig</surname><given-names>J</given-names></name><name><surname>Skuza</surname><given-names>S</given-names></name><name><surname>Sachs</surname><given-names>W</given-names></name><name><surname>Sachs</surname><given-names>M</given-names></name><name><surname>Failla</surname><given-names>AV</given-names></name><name><surname>Rune</surname><given-names>G</given-names></name><name><surname>Meyer</surname><given-names>TN</given-names></name><name><surname>Fester</surname><given-names>L</given-names></name><name><surname>Meyer-Schwesinger</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Thrombospondin type 1 domain-containing 7A localizes to the slit diaphragm and stabilizes membrane dynamics of fully differentiated podocytes</article-title><source>Journal of the American Society of Nephrology</source><volume>30</volume><fpage>824</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1681/ASN.2018090941</pub-id><pub-id pub-id-type="pmid">30971456</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusermann</surname><given-names>W</given-names></name><name><surname>Hean</surname><given-names>J</given-names></name><name><surname>Trojer</surname><given-names>D</given-names></name><name><surname>Steib</surname><given-names>E</given-names></name><name><surname>von Bueren</surname><given-names>S</given-names></name><name><surname>Graff-Meyer</surname><given-names>A</given-names></name><name><surname>Genoud</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>K</given-names></name><name><surname>Pizzato</surname><given-names>N</given-names></name><name><surname>Voshol</surname><given-names>J</given-names></name><name><surname>Morrissey</surname><given-names>DV</given-names></name><name><surname>Andaloussi</surname><given-names>SEL</given-names></name><name><surname>Wood</surname><given-names>MJ</given-names></name><name><surname>Meisner-Kober</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Exosomes surf on filopodia to enter cells at endocytic hot spots, traffic within endosomes, and are targeted to the ER</article-title><source>The Journal of Cell Biology</source><volume>213</volume><fpage>173</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1083/jcb.201506084</pub-id><pub-id pub-id-type="pmid">27114500</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshino</surname><given-names>D</given-names></name><name><surname>Kirkbride</surname><given-names>KC</given-names></name><name><surname>Costello</surname><given-names>K</given-names></name><name><surname>Clark</surname><given-names>ES</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Grega-Larson</surname><given-names>N</given-names></name><name><surname>Tyska</surname><given-names>MJ</given-names></name><name><surname>Weaver</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Exosome secretion is enhanced by invadopodia and drives invasive behavior</article-title><source>Cell Reports</source><volume>5</volume><fpage>1159</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.10.050</pub-id><pub-id pub-id-type="pmid">24290760</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>Z</given-names></name><name><surname>Abudureheman</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Hasim</surname><given-names>A</given-names></name><name><surname>Ainiwaer</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Niyaz</surname><given-names>M</given-names></name><name><surname>Upur</surname><given-names>H</given-names></name><name><surname>Sheyhidin</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Expression, prognosis and functional role of Thsd7a in esophageal squamous cell carcinoma of Kazakh patients, Xinjiang</article-title><source>Oncotarget</source><volume>8</volume><fpage>60539</fpage><lpage>60557</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16966</pub-id><pub-id pub-id-type="pmid">28947992</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacquemet</surname><given-names>G</given-names></name><name><surname>Hamidi</surname><given-names>H</given-names></name><name><surname>Ivaska</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Filopodia in cell adhesion, 3D migration and cancer cell invasion</article-title><source>Current Opinion in Cell Biology</source><volume>36</volume><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2015.06.007</pub-id><pub-id pub-id-type="pmid">26186729</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacquemet</surname><given-names>G</given-names></name><name><surname>Paatero</surname><given-names>I</given-names></name><name><surname>Carisey</surname><given-names>AF</given-names></name><name><surname>Padzik</surname><given-names>A</given-names></name><name><surname>Orange</surname><given-names>JS</given-names></name><name><surname>Hamidi</surname><given-names>H</given-names></name><name><surname>Ivaska</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>FiloQuant reveals increased filopodia density during breast cancer progression</article-title><source>The Journal of Cell Biology</source><volume>216</volume><fpage>3387</fpage><lpage>3403</lpage><pub-id pub-id-type="doi">10.1083/jcb.201704045</pub-id><pub-id pub-id-type="pmid">28765364</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonker</surname><given-names>LT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets</article-title><source>Microcirculation</source><volume>21</volume><fpage>93</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1111/micc.12099</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaech</surname><given-names>S</given-names></name><name><surname>Banker</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Culturing hippocampal neurons</article-title><source>Nature Protocols</source><volume>1</volume><fpage>2406</fpage><lpage>2415</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.356</pub-id><pub-id pub-id-type="pmid">17406484</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanjhan</surname><given-names>R</given-names></name><name><surname>Noakes</surname><given-names>PG</given-names></name><name><surname>Bellingham</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Emerging roles of filopodia and dendritic spines in motoneuron plasticity during development and disease</article-title><source>Neural Plasticity</source><volume>2016</volume><elocation-id>3423267</elocation-id><pub-id pub-id-type="doi">10.1155/2016/3423267</pub-id><pub-id pub-id-type="pmid">26843990</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ketschek</surname><given-names>A</given-names></name><name><surname>Gallo</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Nerve growth factor induces axonal filopodia through localized microdomains of phosphoinositide 3-kinase activity that drive the formation of cytoskeletal precursors to filopodia</article-title><source>The Journal of Neuroscience</source><volume>30</volume><fpage>12185</fpage><lpage>12197</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1740-10.2010</pub-id><pub-id pub-id-type="pmid">20826681</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kriebel</surname><given-names>PW</given-names></name><name><surname>Majumdar</surname><given-names>R</given-names></name><name><surname>Jenkins</surname><given-names>LM</given-names></name><name><surname>Senoo</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Ammu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Narayan</surname><given-names>K</given-names></name><name><surname>Iijima</surname><given-names>M</given-names></name><name><surname>Parent</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Extracellular vesicles direct migration by synthesizing and releasing chemotactic signals</article-title><source>The Journal of Cell Biology</source><volume>217</volume><fpage>2891</fpage><lpage>2910</lpage><pub-id pub-id-type="doi">10.1083/jcb.201710170</pub-id><pub-id pub-id-type="pmid">29884750</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>MW</given-names></name><name><surname>Wang</surname><given-names>CH</given-names></name><name><surname>Wu</surname><given-names>HC</given-names></name><name><surname>Chang</surname><given-names>SJ</given-names></name><name><surname>Chuang</surname><given-names>YJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Soluble THSD7A is an N-glycoprotein that promotes endothelial cell migration and tube formation in angiogenesis</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e29000</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0029000</pub-id><pub-id pub-id-type="pmid">22194972</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee-Hoeflich</surname><given-names>ST</given-names></name><name><surname>Causing</surname><given-names>CG</given-names></name><name><surname>Podkowa</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Wrana</surname><given-names>JL</given-names></name><name><surname>Attisano</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Activation of LIMK1 by binding to the BMP receptor, BMPRII, regulates BMP-dependent dendritogenesis</article-title><source>The EMBO Journal</source><volume>23</volume><fpage>4792</fpage><lpage>4801</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600418</pub-id><pub-id pub-id-type="pmid">15538389</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Wong</surname><given-names>DK</given-names></name><name><surname>Hong</surname><given-names>KY</given-names></name><name><surname>Raffai</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cushioned-Density Gradient Ultracentrifugation (C-DGUC): A refined and high performance method for the isolation, characterization, and use of exosomes</article-title><source>Methods in Molecular Biology</source><volume>1740</volume><fpage>69</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7652-2_7</pub-id><pub-id pub-id-type="pmid">29388137</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>WH</given-names></name><name><surname>Hurley</surname><given-names>JT</given-names></name><name><surname>Raines</surname><given-names>AN</given-names></name><name><surname>Cheney</surname><given-names>RE</given-names></name><name><surname>Webb</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Myosin X and its motorless isoform differentially modulate dendritic spine development by regulating trafficking and retention of vasodilator-stimulated phosphoprotein</article-title><source>Journal of Cell Science</source><volume>126</volume><fpage>4756</fpage><lpage>4768</lpage><pub-id pub-id-type="doi">10.1242/jcs.132969</pub-id><pub-id pub-id-type="pmid">23943878</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>LYM</given-names></name><name><surname>Lin</surname><given-names>MH</given-names></name><name><surname>Lai</surname><given-names>ZY</given-names></name><name><surname>Jiang</surname><given-names>JP</given-names></name><name><surname>Huang</surname><given-names>YC</given-names></name><name><surname>Jao</surname><given-names>LE</given-names></name><name><surname>Chuang</surname><given-names>YJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Motor neuron-derived Thsd7a is essential for zebrafish vascular development via the Notch-dll4 signaling pathway</article-title><source>Journal of Biomedical Science</source><volume>23</volume><elocation-id>59</elocation-id><pub-id pub-id-type="doi">10.1186/s12929-016-0277-9</pub-id><pub-id pub-id-type="pmid">27484901</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lötvall</surname><given-names>J</given-names></name><name><surname>Hill</surname><given-names>AF</given-names></name><name><surname>Hochberg</surname><given-names>F</given-names></name><name><surname>Buzás</surname><given-names>EI</given-names></name><name><surname>Di Vizio</surname><given-names>D</given-names></name><name><surname>Gardiner</surname><given-names>C</given-names></name><name><surname>Gho</surname><given-names>YS</given-names></name><name><surname>Kurochkin</surname><given-names>IV</given-names></name><name><surname>Mathivanan</surname><given-names>S</given-names></name><name><surname>Quesenberry</surname><given-names>P</given-names></name><name><surname>Sahoo</surname><given-names>S</given-names></name><name><surname>Tahara</surname><given-names>H</given-names></name><name><surname>Wauben</surname><given-names>MH</given-names></name><name><surname>Witwer</surname><given-names>KW</given-names></name><name><surname>Théry</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles</article-title><source>Journal of Extracellular Vesicles</source><volume>3</volume><elocation-id>26913</elocation-id><pub-id pub-id-type="doi">10.3402/jev.v3.26913</pub-id><pub-id pub-id-type="pmid">25536934</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maas</surname><given-names>SLN</given-names></name><name><surname>Breakefield</surname><given-names>XO</given-names></name><name><surname>Weaver</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Extracellular vesicles: Unique intercellular delivery vehicles</article-title><source>Trends in Cell Biology</source><volume>27</volume><fpage>172</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2016.11.003</pub-id><pub-id pub-id-type="pmid">27979573</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machesky</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Lamellipodia and filopodia in metastasis and invasion</article-title><source>FEBS Letters</source><volume>582</volume><fpage>2102</fpage><lpage>2111</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2008.03.039</pub-id><pub-id pub-id-type="pmid">18396168</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machesky</surname><given-names>LM</given-names></name><name><surname>Li</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Fascin: Invasive filopodia promoting metastasis</article-title><source>Communicative &amp; Integrative Biology</source><volume>3</volume><fpage>263</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.4161/cib.3.3.11556</pub-id><pub-id pub-id-type="pmid">20714410</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majumdar</surname><given-names>R</given-names></name><name><surname>Tavakoli Tameh</surname><given-names>A</given-names></name><name><surname>Arya</surname><given-names>SB</given-names></name><name><surname>Parent</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Exosomes mediate LTB4 release during neutrophil chemotaxis</article-title><source>PLOS Biology</source><volume>19</volume><elocation-id>e3001271</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3001271</pub-id><pub-id pub-id-type="pmid">34232954</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>S</given-names></name><name><surname>Bourdeau</surname><given-names>A</given-names></name><name><surname>terBrugge</surname><given-names>KG</given-names></name><name><surname>Wallace</surname><given-names>C</given-names></name><name><surname>Letarte</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Analysis of endoglin expression in normal brain tissue and in cerebral arteriovenous malformations</article-title><source>Stroke</source><volume>31</volume><fpage>2653</fpage><lpage>2660</lpage><pub-id pub-id-type="doi">10.1161/01.str.31.11.2653</pub-id><pub-id pub-id-type="pmid">11062290</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattila</surname><given-names>PK</given-names></name><name><surname>Lappalainen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Filopodia: molecular architecture and cellular functions</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>9</volume><fpage>446</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/nrm2406</pub-id><pub-id pub-id-type="pmid">18464790</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConnell</surname><given-names>RE</given-names></name><name><surname>Higginbotham</surname><given-names>JN</given-names></name><name><surname>Shifrin</surname><given-names>DA</given-names><suffix>Jr</suffix></name><name><surname>Tabb</surname><given-names>DL</given-names></name><name><surname>Coffey</surname><given-names>RJ</given-names></name><name><surname>Tyska</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The enterocyte microvillus is a vesicle-generating organelle</article-title><source>The Journal of Cell Biology</source><volume>185</volume><fpage>1285</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1083/jcb.200902147</pub-id><pub-id pub-id-type="pmid">19564407</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConnell</surname><given-names>RE</given-names></name><name><surname>Edward van Veen</surname><given-names>J</given-names></name><name><surname>Vidaki</surname><given-names>M</given-names></name><name><surname>Kwiatkowski</surname><given-names>AV</given-names></name><name><surname>Meyer</surname><given-names>AS</given-names></name><name><surname>Gertler</surname><given-names>FB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A requirement for filopodia extension toward Slit during Robo-mediated axon repulsion</article-title><source>The Journal of Cell Biology</source><volume>213</volume><fpage>261</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1083/jcb.201509062</pub-id><pub-id pub-id-type="pmid">27091449</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menna</surname><given-names>E</given-names></name><name><surname>Disanza</surname><given-names>A</given-names></name><name><surname>Cagnoli</surname><given-names>C</given-names></name><name><surname>Schenk</surname><given-names>U</given-names></name><name><surname>Gelsomino</surname><given-names>G</given-names></name><name><surname>Frittoli</surname><given-names>E</given-names></name><name><surname>Hertzog</surname><given-names>M</given-names></name><name><surname>Offenhauser</surname><given-names>N</given-names></name><name><surname>Sawallisch</surname><given-names>C</given-names></name><name><surname>Kreienkamp</surname><given-names>H-J</given-names></name><name><surname>Gertler</surname><given-names>FB</given-names></name><name><surname>Di Fiore</surname><given-names>PP</given-names></name><name><surname>Scita</surname><given-names>G</given-names></name><name><surname>Matteoli</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Eps8 regulates axonal filopodia in hippocampal neurons in response to brain-derived neurotrophic factor (BDNF)</article-title><source>PLOS Biology</source><volume>7</volume><elocation-id>e1000138</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1000138</pub-id><pub-id pub-id-type="pmid">19564905</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertins</surname><given-names>P</given-names></name><name><surname>Udeshi</surname><given-names>ND</given-names></name><name><surname>Clauser</surname><given-names>KR</given-names></name><name><surname>Mani</surname><given-names>DR</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Ong</surname><given-names>S</given-names></name><name><surname>Jaffe</surname><given-names>JD</given-names></name><name><surname>Carr</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>11</volume><elocation-id>M111</elocation-id><pub-id pub-id-type="doi">10.1074/mcp.M111.014423</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>ZF</given-names></name><name><surname>Wu</surname><given-names>JH</given-names></name><name><surname>Wang</surname><given-names>ZN</given-names></name><name><surname>Zhao</surname><given-names>TT</given-names></name><name><surname>Xu</surname><given-names>HM</given-names></name><name><surname>Song</surname><given-names>YX</given-names></name><name><surname>Xing</surname><given-names>YN</given-names></name><name><surname>Huang</surname><given-names>JY</given-names></name><name><surname>Zhang</surname><given-names>JY</given-names></name><name><surname>Liu</surname><given-names>XY</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>YY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Endoglin overexpression mediates gastric cancer peritoneal dissemination by inducing mesothelial cell senescence</article-title><source>Human Pathology</source><volume>51</volume><fpage>114</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2015.12.023</pub-id><pub-id pub-id-type="pmid">27067789</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miesenböck</surname><given-names>G</given-names></name><name><surname>De Angelis</surname><given-names>DA</given-names></name><name><surname>Rothman</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins</article-title><source>Nature</source><volume>394</volume><fpage>192</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1038/28190</pub-id><pub-id pub-id-type="pmid">9671304</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miihkinen</surname><given-names>M</given-names></name><name><surname>Grönloh</surname><given-names>MLB</given-names></name><name><surname>Popović</surname><given-names>A</given-names></name><name><surname>Vihinen</surname><given-names>H</given-names></name><name><surname>Jokitalo</surname><given-names>E</given-names></name><name><surname>Goult</surname><given-names>BT</given-names></name><name><surname>Ivaska</surname><given-names>J</given-names></name><name><surname>Jacquemet</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Myosin-X and talin modulate integrin activity at filopodia tips</article-title><source>Cell Reports</source><volume>36</volume><elocation-id>109716</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109716</pub-id><pub-id pub-id-type="pmid">34525374</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nassiri</surname><given-names>F</given-names></name><name><surname>Cusimano</surname><given-names>MD</given-names></name><name><surname>Scheithauer</surname><given-names>BW</given-names></name><name><surname>Rotondo</surname><given-names>F</given-names></name><name><surname>Fazio</surname><given-names>A</given-names></name><name><surname>Yousef</surname><given-names>GM</given-names></name><name><surname>Syro</surname><given-names>LV</given-names></name><name><surname>Kovacs</surname><given-names>K</given-names></name><name><surname>Lloyd</surname><given-names>RV</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy</article-title><source>Anticancer Research</source><volume>31</volume><fpage>2283</fpage><lpage>2290</lpage><pub-id pub-id-type="pmid">21737653</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>T</given-names></name><name><surname>Oyama</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>HT</given-names></name><name><surname>Fujioka</surname><given-names>T</given-names></name><name><surname>Hanawa-Suetsugu</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Kawana</surname><given-names>H</given-names></name><name><surname>Saigusa</surname><given-names>D</given-names></name><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Kurata</surname><given-names>R</given-names></name><name><surname>Oono-Yakura</surname><given-names>K</given-names></name><name><surname>Kitamata</surname><given-names>M</given-names></name><name><surname>Kida</surname><given-names>K</given-names></name><name><surname>Hikita</surname><given-names>T</given-names></name><name><surname>Mizutani</surname><given-names>K</given-names></name><name><surname>Yasuhara</surname><given-names>K</given-names></name><name><surname>Mimori-Kiyosue</surname><given-names>Y</given-names></name><name><surname>Oneyama</surname><given-names>C</given-names></name><name><surname>Kurimoto</surname><given-names>K</given-names></name><name><surname>Hosokawa</surname><given-names>Y</given-names></name><name><surname>Aoki</surname><given-names>J</given-names></name><name><surname>Takai</surname><given-names>Y</given-names></name><name><surname>Arita</surname><given-names>M</given-names></name><name><surname>Suetsugu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Filopodium-derived vesicles produced by MIM enhance the migration of recipient cells</article-title><source>Developmental Cell</source><volume>56</volume><fpage>842</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2021.02.029</pub-id><pub-id pub-id-type="pmid">33756122</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nobes</surname><given-names>CD</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia</article-title><source>Cell</source><volume>81</volume><fpage>53</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90370-4</pub-id><pub-id pub-id-type="pmid">7536630</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrowski</surname><given-names>M</given-names></name><name><surname>Carmo</surname><given-names>NB</given-names></name><name><surname>Krumeich</surname><given-names>S</given-names></name><name><surname>Fanget</surname><given-names>I</given-names></name><name><surname>Raposo</surname><given-names>G</given-names></name><name><surname>Savina</surname><given-names>A</given-names></name><name><surname>Moita</surname><given-names>CF</given-names></name><name><surname>Schauer</surname><given-names>K</given-names></name><name><surname>Hume</surname><given-names>AN</given-names></name><name><surname>Freitas</surname><given-names>RP</given-names></name><name><surname>Goud</surname><given-names>B</given-names></name><name><surname>Benaroch</surname><given-names>P</given-names></name><name><surname>Hacohen</surname><given-names>N</given-names></name><name><surname>Fukuda</surname><given-names>M</given-names></name><name><surname>Desnos</surname><given-names>C</given-names></name><name><surname>Seabra</surname><given-names>MC</given-names></name><name><surname>Darchen</surname><given-names>F</given-names></name><name><surname>Amigorena</surname><given-names>S</given-names></name><name><surname>Moita</surname><given-names>LF</given-names></name><name><surname>Thery</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Rab27a and Rab27b control different steps of the exosome secretion pathway</article-title><source>Nature Cell Biology</source><volume>12</volume><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1038/ncb2000</pub-id><pub-id pub-id-type="pmid">19966785</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oxmann</surname><given-names>D</given-names></name><name><surname>Held-Feindt</surname><given-names>J</given-names></name><name><surname>Stark</surname><given-names>AM</given-names></name><name><surname>Hattermann</surname><given-names>K</given-names></name><name><surname>Yoneda</surname><given-names>T</given-names></name><name><surname>Mentlein</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype</article-title><source>Oncogene</source><volume>27</volume><fpage>3567</fpage><lpage>3575</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1211025</pub-id><pub-id pub-id-type="pmid">18223685</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paauwe</surname><given-names>M</given-names></name><name><surname>Heijkants</surname><given-names>RC</given-names></name><name><surname>Oudt</surname><given-names>CH</given-names></name><name><surname>van Pelt</surname><given-names>GW</given-names></name><name><surname>Cui</surname><given-names>C</given-names></name><name><surname>Theuer</surname><given-names>CP</given-names></name><name><surname>Hardwick</surname><given-names>JCH</given-names></name><name><surname>Sier</surname><given-names>CFM</given-names></name><name><surname>Hawinkels</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer</article-title><source>Oncogene</source><volume>35</volume><fpage>4069</fpage><lpage>4079</lpage><pub-id pub-id-type="doi">10.1038/onc.2015.509</pub-id><pub-id pub-id-type="pmid">26804178</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>TD</given-names></name><name><surname>Lewis</surname><given-names>J</given-names></name><name><surname>Zijlstra</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Quantitative analysis of cancer metastasis using an avian embryo model</article-title><source>Journal of Visualized Experiments</source><volume>01</volume><elocation-id>2815</elocation-id><pub-id pub-id-type="doi">10.3791/2815</pub-id><pub-id pub-id-type="pmid">21673636</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>TD</given-names></name><name><surname>Martínez</surname><given-names>CH</given-names></name><name><surname>Vasquez</surname><given-names>C</given-names></name><name><surname>Hebron</surname><given-names>KE</given-names></name><name><surname>Jones-Paris</surname><given-names>C</given-names></name><name><surname>Arnold</surname><given-names>SA</given-names></name><name><surname>Chan</surname><given-names>SM</given-names></name><name><surname>Chalasani</surname><given-names>V</given-names></name><name><surname>Gomez-Lemus</surname><given-names>JA</given-names></name><name><surname>Williams</surname><given-names>AK</given-names></name><name><surname>Chin</surname><given-names>JL</given-names></name><name><surname>Giannico</surname><given-names>GA</given-names></name><name><surname>Ketova</surname><given-names>T</given-names></name><name><surname>Lewis</surname><given-names>JD</given-names></name><name><surname>Zijlstra</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Integrin-free tetraspanin CD151 can inhibit tumor cell motility upon clustering and is a clinical indicator of prostate cancer progression</article-title><source>Cancer Research</source><volume>74</volume><fpage>173</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-0275</pub-id><pub-id pub-id-type="pmid">24220242</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>W</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Qiang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Oncogenic BRAF noncanonically promotes tumor metastasis by mediating VASP phosphorylation and filopodia formation</article-title><source>Oncogene</source><volume>42</volume><fpage>3194</fpage><lpage>3205</lpage><pub-id pub-id-type="doi">10.1038/s41388-023-02829-w</pub-id><pub-id pub-id-type="pmid">37689827</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardali</surname><given-names>E</given-names></name><name><surname>van der Schaft</surname><given-names>DWJ</given-names></name><name><surname>Wiercinska</surname><given-names>E</given-names></name><name><surname>Gorter</surname><given-names>A</given-names></name><name><surname>Hogendoorn</surname><given-names>PCW</given-names></name><name><surname>Griffioen</surname><given-names>AW</given-names></name><name><surname>ten Dijke</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma</article-title><source>Oncogene</source><volume>30</volume><fpage>334</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.418</pub-id><pub-id pub-id-type="pmid">20856203</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peinado</surname><given-names>H</given-names></name><name><surname>Alečković</surname><given-names>M</given-names></name><name><surname>Lavotshkin</surname><given-names>S</given-names></name><name><surname>Matei</surname><given-names>I</given-names></name><name><surname>Costa-Silva</surname><given-names>B</given-names></name><name><surname>Moreno-Bueno</surname><given-names>G</given-names></name><name><surname>Hergueta-Redondo</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>García-Santos</surname><given-names>G</given-names></name><name><surname>Ghajar</surname><given-names>C</given-names></name><name><surname>Nitadori-Hoshino</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>C</given-names></name><name><surname>Badal</surname><given-names>K</given-names></name><name><surname>Garcia</surname><given-names>BA</given-names></name><name><surname>Callahan</surname><given-names>MK</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Martins</surname><given-names>VR</given-names></name><name><surname>Skog</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>RN</given-names></name><name><surname>Brady</surname><given-names>MS</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Bromberg</surname><given-names>J</given-names></name><name><surname>Lyden</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET</article-title><source>Nature Medicine</source><volume>18</volume><fpage>883</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1038/nm.2753</pub-id><pub-id pub-id-type="pmid">22635005</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pérez-Gómez</surname><given-names>E</given-names></name><name><surname>del Castillo</surname><given-names>G</given-names></name><name><surname>Santibáñez</surname><given-names>JF</given-names></name><name><surname>Lêpez-Novoa</surname><given-names>JM</given-names></name><name><surname>Bernabéu</surname><given-names>C</given-names></name><name><surname>Quintanilla</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The role of the TGF-β coreceptor endoglin in cancer</article-title><source>The Scientific World JOURNAL</source><volume>10</volume><fpage>2367</fpage><lpage>2384</lpage><pub-id pub-id-type="doi">10.1100/tsw.2010.230</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popović</surname><given-names>A</given-names></name><name><surname>Miihkinen</surname><given-names>M</given-names></name><name><surname>Ghimire</surname><given-names>S</given-names></name><name><surname>Saup</surname><given-names>R</given-names></name><name><surname>Grönloh</surname><given-names>MLB</given-names></name><name><surname>Ball</surname><given-names>NJ</given-names></name><name><surname>Goult</surname><given-names>BT</given-names></name><name><surname>Ivaska</surname><given-names>J</given-names></name><name><surname>Jacquemet</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Myosin-X recruits lamellipodin to filopodia tips</article-title><source>Journal of Cell Science</source><volume>136</volume><elocation-id>jcs260574</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.260574</pub-id><pub-id pub-id-type="pmid">36861887</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramalho</surname><given-names>JS</given-names></name><name><surname>Tolmachova</surname><given-names>T</given-names></name><name><surname>Hume</surname><given-names>AN</given-names></name><name><surname>McGuigan</surname><given-names>A</given-names></name><name><surname>Gregory-Evans</surname><given-names>CY</given-names></name><name><surname>Huxley</surname><given-names>C</given-names></name><name><surname>Seabra</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Chromosomal mapping, gene structure and characterization of the human and murine RAB27B gene</article-title><source>BMC Genetics</source><volume>2</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2156-2-2</pub-id><pub-id pub-id-type="pmid">11178108</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rilla</surname><given-names>K</given-names></name><name><surname>Pasonen-Seppänen</surname><given-names>S</given-names></name><name><surname>Deen</surname><given-names>AJ</given-names></name><name><surname>Koistinen</surname><given-names>VVT</given-names></name><name><surname>Wojciechowski</surname><given-names>S</given-names></name><name><surname>Oikari</surname><given-names>S</given-names></name><name><surname>Kärnä</surname><given-names>R</given-names></name><name><surname>Bart</surname><given-names>G</given-names></name><name><surname>Törrönen</surname><given-names>K</given-names></name><name><surname>Tammi</surname><given-names>RH</given-names></name><name><surname>Tammi</surname><given-names>MI</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Hyaluronan production enhances shedding of plasma membrane-derived microvesicles</article-title><source>Experimental Cell Research</source><volume>319</volume><fpage>2006</fpage><lpage>2018</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2013.05.021</pub-id><pub-id pub-id-type="pmid">23732660</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>PL</given-names></name><name><surname>Huang</surname><given-names>YN</given-names></name><name><surname>Marchese</surname><given-names>JN</given-names></name><name><surname>Williamson</surname><given-names>B</given-names></name><name><surname>Parker</surname><given-names>K</given-names></name><name><surname>Hattan</surname><given-names>S</given-names></name><name><surname>Khainovski</surname><given-names>N</given-names></name><name><surname>Pillai</surname><given-names>S</given-names></name><name><surname>Dey</surname><given-names>S</given-names></name><name><surname>Daniels</surname><given-names>S</given-names></name><name><surname>Purkayastha</surname><given-names>S</given-names></name><name><surname>Juhasz</surname><given-names>P</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Bartlet-Jones</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Jacobson</surname><given-names>A</given-names></name><name><surname>Pappin</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Multiplexed protein quantitation in <italic>Saccharomyces cerevisiae</italic> using amine-reactive isobaric tagging reagents</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>3</volume><fpage>1154</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.1074/mcp.M400129-MCP200</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>E</given-names></name><name><surname>Bernabeu</surname><given-names>C</given-names></name><name><surname>Smadja</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Endoglin as an adhesion molecule in mature and progenitor endothelial cells: A function beyond TGF-β</article-title><source>Frontiers in Medicine</source><volume>6</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2019.00010</pub-id><pub-id pub-id-type="pmid">30761306</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schell</surname><given-names>MJ</given-names></name><name><surname>Erneux</surname><given-names>C</given-names></name><name><surname>Irvine</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Inositol 1,4,5-trisphosphate 3-kinase A associates with F-actin and dendritic spines via its N terminus</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><fpage>37537</fpage><lpage>37546</lpage><pub-id pub-id-type="doi">10.1074/jbc.M104101200</pub-id><pub-id pub-id-type="pmid">11468283</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoonderwoerd</surname><given-names>MJA</given-names></name><name><surname>Goumans</surname><given-names>MJTH</given-names></name><name><surname>Hawinkels</surname><given-names>LJAC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Endoglin: Beyond the endothelium</article-title><source>Biomolecules</source><volume>10</volume><elocation-id>289</elocation-id><pub-id pub-id-type="doi">10.3390/biom10020289</pub-id><pub-id pub-id-type="pmid">32059544</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shekarabi</surname><given-names>M</given-names></name><name><surname>Kennedy</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The netrin-1 receptor DCC promotes filopodia formation and cell spreading by activating Cdc42 and Rac1</article-title><source>Molecular and Cellular Neurosciences</source><volume>19</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1006/mcne.2001.1075</pub-id><pub-id pub-id-type="pmid">11817894</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Majumdar</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Brewer</surname><given-names>BM</given-names></name><name><surname>Goodwin</surname><given-names>CR</given-names></name><name><surname>McLean</surname><given-names>JA</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Webb</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Glia co-culture with neurons in microfluidic platforms promotes the formation and stabilization of synaptic contacts</article-title><source>Lab on a Chip</source><volume>13</volume><fpage>3008</fpage><lpage>3021</lpage><pub-id pub-id-type="doi">10.1039/c3lc50249j</pub-id><pub-id pub-id-type="pmid">23736663</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Hoshino</surname><given-names>D</given-names></name><name><surname>Hong</surname><given-names>NH</given-names></name><name><surname>Kirkbride</surname><given-names>KC</given-names></name><name><surname>Grega-Larson</surname><given-names>NE</given-names></name><name><surname>Seiki</surname><given-names>M</given-names></name><name><surname>Tyska</surname><given-names>MJ</given-names></name><name><surname>Weaver</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cortactin promotes exosome secretion by controlling branched actin dynamics</article-title><source>The Journal of Cell Biology</source><volume>214</volume><fpage>197</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1083/jcb.201601025</pub-id><pub-id pub-id-type="pmid">27402952</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stahl</surname><given-names>PR</given-names></name><name><surname>Hoxha</surname><given-names>E</given-names></name><name><surname>Wiech</surname><given-names>T</given-names></name><name><surname>Schröder</surname><given-names>C</given-names></name><name><surname>Simon</surname><given-names>R</given-names></name><name><surname>Stahl</surname><given-names>RAK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>THSD7A expression in human cancer</article-title><source>Genes, Chromosomes &amp; Cancer</source><volume>56</volume><fpage>314</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1002/gcc.22440</pub-id><pub-id pub-id-type="pmid">28035718</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steg</surname><given-names>AD</given-names></name><name><surname>Bevis</surname><given-names>KS</given-names></name><name><surname>Katre</surname><given-names>AA</given-names></name><name><surname>Ziebarth</surname><given-names>A</given-names></name><name><surname>Dobbin</surname><given-names>ZC</given-names></name><name><surname>Alvarez</surname><given-names>RD</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Conner</surname><given-names>M</given-names></name><name><surname>Landen</surname><given-names>CN</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Stem cell pathways contribute to clinical chemoresistance in ovarian cancer</article-title><source>Clinical Cancer Research</source><volume>18</volume><fpage>869</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2188</pub-id><pub-id pub-id-type="pmid">22142828</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>W-C</given-names></name><name><surname>Hou</surname><given-names>M-F</given-names></name><name><surname>Lancaster</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Fascin protein is critical for transforming growth factor β protein-induced invasion and filopodia formation in spindle-shaped tumor cells</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>38865</fpage><lpage>38875</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.270413</pub-id><pub-id pub-id-type="pmid">21914811</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>BH</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Kaverina</surname><given-names>I</given-names></name><name><surname>Weaver</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cortactin controls cell motility and lamellipodial dynamics by regulating ECM secretion</article-title><source>Current Biology</source><volume>21</volume><fpage>1460</fpage><lpage>1469</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2011.06.065</pub-id><pub-id pub-id-type="pmid">21856159</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>BH</given-names></name><name><surname>Ketova</surname><given-names>T</given-names></name><name><surname>Hoshino</surname><given-names>D</given-names></name><name><surname>Zijlstra</surname><given-names>A</given-names></name><name><surname>Weaver</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Directional cell movement through tissues is controlled by exosome secretion</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7164</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8164</pub-id><pub-id pub-id-type="pmid">25968605</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>BH</given-names></name><name><surname>Weaver</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Exosome secretion promotes chemotaxis of cancer cells</article-title><source>Cell Adhesion &amp; Migration</source><volume>11</volume><fpage>187</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1080/19336918.2016.1273307</pub-id><pub-id pub-id-type="pmid">28129015</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>BH</given-names></name><name><surname>von Lersner</surname><given-names>A</given-names></name><name><surname>Guerrero</surname><given-names>J</given-names></name><name><surname>Krystofiak</surname><given-names>ES</given-names></name><name><surname>Inman</surname><given-names>D</given-names></name><name><surname>Pelletier</surname><given-names>R</given-names></name><name><surname>Zijlstra</surname><given-names>A</given-names></name><name><surname>Ponik</surname><given-names>SM</given-names></name><name><surname>Weaver</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A live cell reporter of exosome secretion and uptake reveals pathfinding behavior of migrating cells</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2092</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15747-2</pub-id><pub-id pub-id-type="pmid">32350252</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>BH</given-names></name><name><surname>Parent</surname><given-names>CA</given-names></name><name><surname>Weaver</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Extracellular vesicles: Critical players during cell migration</article-title><source>Developmental Cell</source><volume>56</volume><fpage>1861</fpage><lpage>1874</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2021.03.020</pub-id><pub-id pub-id-type="pmid">33811804</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>BH</given-names></name><name><surname>Weaver</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Visualization of exosome release and uptake during cell migration using the live imaging reporter pHluorin_M153R-CD63</article-title><source>Methods in Molecular Biology</source><volume>2608</volume><fpage>83</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-2887-4_6</pub-id><pub-id pub-id-type="pmid">36653703</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Surviladze</surname><given-names>Z</given-names></name><name><surname>Waller</surname><given-names>A</given-names></name><name><surname>Strouse</surname><given-names>JJ</given-names></name><name><surname>Bologa</surname><given-names>C</given-names></name><name><surname>Ursu</surname><given-names>O</given-names></name><name><surname>Salas</surname><given-names>V</given-names></name><name><surname>Parkinson</surname><given-names>JF</given-names></name><name><surname>Phillips</surname><given-names>GK</given-names></name><name><surname>Romero</surname><given-names>E</given-names></name><name><surname>Wandinger-Ness</surname><given-names>A</given-names></name><name><surname>Sklar</surname><given-names>LA</given-names></name><name><surname>Schroeder</surname><given-names>C</given-names></name><name><surname>Simpson</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jennifer</surname><given-names>G</given-names></name><name><surname>Aubé</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><chapter-title>A potent and selective inhibitor of cdc42 gtpase</chapter-title><person-group person-group-type="editor"><name><surname>Surviladze</surname><given-names>Z</given-names></name></person-group><source>Probe Reports from the NIH Molecular Libraries Program</source><publisher-name>National Center for Biotechnology Information</publisher-name></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szubert</surname><given-names>S</given-names></name><name><surname>Moszynski</surname><given-names>R</given-names></name><name><surname>Michalak</surname><given-names>S</given-names></name><name><surname>Nowicki</surname><given-names>M</given-names></name><name><surname>Sajdak</surname><given-names>S</given-names></name><name><surname>Szpurek</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The associations between serum VEGF, bFGF and endoglin levels with microvessel density and expression of proangiogenic factors in malignant and benign ovarian tumors</article-title><source>Microvascular Research</source><volume>107</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.mvr.2016.06.002</pub-id><pub-id pub-id-type="pmid">27312585</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamai</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>N</given-names></name><name><surname>Nakano</surname><given-names>T</given-names></name><name><surname>Kakazu</surname><given-names>E</given-names></name><name><surname>Kondo</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>J</given-names></name><name><surname>Shiina</surname><given-names>M</given-names></name><name><surname>Fukushima</surname><given-names>K</given-names></name><name><surname>Hoshino</surname><given-names>T</given-names></name><name><surname>Sano</surname><given-names>K</given-names></name><name><surname>Ueno</surname><given-names>Y</given-names></name><name><surname>Shimosegawa</surname><given-names>T</given-names></name><name><surname>Sugamura</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Exosome secretion of dendritic cells is regulated by Hrs, an ESCRT-0 protein</article-title><source>Biochemical and Biophysical Research Communications</source><volume>399</volume><fpage>384</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.07.083</pub-id><pub-id pub-id-type="pmid">20673754</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Théry</surname><given-names>C</given-names></name><name><surname>Witwer</surname><given-names>KW</given-names></name><name><surname>Aikawa</surname><given-names>E</given-names></name><name><surname>Alcaraz</surname><given-names>MJ</given-names></name><name><surname>Anderson</surname><given-names>JD</given-names></name><name><surname>Andriantsitohaina</surname><given-names>R</given-names></name><name><surname>Antoniou</surname><given-names>A</given-names></name><name><surname>Arab</surname><given-names>T</given-names></name><name><surname>Archer</surname><given-names>F</given-names></name><name><surname>Atkin-Smith</surname><given-names>GK</given-names></name><name><surname>Ayre</surname><given-names>DC</given-names></name><name><surname>Bach</surname><given-names>JM</given-names></name><name><surname>Bachurski</surname><given-names>D</given-names></name><name><surname>Baharvand</surname><given-names>H</given-names></name><name><surname>Balaj</surname><given-names>L</given-names></name><name><surname>Baldacchino</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>NN</given-names></name><name><surname>Baxter</surname><given-names>AA</given-names></name><name><surname>Bebawy</surname><given-names>M</given-names></name><name><surname>Beckham</surname><given-names>C</given-names></name><name><surname>Bedina Zavec</surname><given-names>A</given-names></name><name><surname>Benmoussa</surname><given-names>A</given-names></name><name><surname>Berardi</surname><given-names>AC</given-names></name><name><surname>Bergese</surname><given-names>P</given-names></name><name><surname>Bielska</surname><given-names>E</given-names></name><name><surname>Blenkiron</surname><given-names>C</given-names></name><name><surname>Bobis-Wozowicz</surname><given-names>S</given-names></name><name><surname>Boilard</surname><given-names>E</given-names></name><name><surname>Boireau</surname><given-names>W</given-names></name><name><surname>Bongiovanni</surname><given-names>A</given-names></name><name><surname>Borràs</surname><given-names>FE</given-names></name><name><surname>Bosch</surname><given-names>S</given-names></name><name><surname>Boulanger</surname><given-names>CM</given-names></name><name><surname>Breakefield</surname><given-names>X</given-names></name><name><surname>Breglio</surname><given-names>AM</given-names></name><name><surname>Brennan</surname><given-names>MÁ</given-names></name><name><surname>Brigstock</surname><given-names>DR</given-names></name><name><surname>Brisson</surname><given-names>A</given-names></name><name><surname>Broekman</surname><given-names>ML</given-names></name><name><surname>Bromberg</surname><given-names>JF</given-names></name><name><surname>Bryl-Górecka</surname><given-names>P</given-names></name><name><surname>Buch</surname><given-names>S</given-names></name><name><surname>Buck</surname><given-names>AH</given-names></name><name><surname>Burger</surname><given-names>D</given-names></name><name><surname>Busatto</surname><given-names>S</given-names></name><name><surname>Buschmann</surname><given-names>D</given-names></name><name><surname>Bussolati</surname><given-names>B</given-names></name><name><surname>Buzás</surname><given-names>EI</given-names></name><name><surname>Byrd</surname><given-names>JB</given-names></name><name><surname>Camussi</surname><given-names>G</given-names></name><name><surname>Carter</surname><given-names>DR</given-names></name><name><surname>Caruso</surname><given-names>S</given-names></name><name><surname>Chamley</surname><given-names>LW</given-names></name><name><surname>Chang</surname><given-names>YT</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Chin</surname><given-names>AR</given-names></name><name><surname>Clayton</surname><given-names>A</given-names></name><name><surname>Clerici</surname><given-names>SP</given-names></name><name><surname>Cocks</surname><given-names>A</given-names></name><name><surname>Cocucci</surname><given-names>E</given-names></name><name><surname>Coffey</surname><given-names>RJ</given-names></name><name><surname>Cordeiro-da-Silva</surname><given-names>A</given-names></name><name><surname>Couch</surname><given-names>Y</given-names></name><name><surname>Coumans</surname><given-names>FA</given-names></name><name><surname>Coyle</surname><given-names>B</given-names></name><name><surname>Crescitelli</surname><given-names>R</given-names></name><name><surname>Criado</surname><given-names>MF</given-names></name><name><surname>D’Souza-Schorey</surname><given-names>C</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Datta Chaudhuri</surname><given-names>A</given-names></name><name><surname>de Candia</surname><given-names>P</given-names></name><name><surname>De Santana</surname><given-names>EF</given-names></name><name><surname>De Wever</surname><given-names>O</given-names></name><name><surname>Del Portillo</surname><given-names>HA</given-names></name><name><surname>Demaret</surname><given-names>T</given-names></name><name><surname>Deville</surname><given-names>S</given-names></name><name><surname>Devitt</surname><given-names>A</given-names></name><name><surname>Dhondt</surname><given-names>B</given-names></name><name><surname>Di Vizio</surname><given-names>D</given-names></name><name><surname>Dieterich</surname><given-names>LC</given-names></name><name><surname>Dolo</surname><given-names>V</given-names></name><name><surname>Dominguez Rubio</surname><given-names>AP</given-names></name><name><surname>Dominici</surname><given-names>M</given-names></name><name><surname>Dourado</surname><given-names>MR</given-names></name><name><surname>Driedonks</surname><given-names>TA</given-names></name><name><surname>Duarte</surname><given-names>FV</given-names></name><name><surname>Duncan</surname><given-names>HM</given-names></name><name><surname>Eichenberger</surname><given-names>RM</given-names></name><name><surname>Ekström</surname><given-names>K</given-names></name><name><surname>El Andaloussi</surname><given-names>S</given-names></name><name><surname>Elie-Caille</surname><given-names>C</given-names></name><name><surname>Erdbrügger</surname><given-names>U</given-names></name><name><surname>Falcón-Pérez</surname><given-names>JM</given-names></name><name><surname>Fatima</surname><given-names>F</given-names></name><name><surname>Fish</surname><given-names>JE</given-names></name><name><surname>Flores-Bellver</surname><given-names>M</given-names></name><name><surname>Försönits</surname><given-names>A</given-names></name><name><surname>Frelet-Barrand</surname><given-names>A</given-names></name><name><surname>Fricke</surname><given-names>F</given-names></name><name><surname>Fuhrmann</surname><given-names>G</given-names></name><name><surname>Gabrielsson</surname><given-names>S</given-names></name><name><surname>Gámez-Valero</surname><given-names>A</given-names></name><name><surname>Gardiner</surname><given-names>C</given-names></name><name><surname>Gärtner</surname><given-names>K</given-names></name><name><surname>Gaudin</surname><given-names>R</given-names></name><name><surname>Gho</surname><given-names>YS</given-names></name><name><surname>Giebel</surname><given-names>B</given-names></name><name><surname>Gilbert</surname><given-names>C</given-names></name><name><surname>Gimona</surname><given-names>M</given-names></name><name><surname>Giusti</surname><given-names>I</given-names></name><name><surname>Goberdhan</surname><given-names>DC</given-names></name><name><surname>Görgens</surname><given-names>A</given-names></name><name><surname>Gorski</surname><given-names>SM</given-names></name><name><surname>Greening</surname><given-names>DW</given-names></name><name><surname>Gross</surname><given-names>JC</given-names></name><name><surname>Gualerzi</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>GN</given-names></name><name><surname>Gustafson</surname><given-names>D</given-names></name><name><surname>Handberg</surname><given-names>A</given-names></name><name><surname>Haraszti</surname><given-names>RA</given-names></name><name><surname>Harrison</surname><given-names>P</given-names></name><name><surname>Hegyesi</surname><given-names>H</given-names></name><name><surname>Hendrix</surname><given-names>A</given-names></name><name><surname>Hill</surname><given-names>AF</given-names></name><name><surname>Hochberg</surname><given-names>FH</given-names></name><name><surname>Hoffmann</surname><given-names>KF</given-names></name><name><surname>Holder</surname><given-names>B</given-names></name><name><surname>Holthofer</surname><given-names>H</given-names></name><name><surname>Hosseinkhani</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Huber</surname><given-names>V</given-names></name><name><surname>Hunt</surname><given-names>S</given-names></name><name><surname>Ibrahim</surname><given-names>AGE</given-names></name><name><surname>Ikezu</surname><given-names>T</given-names></name><name><surname>Inal</surname><given-names>JM</given-names></name><name><surname>Isin</surname><given-names>M</given-names></name><name><surname>Ivanova</surname><given-names>A</given-names></name><name><surname>Jackson</surname><given-names>HK</given-names></name><name><surname>Jacobsen</surname><given-names>S</given-names></name><name><surname>Jay</surname><given-names>SM</given-names></name><name><surname>Jayachandran</surname><given-names>M</given-names></name><name><surname>Jenster</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>SM</given-names></name><name><surname>Jones</surname><given-names>JC</given-names></name><name><surname>Jong</surname><given-names>A</given-names></name><name><surname>Jovanovic-Talisman</surname><given-names>T</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Kalluri</surname><given-names>R</given-names></name><name><surname>Kano</surname><given-names>SI</given-names></name><name><surname>Kaur</surname><given-names>S</given-names></name><name><surname>Kawamura</surname><given-names>Y</given-names></name><name><surname>Keller</surname><given-names>ET</given-names></name><name><surname>Khamari</surname><given-names>D</given-names></name><name><surname>Khomyakova</surname><given-names>E</given-names></name><name><surname>Khvorova</surname><given-names>A</given-names></name><name><surname>Kierulf</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>KP</given-names></name><name><surname>Kislinger</surname><given-names>T</given-names></name><name><surname>Klingeborn</surname><given-names>M</given-names></name><name><surname>Klinke</surname><given-names>DJ</given-names></name><name><surname>Kornek</surname><given-names>M</given-names></name><name><surname>Kosanović</surname><given-names>MM</given-names></name><name><surname>Kovács</surname><given-names>ÁF</given-names></name><name><surname>Krämer-Albers</surname><given-names>EM</given-names></name><name><surname>Krasemann</surname><given-names>S</given-names></name><name><surname>Krause</surname><given-names>M</given-names></name><name><surname>Kurochkin</surname><given-names>IV</given-names></name><name><surname>Kusuma</surname><given-names>GD</given-names></name><name><surname>Kuypers</surname><given-names>S</given-names></name><name><surname>Laitinen</surname><given-names>S</given-names></name><name><surname>Langevin</surname><given-names>SM</given-names></name><name><surname>Languino</surname><given-names>LR</given-names></name><name><surname>Lannigan</surname><given-names>J</given-names></name><name><surname>Lässer</surname><given-names>C</given-names></name><name><surname>Laurent</surname><given-names>LC</given-names></name><name><surname>Lavieu</surname><given-names>G</given-names></name><name><surname>Lázaro-Ibáñez</surname><given-names>E</given-names></name><name><surname>Le Lay</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>YXF</given-names></name><name><surname>Lemos</surname><given-names>DS</given-names></name><name><surname>Lenassi</surname><given-names>M</given-names></name><name><surname>Leszczynska</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>IT</given-names></name><name><surname>Liao</surname><given-names>K</given-names></name><name><surname>Libregts</surname><given-names>SF</given-names></name><name><surname>Ligeti</surname><given-names>E</given-names></name><name><surname>Lim</surname><given-names>R</given-names></name><name><surname>Lim</surname><given-names>SK</given-names></name><name><surname>Linē</surname><given-names>A</given-names></name><name><surname>Linnemannstöns</surname><given-names>K</given-names></name><name><surname>Llorente</surname><given-names>A</given-names></name><name><surname>Lombard</surname><given-names>CA</given-names></name><name><surname>Lorenowicz</surname><given-names>MJ</given-names></name><name><surname>Lörincz</surname><given-names>ÁM</given-names></name><name><surname>Lötvall</surname><given-names>J</given-names></name><name><surname>Lovett</surname><given-names>J</given-names></name><name><surname>Lowry</surname><given-names>MC</given-names></name><name><surname>Loyer</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Lukomska</surname><given-names>B</given-names></name><name><surname>Lunavat</surname><given-names>TR</given-names></name><name><surname>Maas</surname><given-names>SL</given-names></name><name><surname>Malhi</surname><given-names>H</given-names></name><name><surname>Marcilla</surname><given-names>A</given-names></name><name><surname>Mariani</surname><given-names>J</given-names></name><name><surname>Mariscal</surname><given-names>J</given-names></name><name><surname>Martens-Uzunova</surname><given-names>ES</given-names></name><name><surname>Martin-Jaular</surname><given-names>L</given-names></name><name><surname>Martinez</surname><given-names>MC</given-names></name><name><surname>Martins</surname><given-names>VR</given-names></name><name><surname>Mathieu</surname><given-names>M</given-names></name><name><surname>Mathivanan</surname><given-names>S</given-names></name><name><surname>Maugeri</surname><given-names>M</given-names></name><name><surname>McGinnis</surname><given-names>LK</given-names></name><name><surname>McVey</surname><given-names>MJ</given-names></name><name><surname>Meckes</surname><given-names>DG</given-names><suffix>Jr</suffix></name><name><surname>Meehan</surname><given-names>KL</given-names></name><name><surname>Mertens</surname><given-names>I</given-names></name><name><surname>Minciacchi</surname><given-names>VR</given-names></name><name><surname>Möller</surname><given-names>A</given-names></name><name><surname>Møller Jørgensen</surname><given-names>M</given-names></name><name><surname>Morales-Kastresana</surname><given-names>A</given-names></name><name><surname>Morhayim</surname><given-names>J</given-names></name><name><surname>Mullier</surname><given-names>F</given-names></name><name><surname>Muraca</surname><given-names>M</given-names></name><name><surname>Musante</surname><given-names>L</given-names></name><name><surname>Mussack</surname><given-names>V</given-names></name><name><surname>Muth</surname><given-names>DC</given-names></name><name><surname>Myburgh</surname><given-names>KH</given-names></name><name><surname>Najrana</surname><given-names>T</given-names></name><name><surname>Nawaz</surname><given-names>M</given-names></name><name><surname>Nazarenko</surname><given-names>I</given-names></name><name><surname>Nejsum</surname><given-names>P</given-names></name><name><surname>Neri</surname><given-names>C</given-names></name><name><surname>Neri</surname><given-names>T</given-names></name><name><surname>Nieuwland</surname><given-names>R</given-names></name><name><surname>Nimrichter</surname><given-names>L</given-names></name><name><surname>Nolan</surname><given-names>JP</given-names></name><name><surname>Nolte-’t Hoen</surname><given-names>EN</given-names></name><name><surname>Noren Hooten</surname><given-names>N</given-names></name><name><surname>O’Driscoll</surname><given-names>L</given-names></name><name><surname>O’Grady</surname><given-names>T</given-names></name><name><surname>O’Loghlen</surname><given-names>A</given-names></name><name><surname>Ochiya</surname><given-names>T</given-names></name><name><surname>Olivier</surname><given-names>M</given-names></name><name><surname>Ortiz</surname><given-names>A</given-names></name><name><surname>Ortiz</surname><given-names>LA</given-names></name><name><surname>Osteikoetxea</surname><given-names>X</given-names></name><name><surname>Østergaard</surname><given-names>O</given-names></name><name><surname>Ostrowski</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Pegtel</surname><given-names>DM</given-names></name><name><surname>Peinado</surname><given-names>H</given-names></name><name><surname>Perut</surname><given-names>F</given-names></name><name><surname>Pfaffl</surname><given-names>MW</given-names></name><name><surname>Phinney</surname><given-names>DG</given-names></name><name><surname>Pieters</surname><given-names>BC</given-names></name><name><surname>Pink</surname><given-names>RC</given-names></name><name><surname>Pisetsky</surname><given-names>DS</given-names></name><name><surname>Pogge von Strandmann</surname><given-names>E</given-names></name><name><surname>Polakovicova</surname><given-names>I</given-names></name><name><surname>Poon</surname><given-names>IK</given-names></name><name><surname>Powell</surname><given-names>BH</given-names></name><name><surname>Prada</surname><given-names>I</given-names></name><name><surname>Pulliam</surname><given-names>L</given-names></name><name><surname>Quesenberry</surname><given-names>P</given-names></name><name><surname>Radeghieri</surname><given-names>A</given-names></name><name><surname>Raffai</surname><given-names>RL</given-names></name><name><surname>Raimondo</surname><given-names>S</given-names></name><name><surname>Rak</surname><given-names>J</given-names></name><name><surname>Ramirez</surname><given-names>MI</given-names></name><name><surname>Raposo</surname><given-names>G</given-names></name><name><surname>Rayyan</surname><given-names>MS</given-names></name><name><surname>Regev-Rudzki</surname><given-names>N</given-names></name><name><surname>Ricklefs</surname><given-names>FL</given-names></name><name><surname>Robbins</surname><given-names>PD</given-names></name><name><surname>Roberts</surname><given-names>DD</given-names></name><name><surname>Rodrigues</surname><given-names>SC</given-names></name><name><surname>Rohde</surname><given-names>E</given-names></name><name><surname>Rome</surname><given-names>S</given-names></name><name><surname>Rouschop</surname><given-names>KM</given-names></name><name><surname>Rughetti</surname><given-names>A</given-names></name><name><surname>Russell</surname><given-names>AE</given-names></name><name><surname>Saá</surname><given-names>P</given-names></name><name><surname>Sahoo</surname><given-names>S</given-names></name><name><surname>Salas-Huenuleo</surname><given-names>E</given-names></name><name><surname>Sánchez</surname><given-names>C</given-names></name><name><surname>Saugstad</surname><given-names>JA</given-names></name><name><surname>Saul</surname><given-names>MJ</given-names></name><name><surname>Schiffelers</surname><given-names>RM</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Schøyen</surname><given-names>TH</given-names></name><name><surname>Scott</surname><given-names>A</given-names></name><name><surname>Shahaj</surname><given-names>E</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Shatnyeva</surname><given-names>O</given-names></name><name><surname>Shekari</surname><given-names>F</given-names></name><name><surname>Shelke</surname><given-names>GV</given-names></name><name><surname>Shetty</surname><given-names>AK</given-names></name><name><surname>Shiba</surname><given-names>K</given-names></name><name><surname>Siljander</surname><given-names>PRM</given-names></name><name><surname>Silva</surname><given-names>AM</given-names></name><name><surname>Skowronek</surname><given-names>A</given-names></name><name><surname>Snyder</surname><given-names>OL</given-names></name><name><surname>Soares</surname><given-names>RP</given-names></name><name><surname>Sódar</surname><given-names>BW</given-names></name><name><surname>Soekmadji</surname><given-names>C</given-names></name><name><surname>Sotillo</surname><given-names>J</given-names></name><name><surname>Stahl</surname><given-names>PD</given-names></name><name><surname>Stoorvogel</surname><given-names>W</given-names></name><name><surname>Stott</surname><given-names>SL</given-names></name><name><surname>Strasser</surname><given-names>EF</given-names></name><name><surname>Swift</surname><given-names>S</given-names></name><name><surname>Tahara</surname><given-names>H</given-names></name><name><surname>Tewari</surname><given-names>M</given-names></name><name><surname>Timms</surname><given-names>K</given-names></name><name><surname>Tiwari</surname><given-names>S</given-names></name><name><surname>Tixeira</surname><given-names>R</given-names></name><name><surname>Tkach</surname><given-names>M</given-names></name><name><surname>Toh</surname><given-names>WS</given-names></name><name><surname>Tomasini</surname><given-names>R</given-names></name><name><surname>Torrecilhas</surname><given-names>AC</given-names></name><name><surname>Tosar</surname><given-names>JP</given-names></name><name><surname>Toxavidis</surname><given-names>V</given-names></name><name><surname>Urbanelli</surname><given-names>L</given-names></name><name><surname>Vader</surname><given-names>P</given-names></name><name><surname>van Balkom</surname><given-names>BW</given-names></name><name><surname>van der Grein</surname><given-names>SG</given-names></name><name><surname>Van Deun</surname><given-names>J</given-names></name><name><surname>van Herwijnen</surname><given-names>MJ</given-names></name><name><surname>Van Keuren-Jensen</surname><given-names>K</given-names></name><name><surname>van Niel</surname><given-names>G</given-names></name><name><surname>van Royen</surname><given-names>ME</given-names></name><name><surname>van Wijnen</surname><given-names>AJ</given-names></name><name><surname>Vasconcelos</surname><given-names>MH</given-names></name><name><surname>Vechetti</surname><given-names>IJ</given-names></name><name><surname>Veit</surname><given-names>TD</given-names></name><name><surname>Vella</surname><given-names>LJ</given-names></name><name><surname>Velot</surname><given-names>É</given-names></name><name><surname>Verweij</surname><given-names>FJ</given-names></name><name><surname>Vestad</surname><given-names>B</given-names></name><name><surname>Viñas</surname><given-names>JL</given-names></name><name><surname>Visnovitz</surname><given-names>T</given-names></name><name><surname>Vukman</surname><given-names>KV</given-names></name><name><surname>Wahlgren</surname><given-names>J</given-names></name><name><surname>Watson</surname><given-names>DC</given-names></name><name><surname>Wauben</surname><given-names>MH</given-names></name><name><surname>Weaver</surname><given-names>A</given-names></name><name><surname>Webber</surname><given-names>JP</given-names></name><name><surname>Weber</surname><given-names>V</given-names></name><name><surname>Wehman</surname><given-names>AM</given-names></name><name><surname>Weiss</surname><given-names>DJ</given-names></name><name><surname>Welsh</surname><given-names>JA</given-names></name><name><surname>Wendt</surname><given-names>S</given-names></name><name><surname>Wheelock</surname><given-names>AM</given-names></name><name><surname>Wiener</surname><given-names>Z</given-names></name><name><surname>Witte</surname><given-names>L</given-names></name><name><surname>Wolfram</surname><given-names>J</given-names></name><name><surname>Xagorari</surname><given-names>A</given-names></name><name><surname>Xander</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Yáñez-Mó</surname><given-names>M</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Yuana</surname><given-names>Y</given-names></name><name><surname>Zappulli</surname><given-names>V</given-names></name><name><surname>Zarubova</surname><given-names>J</given-names></name><name><surname>Žėkas</surname><given-names>V</given-names></name><name><surname>Zhang</surname><given-names>JY</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Zheutlin</surname><given-names>AR</given-names></name><name><surname>Zickler</surname><given-names>AM</given-names></name><name><surname>Zimmermann</surname><given-names>P</given-names></name><name><surname>Zivkovic</surname><given-names>AM</given-names></name><name><surname>Zocco</surname><given-names>D</given-names></name><name><surname>Zuba-Surma</surname><given-names>EK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines</article-title><source>Journal of Extracellular Vesicles</source><volume>7</volume><elocation-id>1535750</elocation-id><pub-id pub-id-type="doi">10.1080/20013078.2018.1535750</pub-id><pub-id pub-id-type="pmid">30637094</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Mythreye</surname><given-names>K</given-names></name><name><surname>Golzio</surname><given-names>C</given-names></name><name><surname>Katsanis</surname><given-names>N</given-names></name><name><surname>Blobe</surname><given-names>GC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Endoglin mediates fibronectin/α5β1 integrin and TGF-β pathway crosstalk in endothelial cells</article-title><source>The EMBO Journal</source><volume>31</volume><fpage>3885</fpage><lpage>3900</lpage><pub-id pub-id-type="doi">10.1038/emboj.2012.246</pub-id><pub-id pub-id-type="pmid">22940691</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomas</surname><given-names>NM</given-names></name><name><surname>Beck</surname><given-names>LH</given-names></name><name><surname>Meyer-Schwesinger</surname><given-names>C</given-names></name><name><surname>Seitz-Polski</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Zahner</surname><given-names>G</given-names></name><name><surname>Dolla</surname><given-names>G</given-names></name><name><surname>Hoxha</surname><given-names>E</given-names></name><name><surname>Helmchen</surname><given-names>U</given-names></name><name><surname>Dabert-Gay</surname><given-names>AS</given-names></name><name><surname>Debayle</surname><given-names>D</given-names></name><name><surname>Merchant</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>J</given-names></name><name><surname>Salant</surname><given-names>DJ</given-names></name><name><surname>Stahl</surname><given-names>RAK</given-names></name><name><surname>Lambeau</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy</article-title><source>The New England Journal of Medicine</source><volume>371</volume><fpage>2277</fpage><lpage>2287</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1409354</pub-id><pub-id pub-id-type="pmid">25394321</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomas</surname><given-names>NM</given-names></name><name><surname>Meyer-Schwesinger</surname><given-names>C</given-names></name><name><surname>von Spiegel</surname><given-names>H</given-names></name><name><surname>Kotb</surname><given-names>AM</given-names></name><name><surname>Zahner</surname><given-names>G</given-names></name><name><surname>Hoxha</surname><given-names>E</given-names></name><name><surname>Helmchen</surname><given-names>U</given-names></name><name><surname>Endlich</surname><given-names>N</given-names></name><name><surname>Koch-Nolte</surname><given-names>F</given-names></name><name><surname>Stahl</surname><given-names>RAK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A heterologous model of thrombospondin type 1 domain-containing 7A-Associated membranous nephropathy</article-title><source>Journal of the American Society of Nephrology</source><volume>28</volume><fpage>3262</fpage><lpage>3277</lpage><pub-id pub-id-type="doi">10.1681/ASN.2017010030</pub-id><pub-id pub-id-type="pmid">28814510</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uneda</surname><given-names>S</given-names></name><name><surname>Toi</surname><given-names>H</given-names></name><name><surname>Tsujie</surname><given-names>T</given-names></name><name><surname>Tsujie</surname><given-names>M</given-names></name><name><surname>Harada</surname><given-names>N</given-names></name><name><surname>Tsai</surname><given-names>H</given-names></name><name><surname>Seon</surname><given-names>BK</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature</article-title><source>International Journal of Cancer</source><volume>125</volume><fpage>1446</fpage><lpage>1453</lpage><pub-id pub-id-type="doi">10.1002/ijc.24482</pub-id><pub-id pub-id-type="pmid">19533687</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Niel</surname><given-names>G</given-names></name><name><surname>D’Angelo</surname><given-names>G</given-names></name><name><surname>Raposo</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Shedding light on the cell biology of extracellular vesicles</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>19</volume><fpage>213</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1038/nrm.2017.125</pub-id><pub-id pub-id-type="pmid">29339798</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasioukhin</surname><given-names>V</given-names></name><name><surname>Bauer</surname><given-names>C</given-names></name><name><surname>Yin</surname><given-names>M</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Directed actin polymerization is the driving force for epithelial cell-cell adhesion</article-title><source>Cell</source><volume>100</volume><fpage>209</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81559-7</pub-id><pub-id pub-id-type="pmid">10660044</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakayama</surname><given-names>Y</given-names></name><name><surname>Fukuhara</surname><given-names>S</given-names></name><name><surname>Ando</surname><given-names>K</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>Mochizuki</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cdc42 mediates Bmp-induced sprouting angiogenesis through Fmnl3-driven assembly of endothelial filopodia in zebrafish</article-title><source>Developmental Cell</source><volume>32</volume><fpage>109</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2014.11.024</pub-id><pub-id pub-id-type="pmid">25584797</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CH</given-names></name><name><surname>Su</surname><given-names>PT</given-names></name><name><surname>Du</surname><given-names>XY</given-names></name><name><surname>Kuo</surname><given-names>MW</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Yang</surname><given-names>CC</given-names></name><name><surname>Chan</surname><given-names>HS</given-names></name><name><surname>Chang</surname><given-names>SJ</given-names></name><name><surname>Kuo</surname><given-names>C</given-names></name><name><surname>Seo</surname><given-names>K</given-names></name><name><surname>Leung</surname><given-names>LL</given-names></name><name><surname>Chuang</surname><given-names>YJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Thrombospondin type I domain containing 7A (THSD7A) mediates endothelial cell migration and tube formation</article-title><source>Journal of Cellular Physiology</source><volume>222</volume><fpage>685</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1002/jcp.21990</pub-id><pub-id pub-id-type="pmid">20020485</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>IH</given-names></name><name><surname>Kuo</surname><given-names>MW</given-names></name><name><surname>Su</surname><given-names>PT</given-names></name><name><surname>Lai</surname><given-names>ZY</given-names></name><name><surname>Wang</surname><given-names>CH</given-names></name><name><surname>Huang</surname><given-names>WC</given-names></name><name><surname>Hoffman</surname><given-names>J</given-names></name><name><surname>Kuo</surname><given-names>CJ</given-names></name><name><surname>You</surname><given-names>MS</given-names></name><name><surname>Chuang</surname><given-names>YJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Zebrafish Thsd7a is a neural protein required for angiogenic patterning during development</article-title><source>Developmental Dynamics</source><volume>240</volume><fpage>1412</fpage><lpage>1421</lpage><pub-id pub-id-type="doi">10.1002/dvdy.22641</pub-id><pub-id pub-id-type="pmid">21520329</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Kang</surname><given-names>X</given-names></name><name><surname>Kang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>THSD7A as a marker for paraneoplastic membranous nephropathy</article-title><source>International Urology and Nephrology</source><volume>51</volume><fpage>371</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1007/s11255-018-02068-z</pub-id><pub-id pub-id-type="pmid">30607777</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Nikonorova</surname><given-names>IA</given-names></name><name><surname>Silva</surname><given-names>M</given-names></name><name><surname>Walsh</surname><given-names>JD</given-names></name><name><surname>Tilton</surname><given-names>PE</given-names></name><name><surname>Gu</surname><given-names>A</given-names></name><name><surname>Akella</surname><given-names>JS</given-names></name><name><surname>Barr</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Sensory cilia act as a specialized venue for regulated extracellular vesicle biogenesis and signaling</article-title><source>Current Biology</source><volume>31</volume><fpage>3943</fpage><lpage>3951</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2021.06.040</pub-id><pub-id pub-id-type="pmid">34270950</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welsh</surname><given-names>JA</given-names></name><name><surname>Goberdhan</surname><given-names>DCI</given-names></name><name><surname>O’Driscoll</surname><given-names>L</given-names></name><name><surname>Buzas</surname><given-names>EI</given-names></name><name><surname>Blenkiron</surname><given-names>C</given-names></name><name><surname>Bussolati</surname><given-names>B</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Di Vizio</surname><given-names>D</given-names></name><name><surname>Driedonks</surname><given-names>TAP</given-names></name><name><surname>Erdbrügger</surname><given-names>U</given-names></name><name><surname>Falcon-Perez</surname><given-names>JM</given-names></name><name><surname>Fu</surname><given-names>QL</given-names></name><name><surname>Hill</surname><given-names>AF</given-names></name><name><surname>Lenassi</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>SK</given-names></name><name><surname>Mahoney</surname><given-names>MG</given-names></name><name><surname>Mohanty</surname><given-names>S</given-names></name><name><surname>Möller</surname><given-names>A</given-names></name><name><surname>Nieuwland</surname><given-names>R</given-names></name><name><surname>Ochiya</surname><given-names>T</given-names></name><name><surname>Sahoo</surname><given-names>S</given-names></name><name><surname>Torrecilhas</surname><given-names>AC</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Zijlstra</surname><given-names>A</given-names></name><name><surname>Abuelreich</surname><given-names>S</given-names></name><name><surname>Bagabas</surname><given-names>R</given-names></name><name><surname>Bergese</surname><given-names>P</given-names></name><name><surname>Bridges</surname><given-names>EM</given-names></name><name><surname>Brucale</surname><given-names>M</given-names></name><name><surname>Burger</surname><given-names>D</given-names></name><name><surname>Carney</surname><given-names>RP</given-names></name><name><surname>Cocucci</surname><given-names>E</given-names></name><name><surname>Crescitelli</surname><given-names>R</given-names></name><name><surname>Hanser</surname><given-names>E</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Haughey</surname><given-names>NJ</given-names></name><name><surname>Hendrix</surname><given-names>A</given-names></name><name><surname>Ivanov</surname><given-names>AR</given-names></name><name><surname>Jovanovic-Talisman</surname><given-names>T</given-names></name><name><surname>Kruh-Garcia</surname><given-names>NA</given-names></name><name><surname>Ku’ulei-Lyn Faustino</surname><given-names>V</given-names></name><name><surname>Kyburz</surname><given-names>D</given-names></name><name><surname>Lässer</surname><given-names>C</given-names></name><name><surname>Lennon</surname><given-names>KM</given-names></name><name><surname>Lötvall</surname><given-names>J</given-names></name><name><surname>Maddox</surname><given-names>AL</given-names></name><name><surname>Martens-Uzunova</surname><given-names>ES</given-names></name><name><surname>Mizenko</surname><given-names>RR</given-names></name><name><surname>Newman</surname><given-names>LA</given-names></name><name><surname>Ridolfi</surname><given-names>A</given-names></name><name><surname>Rohde</surname><given-names>E</given-names></name><name><surname>Rojalin</surname><given-names>T</given-names></name><name><surname>Rowland</surname><given-names>A</given-names></name><name><surname>Saftics</surname><given-names>A</given-names></name><name><surname>Sandau</surname><given-names>US</given-names></name><name><surname>Saugstad</surname><given-names>JA</given-names></name><name><surname>Shekari</surname><given-names>F</given-names></name><name><surname>Swift</surname><given-names>S</given-names></name><name><surname>Ter-Ovanesyan</surname><given-names>D</given-names></name><name><surname>Tosar</surname><given-names>JP</given-names></name><name><surname>Useckaite</surname><given-names>Z</given-names></name><name><surname>Valle</surname><given-names>F</given-names></name><name><surname>Varga</surname><given-names>Z</given-names></name><name><surname>van der Pol</surname><given-names>E</given-names></name><name><surname>van Herwijnen</surname><given-names>MJC</given-names></name><name><surname>Wauben</surname><given-names>MHM</given-names></name><name><surname>Wehman</surname><given-names>AM</given-names></name><name><surname>Williams</surname><given-names>S</given-names></name><name><surname>Zendrini</surname><given-names>A</given-names></name><name><surname>Zimmerman</surname><given-names>AJ</given-names></name><name><surname>Théry</surname><given-names>C</given-names></name><name><surname>Witwer</surname><given-names>KW</given-names></name><collab>MISEV Consortium</collab></person-group><year iso-8601-date="2024">2024</year><article-title>Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches</article-title><source>Journal of Extracellular Vesicles</source><volume>13</volume><elocation-id>e12404</elocation-id><pub-id pub-id-type="doi">10.1002/jev2.12404</pub-id><pub-id pub-id-type="pmid">38326288</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wit</surname><given-names>CB</given-names></name><name><surname>Hiesinger</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Neuronal filopodia: From stochastic dynamics to robustness of brain morphogenesis</article-title><source>Seminars in Cell &amp; Developmental Biology</source><volume>133</volume><fpage>10</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2022.03.038</pub-id><pub-id pub-id-type="pmid">35397971</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wortzel</surname><given-names>I</given-names></name><name><surname>Dror</surname><given-names>S</given-names></name><name><surname>Kenific</surname><given-names>CM</given-names></name><name><surname>Lyden</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Exosome-mediated metastasis: Communication from a distance</article-title><source>Developmental Cell</source><volume>49</volume><fpage>347</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2019.04.011</pub-id><pub-id pub-id-type="pmid">31063754</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Berg</surname><given-names>JS</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lång</surname><given-names>P</given-names></name><name><surname>Sousa</surname><given-names>AD</given-names></name><name><surname>Bhaskar</surname><given-names>A</given-names></name><name><surname>Cheney</surname><given-names>RE</given-names></name><name><surname>Strömblad</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Myosin-X provides a motor-based link between integrins and the cytoskeleton</article-title><source>Nature Cell Biology</source><volume>6</volume><fpage>523</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1038/ncb1136</pub-id><pub-id pub-id-type="pmid">15156152</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>PTENε suppresses tumor metastasis through regulation of filopodia formation</article-title><source>The EMBO Journal</source><volume>40</volume><elocation-id>e105806</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2020105806</pub-id><pub-id pub-id-type="pmid">33755220</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Torii</surname><given-names>S</given-names></name><name><surname>Yokota-Hashimoto</surname><given-names>H</given-names></name><name><surname>Takeuchi</surname><given-names>T</given-names></name><name><surname>Izumi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Involvement of Rab27b in the regulated secretion of pituitary hormones</article-title><source>Endocrinology</source><volume>143</volume><fpage>1817</fpage><lpage>1824</lpage><pub-id pub-id-type="doi">10.1210/endo.143.5.8823</pub-id><pub-id pub-id-type="pmid">11956164</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zijlstra</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>J</given-names></name><name><surname>Degryse</surname><given-names>B</given-names></name><name><surname>Stuhlmann</surname><given-names>H</given-names></name><name><surname>Quigley</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151</article-title><source>Cancer Cell</source><volume>13</volume><fpage>221</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.01.031</pub-id><pub-id pub-id-type="pmid">18328426</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziman</surname><given-names>M</given-names></name><name><surname>O’Brien</surname><given-names>JM</given-names></name><name><surname>Ouellette</surname><given-names>LA</given-names></name><name><surname>Church</surname><given-names>WR</given-names></name><name><surname>Johnson</surname><given-names>DI</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Mutational analysis of CDC42Sc, a <italic>Saccharomyces cerevisiae</italic> gene that encodes a putative GTP-binding protein involved in the control of cell polarity</article-title><source>Molecular and Cellular Biology</source><volume>11</volume><fpage>3537</fpage><lpage>3544</lpage><pub-id pub-id-type="doi">10.1128/mcb.11.7.3537-3544.1991</pub-id><pub-id pub-id-type="pmid">1904541</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziv</surname><given-names>NE</given-names></name><name><surname>Smith</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Evidence for a role of dendritic filopodia in synaptogenesis and spine formation</article-title><source>Neuron</source><volume>17</volume><fpage>91</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/s0896-6273(00)80283-4</pub-id><pub-id pub-id-type="pmid">8755481</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101673.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Applewhite</surname><given-names>Derek A</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Reed College</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>In this <bold>important</bold> manuscript, the authors reveal novel findings on the role of exosomes in regulating filopodia formation. Filopodia are crucial for various cellular processes, including migration, polarization, directional sensing, and the formation of neuronal synapses. The authors <bold>convincingly</bold> demonstrate that exosomes, particularly those enriched with the protein THSD7A, play a significant role in promoting filopodia formation in both cancer cells and neurons.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101673.3.sa1</article-id><title-group><article-title>Joint Public Review:</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors identify a novel relationship between exosome secretion and filopodia formation in cancer cells and neurons. They observe that multivesicular endosomes (MVE)-plasma membrane (PM) fusion is associated with filopodia formation in HT1080 cells and that MVEs are present on filopodia in primary neurons. Using overexpression and knockdown (KD) of Rab27/HRS in HT1080 cells, melanoma cells and/or primary rat neurons, they find that decreasing exosome secretion reduces filopodia formation, while Rab27 overexpression leads to the opposite result. Furthermore, the decreased filopodia formation is rescued in the Rab27a/HRS KD melanoma cells by the addition of small extracellular vesicles (EVs) but not large EVs purified from control cells. The authors identify endoglin as a protein unique to small EVs secreted by cancer cells when compared to large EVs. KD of endoglin reduces filopodia formation and this is rescued by the addition of small EVs from control cells and not by small EVs from endoglin KD cells. Based on the role of filopodia in cancer metastasis, the authors then investigate the role of endoglin in cancer cell metastasis using a chick embryo model. They find that injection of endoglin KD HT1080 cells into chick embryos gives rise to less metastasis compared to control cells - a phenotype that is rescued by the co-injection of small EVs from control cells. Using quantitative mass spectrometry analysis, they find that thrombospondin type 1 domain containing 7a protein (THSD7A) is down regulated in small EVs from endoglin KD melanoma cells compared to those from control cells. They also report that THSD7A is more abundant in endoglin KD cell lysate compared to control HT1080 cells and less abundant in small EVs from endoglin KD cells compared to control cells, indicating a trafficking defect. Indeed, using immunofluorescence microscopy, the authors observe THSD7A-mScarlet accumulation in CD63-positive structures in endoglin KD HT1080 cells, compared to control cells. Finally, the authors determine that exosome-secreted THSD7A induces filopodia formation in a Cdc42-dependent mechanism.</p><p>Strengths:</p><p>Through proteomic analysis, the authors revealed that endoglin is an important player in the effective trafficking of THSD7A within exosomes. This study offers interesting insights into the dynamic interplay between exosome-mediated protein trafficking and essential cellular processes, emphasizing its significant relevance in both cancer progression and neural function. The authors communicated their findings clearly and effectively.</p><p>(1) While exosomes are known to play a role in cell migration and autocrine signaling, the relationship between exosome secretion and the formation of filopodia is novel.</p><p>(2) The authors identify an exosomal cargo protein, THSD7A, which is essential for regulating this function.</p><p>(3) The data presented provide strong evidence of a role for endoglin in the trafficking of THSD7A in exosomes.</p><p>(4) The authors associate this process with functional significance in cancer cell metastasis and neurological synapse formation, both of which involve the formation of filopodia.</p><p>(5) The data are presented clearly, and their interpretation appropriately explains the context and significance of the findings.</p><p>Weaknesses:</p><p>While the authors showed the important role of exosomal cargo protein THSD7A in neurons, it will be interesting to conduct any in vivo studies to determine whether THSD7A plays a similar role in promoting filopodia and synapse formation in vivo. Some of the comments of the reviewers were not fully addressed, such as rigorous analysis and quantification through Live-cell imaging through TIRF microscopy tracking labeled THSD7A and filopodia formation, which would provide more clarity in timing and strengthen causality of this relationship. The authors need to consider fully characterizing the role of Cdc42. If the authors would like to fully elaborate on the role of Cdc42 in another manuscript, it is better not to mention at all the role of Cdc42 in filopodia formation in this paper.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101673.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>McAtee</surname><given-names>Caitlin</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University School of Medicine</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Mikin R</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Hoshino</surname><given-names>Daisuke</given-names></name><role specific-use="author">Author</role><aff><institution>Kanagawa Cancer Center</institution><addr-line><named-content content-type="city">Yokohama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Sung</surname><given-names>Bong Hwan</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University School of Medicine</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>von Lersner</surname><given-names>Ariana K</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University School of Medicine</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Mingjian</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Nan Hyung</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University School of Medicine</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Anna</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Krystofiak</surname><given-names>Evan</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Zijlstra</surname><given-names>Andries</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University Medical Center</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Weaver</surname><given-names>Alissa M</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>The study significantly advances our understanding of how exosomes regulate filopodia formation. Filopodia play crucial roles in cell movement, polarization, directional sensing, and neuronal synapse formation. McAtee et al. demonstrated that exosomes, particularly those enriched with the protein THSD7A, play a pivotal role in promoting filopodia formation through Cdc42 in cancer cells and neurons. This discovery unveils a new extracellular mechanism through which cells can control their cytoskeletal dynamics and interaction with their surroundings. The study employs a combination of rescue experiments, live-cell imaging, cell culture, and proteomic analyses to thoroughly investigate the role of exosomes and THSD7A in filopodia formation in cancer cells and neurons. These findings offer valuable insights into fundamental biological processes of cell movement and communication and have potential implications for understanding cancer metastasis and neuronal development.</p><p>Weaknesses:</p><p>The conclusions of this study are in most cases supported by data, but some aspects of data analysis need to be better clarified and elaborated. Some conclusions need to be better stated and according to the data observed.</p></disp-quote><p>We appreciate the reviewer's recognition of the impact of our study. We will address the concerns about data analysis and the statement of our conclusions in our full response to reviewers.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>The authors show that small EVs trigger the formation of filopodia in both cancer cells and neurons. They go on to show that two cargo proteins, endoglin, and THSD7A, are important for this process. This possibly occurs by activating the Rho-family GTPase CDC42.</p><p>Strengths:</p><p>The EV work is quite strong and convincing. The proteomics work is well executed and carefully analyzed. I was particularly impressed with the chick metastasis assay that added strong evidence of in vivo relevance.</p><p>Weaknesses:</p><p>The weakest part of the paper is the Cdc42 work at the end of the paper. It is incomplete and not terribly convincing. This part of the paper needs to be improved significantly</p></disp-quote><p>We appreciate the reviewer's recognition of the impact of our study. Indeed, more work needs to be done to clarify the role of Cdc42 in the induction of filopodia by exosome-associated THSD7A. We anticipate that this will be a separate manuscript, delving in-depth into how exosome-associated THSD7A interacts with recipient cells to activate Cdc42 and carrying out a variety of assays for Cdc42 activation.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public review):</bold></p><p>Summary:</p><p>The authors identify a novel relationship between exosome secretion and filopodia formation in cancer cells and neurons. They observe that multivesicular endosomes (MVE)-plasma membrane (PM) fusion is associated with filopodia formation in HT1080 cells and that MVEs are present in filopodia in primary neurons. Using overexpression and knockdown (KD) of Rab27/HRS in HT1080 cells, melanoma cells, and/or primary rat neurons, they found that decreasing exosome secretion reduces filopodia formation, while Rab27 overexpression leads to the opposite result. Furthermore, the decreased filopodia formation is rescued in the Rab27a/HRS KD melanoma cells by the addition of small extracellular vesicles (EVs) but not large EVs purified from control cells. The authors identify endoglin as a protein unique to small EVs secreted by cancer cells when compared to large EVs. KD of endoglin reduces filopodia formation and this is rescued by the addition of small EVs from control cells and not by small EVs from endoglin KD cells. Based on the role of filopodia in cancer metastasis, the authors then investigate the role of endoglin in cancer cell metastasis using a chick embryo model. They find that injection of endoglin KD HT1080 cells into chick embryos gives rise to less metastasis compared to control cells - a phenotype that is rescued by the co-injection of small EVs from control cells. Using quantitative mass spectrometry analysis, they find that thrombospondin type 1 domain containing 7a protein (THSD7A) is downregulated in small EVs from endoglin KD melanoma cells compared to those from control cells. They also report that THSD7A is more abundant in endoglin KD cell lysate compared to control HT1080 cells and less abundant in small EVs from endoglin KD cells compared to control cells, indicating a trafficking defect. Indeed, using immunofluorescence microscopy, the authors observe THSD7A-mScarlet accumulation in CD63-positive structures in endoglin KD HT1080 cells, compared to control cells. Finally, the authors determine that exosome-secreted THSD7A induces filopodia formation in a Cdc42-dependent mechanism.</p><p>Strengths:</p><p>(1) While exosomes are known to play a role in cell migration and autocrine signaling, the relationship between exosome secretion and the formation of filopodia is novel.</p><p>(2) The authors identify an exosomal cargo protein, THSD7A, which is essential for regulating this function.</p><p>(3) The data presented provide strong evidence of a role for endoglin in the trafficking of THSD7A in exosomes.</p><p>(4) The authors associate this process with functional significance in cancer cell metastasis and neurological synapse formation, both of which involve the formation of filopodia.</p><p>(5) The data are presented clearly, and their interpretation appropriately explains the context and significance of the findings.</p><p>Weaknesses:</p><p>(1) A better characterization of the nature of the small EV population is missing:</p><p>It is unclear why the authors chose to proceed to quantitative mass spectrometry with the bands in the Coomassie from size-separated EV samples, as there are other bands present in the small EV lane but not the large EV lane. This is important to clarify because it underlies how they were able to identify THSD7A as a unique regulator of exosome-mediated filopodia formation. Is there a reason why the total sample fractions were not compared? This would provide valuable information on the nature of the small and large EV populations.</p></disp-quote><p>We would like to clarify that there are two sets of proteomics data in the manuscript. The first was comparing bands from a colloidal Coomassie-stained gel from two samples: small EVs and large EVs from B16F1 cells. In this proteomics experiment, we identified endoglin as present in small EVs, but not large EVs. For this experiment, we only sent four bands from the small EV lane, chosen based on their obvious banding pattern difference on the Coomassie gel.</p><p>In the second proteomics experiment, we used quantitative iTRAQ proteomics to compare small EVs purified from B16F1 control (shScr) and endoglin KD (shEng1 and shEng2) cell lines. In this experiment, we sent total protein extracted from small EV samples for analysis. So, these samples included the entire EV content, not just selected bands from a gel. In this experiment, we identified THSD7A as reduced in the shEng small EVs.</p><disp-quote content-type="editor-comment"><p>(2) Data analysis and quantification should be performed with increased rigor:</p><p>a) Figure 1C - The optical and temporal resolution are insufficient to conclusively characterize the association between exosome secretion and filopodia. Specifically, the 10-second interval used in the image acquisitions is too close to the reported 20-second median time between exosome secretion and filopodia formation. Two-5 sec intervals should be used to validate this. It would also be important to correlate the percentage of filopodia events that co-occur with exosome secretion. Is this a phenomenon that occurs with most or only a small number of filopodia? Additionally, resolution with typical confocal microscopy is subpar for these analyses. TIRF microscopy would offer increased resolution to parse out secretion events. As the TIRF objective is listed in the Methods section, figure legends should mention which images were acquired using TIRF microscopy.</p></disp-quote><p>We acknowledge that the frame rate naturally limits our estimates of the timing of filopodia formation after exosome secretion. We set out to show a relationship between exosome secretion and filopodia formation, based on their proximity in timing. While our data set shows a median time interval of 20 seconds, the true median could be between 10-30 seconds, based on our frame rate. Regardless of the exact timing, our data show that exosome secretion is rapidly followed by filopodia formation events.</p><p>To address the question of the percentage of filopodia events that are preceded by exosome secretion, the reviewer is correct in stating that we might need TIRF microscopy and a faster frame rate to observe all the MVB fusion events and get an accurate calculation of this number. The timing of the acquisition was based on the typical timing of filopodia formation, which is slow relative to MVB fusion. Thus, with the current dataset, we could miss secretion events taking place between the 10 second time intervals. Therefore, to address this question, we would need to acquire a new dataset with a much more rapid frame acquisition (multiple frames per second rather than one frame every ten seconds). Regardless, for the secretion events that we visualized with the current dataset, we always observed subsequent filopodia formation.</p><p>No TIRF imaging was used in this manuscript. A TIRF objective was used for selected neuron imaging (see methods); however, it was used for spinning disk confocal microscopy, not for TIRF imaging. This is stated in the methods.</p><disp-quote content-type="editor-comment"><p>b) Figure 2 - It would be important to perform further analysis to concretely determine the relationship between exosome secretion and filopodia stability. Are secretion events correlated with the stability of filopodia? Is there a positive feedback loop that causes further filopodia stability and length with increased secretion? Furthermore, is there an association between the proximity of secretion with stability? Quantification of filopodia more objectively (# of filopodia/cell) would be helpful.</p></disp-quote><p>Our data show that manipulation of general exosome secretion, via Hrs knockdown, affects both de novo filopodia formation and filopodia stability (Fig 2g,h). Interestingly, knockdown of endoglin only affects de novo filopodia formation, while filopodia stability is unaffected (Fig 4g,h). These results suggest that filopodia stability is dependent upon exosome cargoes besides endoglin/THSD7A. Such cargoes might include other extracellular matrix molecules, such as fibronectin. We previously showed that exosomes promote nascent cell adhesion and rapid cell migration, through exosome-bound fibronectin (Sung et al., Nature Communications, 6:7164, 2015). We also previously found that inhibition of exosome secretion affects the persistence of invadopodia, which are filopodia-dependent structures (Hoshino et al., Cell Reports, 5:1159-1168, 2013). We agree that this is an interesting research direction, and perhaps future work could focus on exosomal factors that are responsible for filopodia persistence. This would possibly involve more proteomics analysis to identify candidate exosomal cargoes involved in this process.</p><p>With regard to the way we plotted the filopodia data, we plotted the cancer cell data as filopodia per cell area so that it matched the neuron data, which was plotted as filopodia per 100 µm of dendrite distance. Since the neurons cannot be imaged as a whole cell, the quantification is based on the length of the dendrite in the image. We found that graphing the cancer cell data as filopodia per cell gave similar results as filopodia per cell area. To demonstrate that this quantification gives similar results, we have now plotted the filopodia per cell area data from Fig 2 as filopodia per cell and placed these new plots in Supp Fig 2.</p><disp-quote content-type="editor-comment"><p>c) Figure 6 - Why use different gel conditions to detect THSD7A in small EVs from B16F1 cells vs HT1080 and neurons? Why are there two bands for THSD7A in panels C and E? It is difficult to appreciate the KD efficiency in E. The absence of a signal for THSD7A in the HT1080 shEng small EVs that show a signal for endoglin is surprising. The authors should provide rigorous quantification of the westerns from several independent experimental repeats.</p></disp-quote><p>Detection of THSD7A via Western blot was, unfortunately, not straightforward and simple. Due to the large size (~260 kDa) of THSD7A, its low level of expression in cancer cells, as well as the inconsistency of commercially available THSD7A antibodies, we had to troubleshoot multiple conditions. We found that it was much easier to detect THSD7A in the human fibrosarcoma cell line HT1080 than in the mouse B16F1 cells, both in the cell lysates and in the small EVs. We were unable to detect THSD7A using the same (reducing) conditions for the mouse melanoma B16F1 samples but were successful using native gel conditions. We also detected THSD7A in rat primary neuron samples. All these samples were from different source organisms (human, mouse, rat) and from either cell lysates or extracellular vesicles, further complicating the analyses. Expression and maturation of THSD7A in these different cell types and compartments could involve different post-translational modifications, such as glycosylation, thus requiring different methods needed to detect THSD7A on Western blots and leading to different banding patterns.</p><p>With regard to the level of knockdown of THSD7A in the Western blot shown in Figure 6E, the normalized level is quantitated below the bands. If you compare that quantitation to the filopodia phenotypes in the same panel, they are quite concordant. Figures 7B and 7C show quantification of triplicate Western blots, highlighting the significant accumulation of THSD7A in shEng cell lysates, as well as significant small EV secretion of THSD7A in control and WT rescued conditions.</p><disp-quote content-type="editor-comment"><p>(3) The study lacks data on the cellular distribution of endoglin and THSD7A:</p><p>a) Figure 6 - Is THSD7A expected to be present in the nucleus as shown in panel D (label D is missing in the Figure). It is not clear if this is observed in neurons. a Western of endogenous THSD7A on cell fractions would clarify this. The authors should further characterize the cellular distribution of THSD7A in both cell types. Similarly, the cellular distribution of endoglin in the cancer cells should be provided. This would help validate the proposed model in Figure 8.</p></disp-quote><p>The image in figure 6D shows an HT1080 cell stained with phalloidin-Alexa Fluor 488 to visualize F-actin with or without expression of THSD7A-mScarlet. In order to fully visualize the thin filopodia protrusions, the cellular plane of focus of the images for this panel was purposely taken at the bottom of the cell, where the cell is attached to the coverslip glass. Thus, we interpret the red signal across the cell body as THSD7A-mScarlet expression on the plasma membrane underneath the cell, not in the nucleus. The neuron images only include the dendrite portion of the neurons; therefore, there is no nucleus present in the neuronal images. For the cellular distribution of endoglin, we agree that this is an important future direction to understand how endoglin regulates THSD7A trafficking. We have added the lack of these data to the “Limitations” section at the end of the manuscript.</p><disp-quote content-type="editor-comment"><p>b) Figure 7 - Although the western blot provides convincing evidence for the role of endoglin in THSD7A trafficking, the microscopy data lack resolution as well as key analyses. While differences between shSCR and shEng cells are clear visually, the insets appear to be zoomed digitally which decreases resolution and interferes with interpretation. It would be crucial to show the colocalization of endoglin and THSD7A within CD63-postive MVE structures. What are the structures in Figure 7E shSCR zoom1? It would be important to rule out that these are migrasomes using TSPAN4 staining. More information on how the analysis was conducted is needed (i.e. how extracellular areas were chosen and whether the images are representative of the larger population). A widefield image of shSCR and shEng cells and DAPI or HOECHST staining in the higher magnification images should be provided. Additionally, the authors should quantify the colocalization of external CD63 and mScarlet signals from many independently acquired images (as they did for the internal signals in panel F). Is there no external THSD7A signal in the shEng cells?</p></disp-quote><p>The images for Figure 7E were taken with high resolution on a confocal microscope. Insets for Figure 7E were digitally zoomed so that readers could see the tiny structures. Zoom 1 in Figure 7E shows areas of extracellular deposition, whereas Zoom 2 shows THSD7A colocalization with CD63 in MVE. In the extracellular areas (Zoom 1), we observe small punctate depositions that are positive for CD63 and/or THSD7A-mScarlet. Our interpretation of this staining is that the cells are secreting heterogeneous small EVs that are then attached to the glass coverslip. The images and zooms in Fig 7E were chosen to be representative and indeed reveal that there is more extracellular deposition of THSD7A-mScarlet outside the control shScr cells compared to the shEng cells, consistent with more secretion of THSD7A in small EVs from shScr cells when compared to those of shEng cells (Fig 7A,B). However, we did not quantify this difference, as these experiments were conducted with transient transfection of THSD7A-mScarlet, and it is challenging to determine which cell the extracellular THSD7A-mScarlet came from, complicating any quantitative analysis on a per-cell basis.</p><p>Quantification of internal THSD7A localization is much more straightforward in this experimental regime. Indeed, in Figure 7F, we quantitated internal colocalization of THSD7A-mScarlet and CD63, which we obtained by choosing only cells that were visually positive for THSD7A-mScarlet in each transient transfection and omitting all extracellular signals. Quantifying the extracellular colocalization of THSD7A and CD63 could certainly be a future direction for this project and would require establishing cells that stably express THSD7A-mScarlet.</p><p>With regard to whether the extracellular deposits are migrasomes, we have no reason to believe that they would be migrasomes. The preponderance of our evidence points to exosomes as carrying THSD7A and inducing filopodia. Furthermore, CD63 is an exosome marker (Sung et al., Nat Comm, 2020) and does not induce migrasomes, unlike many other tetraspanins (Huang et al., Nat Cell Bio, 2019).</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>The authors need to clarify the figure labeling and description and conclusions would be better to be drawn based on the findings. Some figures need to more clear e.g. Figure 1E needs to have information on what are green and red fluorescent proteins. Do all figures in 1A have the same scale bar or different? Figure 3A lacks a scale bar. In Figure 3, the GFP signal is in yellow, does it represent a merge or is it just the GFP alone? Figure 6D is missing a D. Figure 4D needs to be better explained. Additionally, both figures 8B and 8C since represent a model based on all the findings of the study would be better to stand alone as a separate figure from figure 8A.</p></disp-quote><p>The figure legend for figure 1E notes that green corresponds to GFP-Rab27b and the red corresponds to mCherry filler. In addition, the labels are marked to the right of the figure. For Figure 1A, we have now indicated in the legend that all scale bars = 10 µm. In figure 3, neurons were co-transfected with GFP or GFP-Rab27b. Thus, the yellow signal in these images is the merge of the mCherry filler with either GFP (expression throughout the neuron body and dendrites) or GFP-Rab27b (punctate colocalization). We have added a scale bar to Fig 3A. Figure 6D has been corrected, with a “D” label added. Figure 4D shows representative images of cells with filopodia under the various conditions, including add-back of control or endoglin-KD EVs. We have clarified the conditions in the figure legend for 4D. For Figure 8, we have now split it into 2 figures: one with data (Fig 8) and one with the model (Fig 9).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>For the most part, this story is strong and well-presented. The findings are interesting and will significantly advance our understanding of how EVs affect various processes such as cancer metastasis. However, the Cdc42 work is not great. They only indirectly implicate Cdc42 with a somewhat iffy inhibitor (ML141) and a constitutively active form transfected into cells. Both approaches have drawbacks such as off-target effects in the case of the inhibitor and possible cross-talk to other GTPases in the case of the active mutant. The activation of Cdc42 should be demonstrated by an activity assay. Several commercial kits are available. Inhibition of Cdc42 should be tested by knockdown in addition to the inhibitor.</p></disp-quote><p>We appreciate the reviewer’s recognition of our work. To address the limitations of our study, particularly the Cdc42 mechanistic work, we have now added a “Limitations of the study” section at the end of the text. Here, we address our experimental limitations and future directions.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><p>(1) Since the purified small EVs contain canonical exosomal markers and originate from MVEs, the authors should consider a more consistent use of the term &quot;exosome&quot; to avoid confusion.</p></disp-quote><p>We acknowledge that the usage of both “exosomes” and “small extracellular vesicles” can seem confusing to many readers. Typically in the EV field, we use the term “exosome” when we can reliably determine that the EVs originate from the endocytic pathway. Thus, we use this term when we have specifically perturbed this pathway by targeting Hrs or Rab27. We use the term “small extracellular vesicles” or SEVs when referring to a purified heterogeneous population of SEVs from unknown or a variety of origins. Thus, when referring to vesicles isolated from the conditioned media, we call them SEVs because we cannot determine their origin. Clarification of this terminology has been added to the introduction of the paper.</p><disp-quote content-type="editor-comment"><p>(2) 1st results section - expressing mCherry as a &quot;filler&quot; is confusing, clarify that this is meant to identify cellular background.</p></disp-quote><p>This has now been clarified in the paper.</p><disp-quote content-type="editor-comment"><p>(3) Figure 3 - Although Rab27a and Rab27b play a role in exosome secretion, Rab27b does not have redundant functions with Rab27a in every cellular context. The authors should mention the specific roles of Rab27a and Rab27b in promoting MVE fusion with the PM and in regulating the anterograde movement of MVEs to the PM, respectively (Ostrowski et al. 2010, Citation 52 in the ms). Although Rab27a is not highly expressed in neurons, it is not currently clear whether Rab27b has a redundant function with Rab27a or whether there is another unknown factor that plays this role. As neurons also do not express endoglin, the mechanisms that mediate how EVs regulate filopodia formation in these cells are most probably different than in cancer cells. This should be highlighted in the discussion.</p></disp-quote><p>We have now added a couple of clarifying sentences about the roles of Rab27a and Rab27b to the results section, including the Ostrowski reference and another reference suggesting possible redundancy of Rab27a and Rab27b. With regard to endoglin not being expressed by neurons, that is one reason why we carried out the proteomics with control and endoglin-KD EVs to find a universal cargo that would directly induce filopodia formation. Indeed, THSD7A seems to be such a universal cargo, expressed in both cancer cell and neuron EVs and inducing filopodia in both cell types. This point, along with the requirement for regulation of THSD7A by other molecules in neurons, is discussed in the results and discussion sections.</p><disp-quote content-type="editor-comment"><p>(4) As the authors note, the mechanistic link between endoglin-sorted, exosomal THSD7A and Cdc42-mediated filopodia formation remains unclear. While the findings on Cdc-42 are clear, they are not surprising. What is the role of mDia/ENA/VASP or BAR proteins in this? The authors should also consider an assay to determine whether exosomal THSD7A binds to the PM to cause the signaling or if the cargo is first internalized before performing its function. Since this process is both autocrine and paracrine, the authors could co-culture THSD7A-mScarlet cells with vector control cells and observe how THSD7A-mScarlet is localized in the non-expressing cells.</p></disp-quote><p>As other reviewers also noted, the Cdc42 mechanistic data at the end of the paper has clear limitations that are now addressed within the manuscript in a “Limitations of the Study” section. Here we discuss our experimental troubleshooting and approach to assaying Cdc42 involvement in this process. We acknowledge there are many rigorous experiments that could be pursued in the future to strengthen our mechanism and proposed model.</p><p>We also agree that elucidating how THSD7A specifically interacts with target cells would be very informative and insightful. This would be most effectively assayed using a cell line that is stably expressing THSD7A-mScarlet and could be a future direction of this project. However, it is out of the scope of this current publication.</p></body></sub-article></article>